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Chapter 1. 
Introduction 
 
During the last century, life expectancy has increased substantially worldwide. In Europe, the 
mean life duration has evolved from 65.6 years in the late 1950’s to 76.5 years currently. At 
this rate, by 2095-2100, life expectancy across Europe will rise to 87.4 years (United Nations, 
2013). This evolution can be partly explained by the drop in coronary heart disease (CHD) 
mortality rates during the latest decades. Nevertheless, CHD remains the most common cause 
of death in Europe, responsible for one out of every five lives lost (Nichols et al, 2012). A 
great variation in death rates exists across different geographical areas, with the highest rates 
observed in central and eastern European countries, and the lowest mortality rates seen in 
southern European countries (Nichols et al, 2012). 
Likewise, CHD is also a major cause of morbidity. Population ageing is associated with an 
increase in number of patients suffering from coronary disease (Nichols et al, 2012). 
According to the WHO, 10% of all disability adjusted life years in Europe can be attributed to 
CHD (Nichols et al, 2012; World Health Organisation, 2013a). 
Indeed, CHD remains a ubiquitous illness requiring expensive treatment. The economic 
burden associated with the disease rises to €60 billion per year in the European Union (EU), 
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of which 33% is related to direct health care costs, 29% to productivity losses (20% because 
of mortality and 9% because of morbidity) and 38% to the informal care (Nichols et al, 2012). 
Conventional medicine is mainly focused on clinical measures and functional outcomes; 
however, morbidity and mortality rates do not reflect all aspects of health. Over the years, 
patients’ self-perceived emotional, social and physical well-being has gained attention, 
especially in long-term chronic conditions, when full recovery is quite unlikely. Many 
patients consider the quality of the additional life years gained equally important as the length 
of life (Thompson et al, 2003). Due to pain, physical and social restrictions, anxiety or 
depression, cardiovascular patients are particularly vulnerable to have an impaired self-
perceived quality of life (Mols et al, 2009; Schweikert et al, 2009; Thompson et al, 2003; Xie 
et al, 2008). The goal of today’s medicine is therefore not merely to simply extend a person’s 
life expectancy, but also to ensure a sufficiently high long-term health-related quality of life 
(HRQoL) (Dunning et al, 2008; Oldridge et al, 2005). Consequently, HRQoL assessment is 
increasingly being used; initially for scientific research purposes only, but later on also in 
daily clinical practice.  
1.1 CORONARY HEART DISEASE AND ITS PREVENTION 
CHD is a disease of the arteries and vessels supplying blood and nutrients to the heart muscle. 
Due to plaque build-up over the years, the arteries narrow and harden (i.e. atherosclerosis), 
hence preventing an adequate blood flow (World Health Organisation, 2004). Such a 
blockage can lead to myocardial ischemia, which is characterized by angina or chest pain. 
When left untreated, this may evolve into an acute myocardial infarction (AMI), also known 
as a heart attack. Percutaneous Coronary Intervention (PCI) and Coronary Artery Bypass 
Grafting (CABG) are frequently used interventions proven to be effective in reducing the 
subsequent risk for a recurrent coronary event (Bravata et al, 2007). 
About 22% females and 20% males die from the illness (1.8 million deaths across Europe per 
year). Standardized case fatality rates vary greatly between countries, but on average the 30-
day case fatality after admission for an AMI amounts to 4.8%. During the latest decade, the 
average hospital discharge rate for CHD lies around 800 per 100,000 discharges across 
Europe and about 10% of all Disability Adjusted Life Years (DALYs) are caused by CHD 
(Nichols et al, 2012). Between 1995 and 2007 a major increase in medication use has been 
observed in CHD patients. The use of antiplatelet therapy increased from 81% to 93%,  the 
use of blood pressure lowering drugs increased from 84% to 97%; the use of Beta-blockers 
increased from 56% to 86%, the used of lipid lowering drugs increased from 32% to 89%, and 
statin use increased from 18% to 87% (Kotseva et al, 2009a). 
Over the years several CHD risk factors have been described. In this thesis, we distinguish 
four risk factor categories (Gaziano et al, 2001). First there are the non-modifiable 
predisposing risk factors such as age, gender, family history, genetic predisposition, 
educational level and socio-economic status. Secondly, metabolic risk factors exist such as 
elevated cholesterol, high blood pressure (BP), diabetes, overweight and obesity. Thirdly, 
behavioural risk factors exist, such as smoking, lack of physical activity, an unhealthy diet 
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and excessive alcohol intake. And finally psychosocial factors such as stress, anxiety and 
depression as well as an impaired self-perceived health status and general health perceptions 
are considered CHD risk factors (Berry et al, 2012; Buttar et al, 2005; DeSalvo et al, 2006; 
World Health Organisation, 2002; World Health Organisation, 2004).  
According to the EUROBAROMETER survey, 29% of citizens across the EU are smokers 
(Eurobarometer, 2010). Over 30% of Europeans citizens do not perform any kind of 
recreational or leisure time physical activity (Eurobarometer, 2006) and the national mean 
body mass index (BMI) levels for both men and women across Europe vary between around 
24 and 28 kg/m
2
, whereas the optimal value for the health of a population is 21 kg/m
2
 
(Nichols et al, 2012).  
A survey in 4366 asymptomatic high risk patients (patients on antihypertensive and/or lipid-
lowering and/or anti-diabetes treatments, but with no history of a coronary or other 
atherosclerotic disease) across the general practices of 12 European countries, revealed  that  
16.9% of patients were smokers, 43.5% had a BMI ≥30 kg/m², 70.8% had a BP ≥140/ 
90mmHg (≥130/80 in people with diabetes mellitus), 66.4% had a total cholesterol (TC) 
≥5.0mmol/l (≥4.5mmol/l in people with diabetes) and 30.2% reported a history of diabetes 
(Kotseva et al, 2010).  
A sample of CHD patients revealed that 17% of patients were smokers, 35% were obese and 
52% centrally obese, 56% had a BP ≥140/90 mmHg (≥130/80 in people with diabetes 
mellitus), 51% had a serum TC ≥4.5 mmol/l and 25% reported a history of diabetes (Kotseva 
et al, 2009b). 
A profound study by Yusuf et al (2004), indicated that smoking, hypercholesterolemia, 
hypertension, diabetes and obesity are responsible for 80% of the risk for a first acute AMI. 
Hence, adequate lifestyle changes are crucial in order to decrease CHD related morbidity and 
mortality rates. Several guidelines on cardiovascular prevention emphasize the importance of 
adopting a healthier lifestyle in order to prevent coronary events both in CHD patients as well 
as in high risk patients. In 1994, the European Society of Cardiology (ESC) has published 
formal recommendations on the prevention of CHD in clinical practice aiming to summarise – 
from a clinical point of view – the most important issues in CHD prevention based on the 
available evidence, in order to help physicians in their everyday clinical medical decision 
making (Pyorala et al, 1994).  Regular updates of the guidelines have been published since; 
the latest version was made available in 2012 (Perk et al, 2012).   
Tobacco use is estimated to be responsible for nearly 10% of cardiovascular diseases (World 
Health Organisation et al, 2011), therefore, smoking cessation aid should be offered and 
second-hand or passive smoking should be avoided (Perk et al, 2012; World Health 
Organisation et al, 2011). Furthermore, attention should be given to dietary habits, since an 
unhealthy diet, consisting of a high fat and salt intake and a low fruit, vegetables and fish 
intake is associated with an increased CHD risk (World Health Organisation et al, 2011). 
Healthy dietary habits should be adopted by reducing saturated fatty acids intake (<10% of 
total energy intake) through replacement by polyunsaturated fatty acids intake, by avoiding 
trans unsaturated fatty acids intake, by reducing salt intake (<5g/day), by increasing fibre 
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intake (30-45g/day), fruit and vegetable intake (200g/day each), and fish intake (2x/week), 
and by limiting alcohol intake (2 glasses/day for men, and 1 glass/day for women) (Perk et al, 
2012). Currently, more than 60% of people worldwide do not meet the physical activity 
targets (World Health Organisation, 2004). Healthy adults are advised to spend 2.5 to 5 
hours/week of moderate intensity physical activity, or 1 to 2.5 hours/week of vigorous 
intensity physical activity (Perk et al, 2012). An imbalance between energy intake and energy 
expenditure can lead to overweight (BMI ≥25kg/m² and <30kg/m²) and obesity (BMI 
≥30kg/m²), resulting in adverse metabolic effects on BP, cholesterol, triglycerides and insulin 
resistance (World Health Organisation et al, 2011). In addition, waist circumference targets 
are set at <94 cm and <80 cm in men and women respectively. Overweight and obese persons 
should be recommended to lose weight in order to achieve a BMI <25kg/m² (Perk et al, 2012). 
Treatment of risk factors should further include treatment of hypertension since, in terms of 
attributable deaths, a raised BP is the leading cardiovascular risk factor globally (World 
Health Organisation et al, 2011). Prevention should focus on behavioural strategies and 
antihypertensive drug treatment if necessary, in order to lower the BP to <140/90mmHg (Perk 
et al, 2012).  Diabetes is associated with a 2 to 3 fold increased risk for cardiovascular disease 
(CVD) (World Health Organisation et al, 2011). Hence patients with diabetes should be 
treated in order to reduce the glycated haemoglobin (HbA1c) level <7.0%; furthermore their 
BP should be lowered to <140/80mmHg and the use of statins is recommended in all diabetes 
patients. Indeed, cholesterol is another major risk factor. A third of CHD is caused by 
elevated cholesterol levels (World Health Organisation et al, 2011). In coronary patients, the 
recommended low density lipoprotein cholesterol (LDL-C) target is <1.8mmol/L or a ≥50% 
LDL-C reduction when the target level cannot be reached (Perk et al, 2012).   
Moreover, coronary patients are at higher risk to develop both depressive and anxious feelings 
as well as to suffer from impaired HRQoL outcomes, due to pain, physical and social 
restrictions. Depression, psychosocial stress, emotional but also physical well-being are in 
turn independent predictors of worse CHD outcomes (World Health Organisation, 2004; 
Spertus et al, 2002; Schenkeveld et al, 2010; Rumsfeld et al, 1999; Pedersen et al, 2007; 
Pedersen et al, 2011; Kivimaki et al, 2012). Hence, tackling patients’ depressive and anxious 
feelings as well as improving their HRQoL is of utmost importance. Knowledge on how to 
improve HRQoL outcomes is scarce, although some suggest that the effect of changing 
lifestyle behaviours is twofold; not only will it have a direct impact on obesity, cholesterol, 
BP and blood glucose but also an indirect impact by influencing a individual’s HRQoL (Bize 
et al, 2007; Piper et al, 2012; Sarna et al, 2008; Sevinc et al, 2010). 
The IMPACT model, developed by Capewell and colleagues revealed that between 1981 and 
2000, CHD mortality rates in England and Wales decreased by 62% in men and 45% in 
women. About 42% of this decrease could be attributed to treatments in individuals. 
Secondary prevention accounted for an 11% reduction, heart failure treatment for 12%, AMI 
treatment for 8%, hypertension treatment for 3% and angina treatment for 9%. Population risk 
reductions make up 58% of the mortality decrease. Smoking cessation accounted for 48%; 
blood pressure lowering for 9.5%; and cholesterol lowering 9.5%; deprivation decrease for 
3%. Adverse trends were seen for physical activity, obesity and diabetes, responsible for a 
4.4%, 3.5% and 4.8% increase in CHD mortality respectively (Unal et al, 2004). 
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1.2 HEALTH-RELATED QUALITY OF LIFE: FROM ORIGIN TO MEASUREMENT 
The interest in the concept ‘quality of life’ dates back to the ancient Greek era. In their moral 
theories Socrates, Plato and Aristotle defined ‘happiness’ as an important goal of action. They 
wondered how one should live to be happy. In his Nicomachean Ethics, Aristotle explored the 
concept Eudaimonia, which can be translated as ‘the good life’, ‘well-being’ or ‘happiness’. 
And although modern philosophers are still discussing about the correct meaning and 
translation of the concept, there is agreement about the theory of Eudemonism being closely 
related to a person’s self-perceived quality of life. What Aristotle considered as being the 
‘highest of all goods’ in human beings, is still believed to be the ultimate goal in every 
person’s life. The term quality of life is frequently being used in social science. However, in 
order to differentiate between a person’s overall happiness or quality of life and his/her 
health-related well-being the concept HRQoL has been introduced.  
The interest in patients’ self-perceived health-related well-being was already reflected shortly 
after World War II in the preamble of the constitution of the WHO. Within this preamble 
(1946), health was defined as "a state of complete physical, mental, and social well-being; not 
merely the absence of disease or infirmity”, including mental and social well-being as a 
substantive part of health (World Health Organisation, 1948). However, it was not until the 
mid-70’s that HRQoL was included as a keyword in the Index Medicus (Snoek, 2000). Ever 
since, a large number of definitions explaining the concept have emerged. A few of them are 
listed below: 
According to Wegner and Furberg (1990) (Spilker, 1990) HRQoL can be defined as:  
“Those attributes valued by patients, including: their resultant comfort or 
sense of well-being; the extent to which they were able to maintain reasonable 
physical, emotional and intellectual function; and the degree to which they 
retain their ability to participate in valued activities within the family, in the 
workplace and in the community”  
According to Revicki (2000) (Revicki et al, 2000) HRQoL can be defined as: 
“The subjective assessment of the impact of disease and treatment across the 
physical, psychological, social and somatic domains of functioning and well-
being” 
 And the WHO (World Health Organisation, 1995) defines HRQoL as : 
“The individual perception of their position in life in the context of their 
culture and value systems in which they live and in relation to their personal 
goals, expectations, standards and concerns” 
Clearly HRQoL is highly individual and means different things to different people, depending 
on demographic, psychological, socioeconomic and other characteristics (Carr et al, 2001). 
Each person has his/her own interpretation of the concept, driven by his/her own expectations, 
hopes and ambitions (Carr et al, 2001). As suggested by Schipper et al (1996), HRQoL 
measurement is subjective in two ways. First of all, HRQoL dimensions are hardly physically 
measurable and secondly the patient’s view on a disease is as important as the disease itself. 
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In any case HRQoL should be used in addition to and by no means replace objective disease 
outcome measures (Higginson et al, 2001; Duenas et al, 2012). Despite the extensive use of 
the concept, consensus is lacking on the definition of HRQoL. The term is used to describe a 
variety of concepts, such as functioning, health status, perceptions, life conditions, behaviour, 
happiness, lifestyle, symptoms etc. (Simko et al, 1999), therefore HRQol is sometimes 
referred to as an umbrella term (Feinstein et al, 1987). However, in essence HRQoL captures 
a person’s self-perceived impact of a medical condition, its symptoms and its treatment 
(Schipper et al, 1996). In this context, not only the patients’ perceived level of satisfaction 
with their physical functioning, but also with their emotional and social functioning should be 
assessed (Moons et al, 2004). In the literature the term HRQoL is frequently used to refer to 
perceived health status. Although these concept are often used interchangeably, there are 
subtle differences between the terms, with health status actually being a determinant for 
HRQoL. A review by Smith et al (1999), revealed that from a patient perspective health status 
and HRQoL are two distinct constructs. Whereas, compared to physical functioning, mental 
health has the greatest impact on HRQoL, the reverse is true for perceived health status, with 
physical functioning being the main determinant. 
The revised Wilson and Cleary Model for HRQoL provides a theoretical background of the 
different concepts constituting HRQoL (figure 1) (Ferrans et al, 2005). 
 
Figure 1: Revised Wilson and Cleary model for Health-related Quality of life. Ferrans, et al. (2005). Adapted from Wilson & Cleary 
(1995). Copyright JAMA.  
To start, intrapersonal factors, interpersonal factors, institutional factors, community factors 
and public policy are linked with all components determining HRQoL. Secondly, five types 
of measures of patient outcomes can be distinguished. Biological function encompasses 
molecular, cellular, and whole organ level processes and can be assessed by laboratory tests, 
physical assessment, and medical diagnoses. Biological functions are directly linked with 
symptoms, the second patient outcome. Symptoms can be defined as “a patient’s perception 
of an abnormal physical, emotional or cognitive state”. Instruments to measure symptoms 
can be divided into global measures (e.g. Symptom Impact Inventory (Miller et al, 2001)); 
condition specific measures (e.g. Unstable Angina Symptom Questionnaire (DeVon & Zerwic, 
2003)); and symptom specific measures (e.g. the Hospital Anxiety and Depression scale 
Biological
function
Symptoms
e.g. HADS
Functional status 
e.g. SF-12, EQ-5D
General health 
perceptions
Quality of life
Characteristics of the individual
Characteristics of the environment
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(HADS) (Zigmond et al, 1983)). Functional status is being defined as “the ability to perform 
tasks in multiple domains such as physical function, social function, role function and 
psychological function”. Both objective (e.g. the Shuttle Walk Test where the patients is 
asked to walk up and down over a 10 meters distance (= a shuttle) with an audio signal used 
to guide the walking speed of the patient (Singh et al, 1992)) and subjective (patient perceived 
health status) instruments can be used. The most often used generic self-perceived health 
status instruments are the 36-item Short Form health survey (SF-36), the 12-item Short Form 
health survey (SF-12) (Ware et al, 2002; Ware et al, 1996) and the EuroQol 5 dimensions 
(EQ-5D) (The EuroQol Group, 1990; The EuroQol Group's International Task Force on Self-
Reported Health, 2004). Widely used disease specific instruments in coronary patients are the 
Seattle Angina Questionnaire (SAQ) (Spertus et al, 1995) and the Myocardial Infarction 
Dimensional Assessment Scale (MIDAS) (Thompson et al, 2002). Next we have the general 
health perception, which should be measured with a single global question, asking people to 
rate their health ranging from poor to excellent. These can be standalone measures with one 
single item or they can be part of a more comprehensive measure, with 1 item assessing the 
general health perception (e.g SF-36, SF-12). The final component of the model captures the 
subjective well-being of how happy or satisfied someone is with his/her (health-related) life as 
a whole (Ferrans et al, 2005). Examples of such instruments for use in coronary patients are 
the MacNew Heart Disease Health-related Quality of Life Questionnaire for heart failure, 
coronary disease and myocardial infarction (Valenti et al, 1996; Lim et al, 1993), and more 
recently HeartQoL for patients with angina, MI, or ischemic heart failure (Oldridge et al, 
2005). The above described patient outcome measures are dynamic and can change over time 
not only due to the changes in a patient’s physical condition but also because of changes 
inherent in life, such as ageing.  
 
As mentioned, both generic measures as well as disease specific tools exist. The former are 
applicable across a wide range of different patient groups and populations focusing on more 
general issues. Hence, comparison of the outcomes with other patient groups or with the 
general population is possible, allowing to assess the particular impact of a given condition. 
They have the potential limitation however, not to capture certain issues associated with an 
illness. Disease specific measures on the contrary, serve for specific use in a certain disease 
area. They are more appropriate to capture changes associated with the disease (Swenson et al, 
2000) but do not allow comparison with the general population, making interpretation rather 
difficult.  
Within the context of this PhD research, we made use of three instruments, which were 
included in the EUROASPIRE III (EURopean Action on Secondary Prevention through 
Intervention to Reduce Events) protocol, as further discussed in chapter 2.  
The EQ-5D instrument, developed by the EuroQol group in 1990, is a standardized 
instrument to measure one’s self-perceived health status (Bowling, 2005; Ferrans et al, 2005). 
It can be used across different conditions, treatments and settings. Designed for self-
completion it is applicable for use in postal surveys, in clinics, and in face-to-face interviews. 
Within the current study we have used the EQ-5D-3L (3 level) version. The instrument is 
composed of two parts: the EQ-5D descriptive system and the EQ visual analogue scale (EQ-
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VAS). The former includes five questions covering five different dimensions: mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression. Each question has 3 response 
categories: no problems, some problems, and severe problems, allowing the respondent to rate 
their own health. For the mobility dimension for example the respondent is asked to place a 
tick next to one of the following options: ‘I have no problems in walking about’; ‘I have some 
problems in walking about’; ‘I am confined to bed’. The outcome of the descriptive system 
can be represented as a health state. A respondent for example having no problems with 
mobility, some problems with self-care, some problems with usual activities, having no pain 
or discomfort and being extremely anxious or depressed will have ‘12213’ as health state, 
from which a single EQ-5Dindex score, also known as a utility (see below), can be calculated 
(Dolan, 1997; Rabin et al, 2011; Rabin et al, 2001). An index score of 1 represents perfect 
health, a value of 0 represents death, and a value below 0 represents a health state perceived 
worse than death. The second part of the instrument, the EQ-VAS is a 20-cm vertical scale, 
ranging between 0 (worst imaginable health state) and 100 (best imaginable health state) on 
which the respondent is asked to indicate how good or bad his or her health is today. 
The second measure used is the SF-12. Originally developed in 1994, the SF-12 is a 
downsized version of the SF-36, and is intended to measure functional health and well-being 
from a patient perspective. Similar to the EQ-5D instrument, the SF-12 tool is classified as a 
broader health measure (Bowling, 2005). The SF-12 is available in a standard (4-week recall 
period) and an acute (1-week recall period) version. In the current study the second version of 
the standard SF-12 is being used (the SF-12v2, hereafter referred to as SF-12). The instrument 
consists of 12 questions, with 3 to 5 response levels each, covering 8 health domains: physical 
functioning (PF - two questions), role physical (SF-12/RP - two questions), bodily pain (SF-
12/BP - one question), general health (SF-12/GH - one question), vitality (SF-12/VT - one 
question), social functioning (SF-12/SF - one question), role-emotional (SF-12/RE - two 
questions), and mental health (SF-12/MH - two questions). From the different responses on 
the individual questions, a single score between 0 and 100 can be calculated for each 
dimension, with a higher score indicating a better health status (Ware et al, 2002). Using a 
scoring algorithm, two component measures can be calculated from these scales, a Physical 
Component Summary (PCS-12) score and a Mental Component Summary (MCS-12) score, 
represented by a value ranging between 0 and 100 (Ware et al, 2002). The scores allow 
assessment of both physical and mental functioning respectively. In the general population, on 
average an overall mean theoretical score of 50 (SD=10) is expected on both measures. Lower 
and higher scores indicate worse and better health outcomes respectively. In addition, an 
algorithm was developed in order to calculate a utility score based on the SF-12 outcomes 
(Brazier et al, 2004b). 
Finally, the HADS was used. This instrument, developed in 1983, was initially intended for 
use in a hospital setting, but has also been proven to be reliable and valid in a primary care 
setting (Zigmond et al, 1983; Bowling, 2005). This scale is useful for measuring 
psychological well-being (Bowling, 2005). The instrument gives information about possible 
or probable anxiety or depression, but it is not appropriate for clinical depression screening 
because, unlike the Beck Depression Inventory (BDI) (Beck et al, 1996) or the Patient Health 
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Questionnaire (PHQ), this instrument is not based on the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) criteria. The scale contains 7 items related to anxiety and 7 to 
depression, each with a 4-point response scale. The questions cover the following issues: 
feeling tense, restless or relaxed; enjoying things, laugh and feeling cheerful; frightened 
feelings, feelings of panic and worrying; feeling slowed down and loss of interest in 
appearance. Item scores can be added to obtain the summary scores on anxiety (HADS-A) 
and depression (HADS-D) separately. Scores range from 0 to 21 with lower scores 
representing less anxious or depressive feelings respectively. A score below 8 can be 
considered as being in the normal range, a score between 8 and 10 suggests a possible 
depression or anxiety disorder a score greater than or equal to 11 indicates a probable 
depression or anxiety disorder.  
1.3 HEALTH-RELATED QUALITY OF LIFE AND HEART DISEASE 
As mentioned above, CHD is associated with a substantial mental and physical burden (Ski et 
al, 2010). Depression and anxiety are highly prevalent in coronary patients. A recent review 
by Celano et al (2011) concluded that 31% to 45% of coronary patients suffer from depressive 
feelings. According to Todaro et al (2007) 36% of CHD patients suffer from at least one 
anxiety disorder whereas Bankier et al (2004) mention an anxiety prevalence of 24% among 
stable CHD patients. Similar results were found in the EUROASPIRE III (EUROpean Action 
on Secondary and Primary Prevention through Intervention to Reduce Events) survey with a 
prevalence of depressed patients (HADS-D ≥8) amounting to 21% in men and 32% in women, 
and a prevalence of anxiety (HADS-A ≥8) reaching 27% in men and 44% in women (Pajak et 
al, 2013). Likewise, self-perceived  health status is significantly impaired in CHD patients. A 
study performed by Xie et al. (2008) in the United States, indicated significant differences in 
self-perceived health status between CHD patients and the general population, particularly on 
general and physical health. Decrements in health status seemed to be larger in younger 
persons and in women. The MONICA/KORA registry in Germany revealed similar results, 
with MI survivors being at higher risk for reporting problems with regard to pain/discomfort, 
usual activities, and anxiety/depression (Schweikert et al, 2009). 
These are important findings since impaired health status, depression and anxiety are known 
risk factors for cardiovascular disease, as well as independent predictors of mortality and 
cardiac outcome in coronary patients. Several studies have indicated clinical depression as an 
independent risk factor for adverse cardiac outcome and mortality, both in the general 
population as well as in CHD patients. Within the general population, the Health Study of 
Nord-Trøndelag County (HUNT-2) has demonstrated a higher risk for both CHD (1.3-fold 
increased risk) as well as mortality (1.5-fold increased risk) in depressed persons (Mykletun et 
al, 2009, Gustad et al, 2013). According to Luukinen et al (2003) depression is associated 
with a 2.7-fold higher risk of sudden cardiac death and a 1.7-fold higher risk for all-cause 
mortality. The meta-analysis by Van Melle et al (2004) has shown a 2- to 2.5-fold increased 
risk of impaired cardiovascular outcome in post MI depression. Depression was significantly 
associated with all-cause and cardiac mortality and new cardiovascular events (van Melle et al, 
2004). According to the meta-analysis performed by Barth et al (2004), the 2-year overall 
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mortality risk of depressed CHD patients was two times higher than in non-depressed CHD 
patients. Similar results were found regarding long-term prognosis. A recent study by Nabi et 
al. (2010) investigating 5936 middle-aged men and women from the British Whitehall II 
study showed a additive interaction between depressive symptoms and CHD with regard to 
mortality. According to the most recent meta-analysis performed by Meijer et al (2011) post-
MI depression was associated with a 1.6- to 2.7-fold increased two-year risk of impaired 
outcomes.  
Similar results were found with regard to anxiety. According to a meta-analysis performed by 
Roest et al. (2010a) in healthy persons, anxiety was significantly associated with a greater risk 
for both CHD (1.3-fold increased risk) and cardiac death (1.5-fold increased risk). A meta-
analysis in coronary patients showed that post-MI anxiety was associated with a 36% 
increased risk of adverse cardiac outcomes, a 47% increased risk of all-cause mortality, a 23% 
increased risk of cardiac mortality and a 71% increased risk of new cardiac events (Roest et al, 
2010b). Freasure-Smith (1995) found a 1-year OR of 2.52 for a recurrent cardiac event  in 
anxious post MI patients. 
Likewise, functional status, general health perception and HRQoL measures have been shown 
to be independent predictors of cardiovascular outcome. Physical health status assessed 
during hospitalization for acute coronary syndrome (ACS) predicted mortality 12 months later 
(Thombs et al, 2008); Seattle Angina Questionnaire (SAQ) scores were independently 
associated with 1-year mortality and ACS in coronary patients (Spertus et al, 2002) and Kato 
et al. (2011) found that the outcome of the Minnesota Living with Heart Failure (MLHF) 
questionnaire was an independent predictor of cardiac events and death. Furthermore 
Pedersen (2007) concluded that poor MacNew outcomes were a predictor of early death/MI 
but not late death/MI. Likewise, Agewall (2012) stated that a low self-estimated HRQoL was 
associated with poor outcome after MI. Even a single question assessing the general health 
perceptions was a significant predictor of mortality (Burstrom et al, 2001; DeSalvo et al, 
2006). According to De Salvo (2006), compared to patients in excellent health, patients with a 
poor self-rated health had a 2-fold greater mortality.  
Research on the link between physical and mental well-being and cardiovascular outcome is 
still on-going. Two main directions concerning the link can be distinguished. First, impaired 
patient reported outcomes can cause a coronary event, and secondly CHD patients are more 
prone to develop depressive and anxious feelings and to have impaired functional status or 
HRQoL outcomes. Several possible mechanisms, explaining the link have been proposed. 
First of all CHD risk factors such as smoking, high cholesterol, hypertension, diabetes and 
obesity tend to cluster in depressed patients putting them at higher risk for developing a 
cardiac event (Joynt et al, 2003; Pozuelo et al, 2009). Moreover, clinical depression can 
increase noncompliance with medical treatment and lifestyle changes (Joynt et al, 2003; 
Pozuelo et al, 2009). Due to the outlook of hopelessness, depressed patients often have no 
confidence in the benefits of CHD treatment, furthermore they also seem to be more sensitive 
to adverse events and are thus more likely to discontinue medication use (Gehi et al, 2005). 
According to Kurdyak (2011), self-reported cardiac functional health status may serve as a 
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key causal pathway explaining the association between depression and mortality after AMI 
with functional capacity, in particular physical inactivity being a predictor of mortality. 
In addition to these behavioural patterns, some physiologic changes are observed in 
depressive patients. We shortly address the main pathways. Stress induces a decreased 
parasympathetic and increased sympathetic nervous system activity (autonomic nervous 
system dysfunction). This imbalance is associated with decreased heart rate variability, which 
is a risk factor for arrhythmia and sudden cardiac death. Furthermore, hyperactivity of 
hypothalamus pituitary-adrenal axis is seen in depressed  patients leading to increased cortisol 
levels. Although this is an important beneficial effect in response to stress, chronic stress will 
lead to chronically elevated cortisol levels increasing the risk of CVD trough adverse 
metabolic effects (visceral obesity, insulin resistance, endothelial dysfunction, increased 
LDL-cholesterol and triglyceride levels and increased intake of comfort food). On the other 
hand, sympathoadrenal activation -often seen in depressed patients- can lead to increased 
levels of catecholamines, causing vasoconstriction, a rapid heart rate, and platelet activation. 
The activation of platelets (platelet factor IV and beta-thromboglobulin) can induce vascular 
damage and thrombosis. Finally, an increase in inflammatory markers is observed in 
depressed patients which is associated with atherosclerosis and hence CHD (Celano et al, 
2011; Joynt et al, 2003; Pozuelo et al, 2009).  
1.4 RELEVANCE OF HEALTH-RELATED QUALITY OF LIFE 
As mentioned above, the use of patient reported outcome measures has increased over the 
years. Such assessment is useful in evaluating a medical treatment in clinical research, but can 
just as easily be used in daily clinical practice to identify health needs or to measure disease 
impact. Hence, by monitoring changes and outcomes in self-reported health among patients, 
treatment plans can be adjusted where needed (Mayou et al, 1993). The more objective 
clinical outcomes are not always a reflection of how a disease, its symptoms and treatment are 
experienced by the patient (Guyatt et al, 1993). Pain for example is difficult to capture with 
the conventional measures. In addition, great differences have been observed in health status 
outcomes between patients with the same clinical profile, stressing the importance of 
assessing patient’s self-perceived health in order to adjust treatment accordingly. Health status 
and HRQoL information can also be helpful for audit purposes, and for assessing the quality 
of delivered health care. Finally, these measures can also be used in health policy decision 
making (Guyatt et al, 1993; Mayou et al, 1993). Scarce health care resources have led to the 
development of health economic evaluations. These are used as decision making tool in order 
to maximize health benefits with the available financial means. Health benefits are often 
expressed as a combination of patients’ prolongation of life and their self-perceived health 
status during that time period. Health economic analyses might be particular important to 
assess the cost-effectiveness ratio of CHD prevention. As discussed above, CHD is a major 
cause of health care expenses and impaired health status and HRQoL outcomes. CHD 
prevention can help to reduce the morbidity and mortality burden associated with the illness. 
Health economic analyses are useful in prioritizing policy goals and allocating resources to 
the most appropriate intervention. 
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1.5 AIMS AND SCOPE OF THIS STUDY 
The general aim of this thesis was to focus on functional status and psychological well-being 
using a large database of stable coronary patients, the EUROASPIRE III survey. Figure 2 
gives a conceptual overview of our research questions. Despite the conceptual difference 
between health status and HRQoL as discussed above, we will talk about HRQoL and 
psychological distress in the remainder of this thesis to indicate the three measures (EQ-5D, 
SF-12, HADS) used. 
To start, we investigated whether the three instruments (EQ-5D, SF-12 and HADS) used were 
valid and reliable within the EUROASPIRE III sample (chapter 3). Some studies have already 
performed psychometric analyses in CHD patients, however often based on smaller samples, 
or samples of acute CHD patients. Furthermore, the interpretation of the  outcomes is difficult, 
if not impossible in the absence of reference values from the general population, hence, EQ-
5D results from the EUROASPIRE III sample were compared with published country-
specific normative values (chapter 4). 
The primary purpose of this thesis however, was to investigate the association between CHD 
and HRQoL/psychological distress, and to determine the factors possibly responsible for 
HRQoL/psychological distress impairments. Prior studies have found an association between 
impaired HRQoL, anxiety, depression and worse long-term cardiovascular outcomes (Thombs 
et al, 2008; Spertus et al, 2002; Kurdyak et al, 2011). Hence, investigating the association 
between cardiovascular risk profiles in CHD patients and their HRQoL/psychological distress, 
as well as investigating the relationship between risk factor level awareness and 
HRQoL/psychological distress can be important both for patients and families, for health-care 
providers, as well as for decision makers in order to tailor patient treatment and policy goals 
accordingly. 
First of all, we hypothesised that patient characteristics and their cardiovascular risk profile 
(chapter 5) would be associated with their HRQoL outcomes. We investigated the influence 
of geographical location on HRQoL in CHD patients. Furthermore we assessed whether there 
was a significant association between predisposing risk factors (age, gender, educational level 
and cardiovascular history) and HRQoL. Likewise the association with metabolic (BP, TC, 
LDL-C, fasting glucose and HbA1c) and behavioural risk factors (smoking, physical activity 
and healthy diet) was investigated. We hypothesized that poor cardiovascular risk profiles 
would be associated with worse HRQoL outcomes in coronary patients. Within the general 
population, patient characteristics are significantly associated with HRQoL outcomes, with 
increasing age, female gender, low education, diabetes, obesity and cardiovascular events 
being associated with worse outcomes (Franco et al, 2012; Martinelli et al, 2008). Similarly, 
smoking and physical inactivity are associated with impaired HRQoL results (Piper et al, 
2012; Bize et al, 2007). With regard to metabolic risk factors, a significant association 
between HRQoL and hypertension has been reported in coronary patients, whereas no 
association was found with hypercholesterolemia (Soini et al, 2010; Sevinc et al, 2010; 
Herlitz et al, 2005).  
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Figure 2: Research questions addressed within this thesis. The blue rounded squares indicate the 
investigated topics. The pink arrow shows what is already known from the literature. The dotted orange 
line indicates how HRQoL and psychological distress can be used in practice. 
Additionally, we investigated the association with behavioural changes. Lifestyle changes are 
directly related to risk factors and cardiovascular prognosis (Yusuf et al, 2004). We 
hypothesized that coronary patients who have not made an attempt to change their behaviour 
in order to adopt a healthier lifestyle would also have worse HRQoL/psychological distress 
outcomes (chapter 6). Indeed, in the general population smoking cessation is associated with 
improved HRQoL/psychological distress outcomes. Piper et al (2012), has found a fast 
improvement after cessation that sustained over at least 3 years, whereas Within the Nurses’ 
Health Study, HRQoL scores improved gradually with longer time since quitting (Sarna et al, 
2008). Likewise improvements in physical activity seem to be associated with better HRQoL 
outcomes (Martin et al, 2009; Bize et al, 2007). In addition to the studies performed in the 
general population, some studies report on these findings in coronary patients, however, the 
sample size is often limited and geographical areas are often restricted to a single region or 
country. 
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Moreover, we hypothesized that risk factor awareness in CHD patients would be associated 
with improved HRQoL/psychological distress outcomes (chapter 7). We investigated the 
association between risk factor level awareness in patients and their HRQoL/psychological 
distress, and searched for different pathways possibly explaining the association. This issue 
has not yet been addressed previously in CHD patients. In the general population hypertensive 
patients who were aware of their elevated BP had worse HRQoL/psychological distress 
outcomes, compared to those persons unaware of their hypertension. Furthermore, a higher 
sick leave is reported in such patients (Mena-Martin et al, 2003). 
Secondly, we investigated the interchangeability between two different HRQoL measures in 
our sample of coronary patients: the EQ-5D and the SF-12 (chapter 8). Both measures allow 
calculating a utility value, which can be used in health-economic evaluations. A recent study 
by Joore et al. (2010) reported remarkable differences in cost-effectiveness results, depending 
on the instrument used. Patients with mild health conditions had higher SF-6D scores, 
whereas patients with severe conditions had higher EQ-5D scores. This leads to better or 
worse cost-effectiveness outcomes, depending on the HRQoL instrument used. The 
incomparability of the results using different instruments poses a real threat on the usefulness 
and credibility of cost-effectiveness analyses. Within our knowledge, only one study reports 
on the comparison between EQ-5D utility values and SF-36 utility values in a sample of 
coronary patients (van Stel et al, 2006).  
Finally, the usefulness of HRQoL as policy tool was tested. The individual EQ-5D utilities 
from the EUROASPIRE III sample were used to calculate the cost-effectiveness of optimal 
cardiovascular prevention in coronary patients. Whereas many studies already reported on the 
cost-effectiveness of single prevention strategies, none conducted an integrated tailor-made 
cost-effectiveness analysis on secondary cardiovascular prevention targeting different 
intervention strategies simultaneously, adapted to the current prevention status of patients 
(chapter 9). 
In summary, the outline of the thesis is as follows: 
 Chapter 1 gives an introduction regarding the research questions.  
 Chapter 2 reports on the methodology used throughout the doctoral thesis. 
 Chapter 3 investigates the psychometric properties of the EQ-5D, SF-12 and HADS 
instrument in order to assess the validity and reliability of these tools in stable 
coronary patients .  
 Chapter 4 reports on the comparison in EQ-5D outcomes between coronary patients 
and the normative population.  
 Chapter 5 examines the relationship between the cardiovascular profile of coronary 
patients and their EQ-5D and SF-12. 
 Chapter 6 explores the relation between several self-reported lifestyle changes and 
EQ-5D, SF-12 and HADS  outcomes in coronary patients.  
 Chapter 7 investigates the association between risk factor level awareness among 
patients and their EQ-5D, SF-12 and HADS. 
 Chapter 8 assesses the inter-changeability between EQ-5D and SF-12 utility outcomes. 
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 In chapter 9, we assessed the cost-effectiveness of secondary prevention in coronary 
patients.  
 The general discussion presented in chapter 10 provides a brief summary of the main 
findings, and subsequently proceeds with a profound discussion, evaluating the 
possible consequences for clinical practice. 
Previous research has reported on the significant association between HRQoL/psychological 
distress and cardiovascular outcome. Within this PhD thesis, we further investigated the 
association between risk factor profile, lifestyle changes and risk factor level awareness and 
HRQoL/psychological distress in CHD patients. Furthermore some theoretical concepts were 
investigated: validity and reliability of the instruments, and comparison of 
HRQoL/psychological distress outcomes between CHD patients and the general population. 
Finally, the usefulness of HRQoL instruments in decision making was investigated. First, by 
analysing the interchangeability between instruments and secondly, by performing a cost-
effectiveness study of secondary prevention in the EUROASPIRE sample. 
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Chapter 2. 
General methodology 
 
2.1 EUROASPIRE III: STUDY DESIGN 
Analyses included in this thesis are based on EUROASPIRE III (European Action on 
Secondary and Primary Prevention Through Intervention to Reduce Events) data. In order to 
evaluate the guideline implementation in daily practice, the European Society of Cardiology 
(ESC) has carried out several surveys during the latest decades. The first EUROASPIRE 
survey, conducted in 1995-1996 was based on a previously conducted survey in the UK 
(1995-1996), the ASPIRE (Action on Secondary Prevention through Intervention to reduce 
Events) survey (Bowker et al, 1996). EUROASPIRE I was carried out in 21 centres across 
nine European countries (Czech Republic, Finland, France, Germany, Hungary, Italy, the 
Netherlands, Slovenia and Spain). The purpose of EUROASPIRE I, was to assess whether the 
guidelines published in 1994 on prevention of Coronary Heart Disease (CHD) in clinical 
practice were being followed (EUROASPIRE Study Group, 1997; Pyorala et al, 1994). In 
1998 an update of the guidelines was published, hence a second survey (1999-2000) was 
carried out, including 47 centres from 15 countries (EUROASPIRE I + Belgium, Greece, 
Ireland, Poland, Sweden, UK). The aim of EUROASPIRE II was to investigate whether 
clinical practice was changing to achieve the full potential benefits of CHD prevention 
(EUROASPIRE II Study Group, 2001; Wood et al, 1998). 
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Both surveys indicated a high prevalence of unhealthy lifestyles, modifiable risk factors and 
inadequate use of drug therapies, with great variation across countries. Moreover a substantial 
increase in obesity, and smoking among younger patients was seen when comparing both 
surveys (EUROASPIRE I and II Group, 2001). Hence, there was a need to raise the standard 
of preventive cardiology through more effective lifestyle interventions, control of other risk 
factors and appropriate use of cardio-protective medication. 
After publishing the third revision of the ESC guidelines (De Backer et al, 2003) on 
cardiovascular prevention, EUROASPIRE III was conducted in 76 hospital centres across 22 
countries (EUROASPIRE I + Belgium, Greece, Ireland, Poland, UK, Bulgaria, Croatia, 
Cyprus, Latvia, Lithuania, Romania, Russian Federation, Turkey). The participating countries 
represent different geographical areas of Europe with large differences in the organization of 
medical care and economic resources. Only those areas with a large defined population (> 
half a million of people) were selected. Within the selected area, at least one hospital offers 
interventional cardiology and cardiac surgery and one or more hospitals offer acute care for 
patients with acute myocardial infarction (AMI) and ischemia.  
Patients, men or women, aged ≥18 years and <80 years at the time of identification, 
hospitalized for a first or recurrent clinical diagnosis or treatment were identified 
retrospectively from diagnostic registers, hospital discharge lists or other sources. Eligible 
patients were patient hospitalized for: 
- an elective or emergency Coronary Artery Bypass Graft surgery (CABG), with the 
exclusion of surgery in the context of valve replacement, or when the primary 
diagnosis is not coronary artery disease 
- an elective or emergency Percutaneous Coronary Intervention (PCI), both stents or 
other devices 
- a first or recurrent acute myocardial infarction (AMI), ST elevation and Non ST 
elevation myocardial infarction (MI) 
- an acute myocardial ischemia with no evidence of infarction (Troponin negative).  
Patients were interviewed and examined at least 6 months and not later than 3 years after their 
index hospital admission. Data collection was organized using standardized methods and 
instruments. To capture information from the index hospital admission, trained research staff 
reviewed patients’ medical records. Personal and demographic details as well as personal 
cardiovascular history, including stroke and transient ischaemic attack were extracted from the 
medical records. Furthermore information on other medical history, including hypertension, 
hyperlipidaemia and diabetes were obtained. Recorded measurements of blood pressure (BP), 
diabetes, lipids and smoking status and medication (generic name and total daily dose) were 
gathered if available. 
At interview, structured questionnaires were used to collect personal and demographic details; 
personal cardiovascular history, including stroke, transient ischaemic attack and peripheral artery 
disease; other medical history, including hypertension, hyperlipidaemia and diabetes; family 
history of CHD for patients with premature disease (men <55 years and women <65 years); 
reported lifestyle and other risk factor management in relation to smoking, diet (including weight 
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reduction), exercise, BP, lipids and glucose; medication (generic name and total daily dose); and 
level of education, school attendance and employment status. 
The following measurements were performed: height (Seca MEASURING Stick model 220) and 
weight (SECA scale model 701) in light indoor clothes without shoes and calculated body mass 
index (BMI=weight/height²); waist circumference (metal tape measures); BP (Omron M5-I 
automatic digital sphygmomanometer; Omron Healthcare, Japan) was measured twice in a 
sitting position on the right upper arm and the mean of the two measurements was used in the 
analyses; heart rate; venous blood for serum total cholesterol (TC), high density lipoprotein-
cholesterol (HDL-C), triglycerides, calculated low density lipoprotein-cholesterol (LDL-C) 
according to the Friedewald formula (=TC - HDL-C - (triglycerides/5)), plasma glucose and 
glycated haemoglobin (HbA1c) in patients with diabetes; breath carbon monoxide (Smokerlyser 
Bedfont Scientific, Model Micro 4; Bedfont scientific Ltd., Rostester, Kent, UK); validated self-
administered questionnaires: Hospital anxiety and depression scale (HADS) (Zigmond et al, 
1983); EuroQoL-5D (EQ-5D) (Rabin et al, 2001), 12- item Short Form Health Survey (SF-12) 
(Ware et al, 2002) and international physical activity questionnaire (IPAQ) (IPAQ core group, 
2005). 
The risk factor targets used, were based on the third joint European guidelines on cardiovascular 
prevention (De Backer et al, 2003). A raised BP was defined as systolic blood pressure 
(SBP)/diastolic blood pressure (DBP) ≥140/90 mmHg (≥130/80 mmHg in patients with 
diabetes). An elevated TC was defined as TC ≥4.5 mmol/L. Raised LDL-C was defined as LDL-
C ≥2.5 mmol/L and low high density lipoprotein-cholesterol (HDL-C) was defined as HDL-C 
<1/1.2 mmol/L for men/women. Raised fasting glucose was defined as fasting glucose ≥6.1 
mmol/L among patients with self-reported diabetes and raised HbA1c as HbA1c ≥6.5% among 
patients with self-reported diabetes. Low physical activity was defined as less than 20 min 
moderate physical activity, three times a week. Central obesity was defined as waist 
circumference >102/88 cm (men/women). The World Health Organisation (WHO) classes 
were used for BMI classification: normal range was defined as BMI <24.9 kg/m²; overweight 
was defined as BMI between 25 kg/m² and 29.9 kg/m², and obesity as BMI ≥30 kg/m². 
Smokers were those who reported to be a current smoker or who had a carbon monoxide in 
breath value exceeding 10 ppm at the time of the interview. IPAQ classes were calculated 
according to the guidelines for data processing and analysis (IPAQ core group, 2005). A low 
IPAQ score was defined as no activity or some activity reported but not enough to meet the 
other categories. A moderate IPAQ score was defined as 3 or more days of vigorous-intensity 
activity of at least 20 minutes per day, or 5 or more days of moderate intensity activity and/or 
walking of at least 30 minutes per day, or 5 or more days of any combination of walking, 
moderate-intensity, or vigorous-intensity activities achieving a minimum total physical 
activity of at least 600 MET-minutes/week. Metabolic equivalent (MET) is a common 
outcome measure used to express the energetic expenditure of different physical activities. A 
high IPAQ score was defined as vigorous-intensity activity on at least 3 days and 
accumulating at least 1500 MET-minutes/week or 7 or more days of any combination of 
walking, moderate- or vigorous- intensity activities accumulating at least 3000 MET-
minutes/week. Patient were asked to describe their self-perceived physical activity level on 
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the following scale: no physical activity; light physical activity; vigorous physical activity for 
20 minutes, 2 or 3 times a week; or vigorous physical activity for 20 minutes >3 times a week. 
Of the 13,935 patients eligible for the survey, 8966 (participation rate=73%) were interviewed 
and examined at least 6 months and not later than 3 years after their index hospital admission 
(median=1.24 year). Full information on EQ-5D and/or SF-12 and/or HADS was available for 
8745 patients. The results of EUROASPIRE III revealed that a substantial proportion of CHD 
patients did not achieve the goals as put forward in the guidelines on cardiovascular 
prevention (Kotseva et al, 2009b). Overall, at the time of interview, the prevalence of 
smoking was 17%, although most smokers had received advice to quit smoking, 52% of 
patients smoking at the index event, were still smoking at the time of the interview. About 35% 
of CHD patients were obese and 53% of patients were centrally obese. In order to lose weight, 
52% of obese patients had undertaken dietary actions and 38% had increased their physical 
activity level since their index event. However, more than 1 in 3 obese patients had not 
undertaken any action to lose weight. Furthermore, 56% of patients had an elevated BP, 51% 
had an elevated TC and 25% of patients reported having diabetes (Kotseva et al, 2009b). 
Great variations were seen across countries. 
Comparison of the different EURASPIRE surveys, indicated a time trend, calling for a more 
effective lifestyle management of patients with CHD. Although the proportion of smokers 
remained the same, the proportion of female smokers <50 years had increased. Furthermore, 
the frequency of obesity as well as the frequency of self-reported diabetes has increased over 
the years. In contrast, the proportion of patients with a raised BP has remained similar, and the 
proportion of patients with an elevated TC has decreased substantially over the three surveys 
(Kotseva et al, 2009a). 
2.2 HEALTH ECONOMIC EVALUATION 
Health economic evaluations compare several treatment modalities designated to treat a 
certain disorder, e.g. comparing a new therapy with the current treatment method. Both costs 
as well as consequences are compared (cost per unit of health effect). The costs are often 
limited to direct medical costs, including the expenditures made by patients, health insurance 
or government. The consequences, effects or outcomes of a certain treatment strategy can be 
expressed in several ways such as for example: number of life years gained, number of 
symptom-free days, points of BP reduction, or quality adjusted life years (QALY’s). The 
latter combines both the quantity and quality of life. HRQoL outcomes, expressed as utility 
values, simply known as utilities, are used to calculate QALY’s. Utilities usually range 
between 0 (death) and 1 (perfect health), although values below 0 exist (health states that are 
perceived worse than death). A variety of tools can be used to assess utilities e.g. EQ-5D; 
Quality of well-being scale (QWB); Health Utility Index (HUI); 6 dimensional health state 
classification (SF-6D); 15 dimensional instrument (15D); Assessment of Quality of Life 
(AQol). Despite the discussion concerning different cost-utility outcomes, depending on the 
utility measure used, the general advice on cost-utility analyses is to make use of EQ-5D 
utility values whenever possible (National Institute for Health and Care Excellence, 2013). 
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QALY’s are calculated by multiplying this utility value with the number of life years a patient 
spends in a certain utility state. 
The incremental cost-effectiveness ratio (ICER) is calculated as the ratio of the difference in 
cost between both treatments and the difference in QALY’s between the two treatments 
(Drummond et al, 2005).  
     
(               )
(               )
 
ICER= incremental cost-effectiveness ratio 
C= costs 
E= effect/outcome often expressed as QALY’s 
A higher ratio indicates a worse result for the new treatment modality. Whether or not a 
treatment will be considered cost-effective, depends on the willingness of the society to pay  
for each additional year in perfect health (1 QALY). Depending on the geographical area 
different willingness-to-pay thresholds are being used. According to the WHO, the wealth of a 
country should determine the cost-effectiveness threshold. Hence, a ICER below the Gross 
Domestic Product (GDP) per person in a given country can be considered as cost-effective. In 
western European countries a cost-effectiveness threshold of 30,000€/QALY is frequently 
used (Annemans, 2008).  Often a range is being applied. The UK uses an ICER threshold 
range of £20,000 to £30,000 per QALY. Some countries use an ICER threshold based on 
passed resource allocation decision, such as Australia: AU$69,9000/QALY; New Zealand: 
NZ$20,000/QALY; Canada: acceptance range: <CAN$80,000/QALY; rejection range: 
CAN$31,000 to CAN$137,000 per QALY. In the USA a threshold of $50,000/QALY and  in 
the Netherlands a threshold of 80,000€/QALY is proposed (Cleemput et al, 2008) 
To goal of todays health care is to produce health. In the past, decisions about reimbursement 
of/ investment in therapeutic or preventive actions were not always organized in a consistent 
matter. They were often taken because ‘this is what we did last time’, or based on ‘an 
educated guess’ (Drummond et al, 2005). With the increasing health care expenses in many 
countries, health care payers need to find adequate ways for decision making. Within most 
countries attempts are being made to standardize the decision making regarding investment 
and reimbursement, by defining a set of criteria. In addition to effectiveness, safety, social 
need and feasibility, more interest is going to cost-effectiveness and budget impact (Cleemput 
et al, 2008; World Health Organisation, 2013b). However decision making remains a complex 
process, not only based on rational assessment of problems, alternatives or best solutions but 
also on political considerations (Cleemput et al, 2008).  
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Abstract 
Objective: To investigate the validity and reliability of the EuroQol 5D (EQ-5D), the 12 item 
Short Form Health Survey (SF-12), and the Hospital Anxiety and Depression Scale (HADS) 
in a stable coronary population.  
Study design: Cross-sectional study EUROASPIRE III.  
Setting: Health-related quality of life (HRQoL)/psychological distress data were available on 
8745 patients hospitalized for coronary artery bypass graft (CABG), percutaneous coronary 
intervention (PCI), acute myocardial infarction (AMI), or myocardial ischemia. They were 
interviewed and examined at least 6 months after their hospital admission. Reliability and 
validity of the 3 instruments were tested. Internal consistency, and discriminative, convergent, 
criterion and construct validity were assessed.  
Results: Cronbach's alpha indicated good internal consistency for all measures (0.73 to 0.87). 
Discriminative validity analyses confirmed significant HRQoL/psychological distress 
differences between known groups: age, gender, educational level. In addition, all 
hypothesized correlations between HRQoL/psychological distress constructs (convergent 
validity) and items (criterion validity) were confirmed with significant correlations. 
Confirmatory factor analyses indicated good construct validity for HADS and SF-12. On 
country-specific level, results were roughly similar.  
Conclusion: The EQ-5D as well as the SF-12 and the HADS are reliable and valid 
instruments for use in a stable coronary population, both on aggregate European level and on 
country-specific level. However, our results must be generalized with caution, because 
EUROASPIRE III patients might not be representative for all patients with stable coronary 
heart disease. 
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1. Introduction 
Due to improved cardiovascular prevention and management, coronary heart disease (CHD) 
death rates have decreased in Western, Northern, and Southern European countries during the 
last decades (Allender et al, 2008; Leal et al, 2006). Despite this reduction, CHD remains the 
most common cause of disease burden throughout Europe. Conventional medicine focuses 
mainly on clinical measures and functional outcomes; however, the use of health-related 
quality of life (HRQoL) instruments has become increasingly important to assess the patient's 
emotional, social and physical well-being (Celano et al, 2011; Cepeda-Valery et al, 2011). 
Patients suffering from CHD are likely to have an impaired HRQoL, due to pain, anxiety, 
functional and social limitations (Dyer et al, 2010; Mols et al, 2009; Thombs et al, 2006; Xie 
et al, 2008). Although still under debate, several studies have observed a relationship between 
HRQoL, depression, anxiety and worse long-term health outcomes (Burstrom et al, 2001; 
DeSalvo et al, 2006; Meijer et al, 2011; Nicholson et al, 2006; Roest et al, 2010). Many 
HRQoL measures are available, and most of them have been comprehensively tested in the 
general population with regard to their reliability and validity. In addition, different studies 
have assessed the psychometric properties of HRQoL instruments in various disease-specific 
samples, including CHD patients; however in general, cross-European data were limited 
(Bjelland et al, 2002; Coons et al, 2000; Cosco et al, 2012; Haywood et al, 2005).  
Within the EUROASPIRE III program (EUROpean Action on Secondary and Primary 
Prevention through Intervention to Reduce Events), a multicentre European survey developed 
to assess how clinical guidelines on cardiovascular disease prevention are implemented 
throughout Europe, HRQoL/psychological distress assessment was performed on the basis of 
3 questionnaires: the EuroQol-5D (EQ-5D) (The EuroQol Group, 1990; Rabin et al, 2011), 
the 12-item Short-Form Health Survey (SF-12) (Ware et al, 1996), and the Hospital Anxiety 
and Depression Scale (HADS) (Zigmond et al, 1983). 
EQ-5D is a widely used simple, generic instrument to measure health in a standardized way. 
The measure is applicable to a wide range of conditions and treatments and contains a self-
classifier and a visual analogue scale. Based on the self-classifier, a single index value can be 
calculated, representing the overall health status (Rabin et al, 2011; Rabin et al, 2001). 
Another commonly used health status questionnaire is the SF-12, a downsized version of the 
SF-36 and therefore useful for large studies. The measure allows to calculate a Physical 
Component Summary (PCS-12) score and a Mental Component Summary (MCS-12) score 
(Ware et al, 1996). In addition to these general health measures, specific instruments are 
available for assessing anxiety, depression or depressive symptoms; feelings that are highly 
common in coronary patients (Roest et al, 2010; Thombs et al, 2006). In order to adapt 
treatment accordingly, screening for depressive feelings and anxiety is important. The HADS 
instrument permits to calculate both anxiety (HADS-A) and depression (HADS-D) scores.  
The present study investigates the psychometric properties of the EQ-5D, SF-12 and HADS 
instruments in a large multi-country European cross-sectional sample of coronary patients, the 
EUROASPIRE III survey. 
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2. Methods 
Study population and data collection 
Analyses were based on data gathered during the EUROASPIRE III survey. The details of the 
study have been reported elsewhere (Kotseva et al, 2009b). In brief, EUROASPIRE III, 
performed in 2006–2007 among patients with established CHD, is a cross-sectional study 
aimed at determining whether the European recommendations of cardiovascular disease 
prevention are being followed in daily practice. Patients, aged 80 years or less, hospitalized 
for coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), acute 
myocardial infarction (AMI) or myocardial ischemia were retrospectively identified from 
diagnostic registers, hospital discharge lists or other sources at 76 different hospital centres in 
22 European countries: Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Poland, Romania, Russia, 
Slovenia, Spain, The Netherlands, Turkey, and the United Kingdom (UK). Data collection 
was conducted by trained research staff using standardized methods and instruments. Of the 
13,935 patients identified, 8966 were interviewed and examined at least 6 months and not 
later than 3 years after their index hospital admission. In addition to the collection of disease 
related clinical measures, patients were asked to fill in 3 self-administered questionnaires 
related to HRQoL and perceived overall health status: EQ-5D, HADS and SF-12. In each 
country, questionnaires were administered in the official language. EQ-5D contains a self-
classifier (EQ-5Dindex) and a visual analogue scale (EQ-VAS). The former is made up of five 
Likert-scale items covering the following dimensions: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. A single summary index, according to the weighting 
system derived by Dolan (Dolan, 1997) is derived from the answers given on the self-
classifier; with 1 representing perfect health, 0 representing death, and <0 representing a 
health state perceived worse than death (Dolan, 1997; Rabin et al, 2001). The EQ-VAS is a 
20-cm vertical scale, ranging between 0 (worst imaginable health state) and 100 (best 
imaginable health state) on which the respondent is asked to indicate how good or bad his or 
her health is today. The SF-12 consists of 12 questions, with 3 to 5 response levels, and is 
intended to asses both physical and mental functioning, represented by a Physical Component 
Summary (PCS-12) score and a Mental Component Summary (MCS-12) score respectively. 
The PCS-12 and MCS-12 scores were calculated based on a US general population scoring 
algorithm (Ware et al, 2002). Results are represented by a value ranging between 0 and 100, 
with 0 representing the lowest level of health and 100 the highest level of health. The SF-12 
was not administered in Hungary. In Germany, the SF-36 was used instead of the SF-12; 
however, an overall physical and mental component score could be calculated using the SF-12 
items embedded in the SF-36. The HADS, intended for use in a hospital setting, contains 14 
items, each with a four-point response scale. Seven items are related to anxiety and the other 7 
items to depression. The instrument gives information about possible or probable anxiety or 
depressive feelings, but it is not appropriate in screening for clinical depression. Item scores 
can be added to obtain the summary scores on anxiety (HADS-A) and depression (HADS-D) 
separately. The total score on each subscale ranges between 0 and 21. A score <8 can be 
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considered as being in the normal range, higher scores can indicate a possible or probable 
disorder (Stafford et al, 2007; Zigmond et al, 1983). 
Psychometric analyses 
Psychometrics aims to evaluate the reliability and validity of measures by assessing the 
characteristics of scales (Hays et al, 1993). Stratification by country, gender, age and 
educational level was performed. Four age groups were considered: <50 years, 50–59 years, 
60–69 years and >70 years. And 3 educational levels were used: primary education, defined 
as primary school or less; secondary education, defined as secondary school completed, high 
school completed or intermediate between secondary level completed; and high education, 
defined as a university/college degree or equivalent. Patient records for which no summary 
score could be calculated were excluded from the analyses. 
Reliability 
Internal consistency of the EQ-5D self-classifier, PCS-12, MCS-12, HADS-A and HADS-D 
was examined using the Cronbach's coefficient alpha (Hays et al, 1993). A threshold of 0.7 
was considered acceptable, a value >0.8 indicated good internal consistency, and a value >0.9 
indicated excellent internal consistency (Nunnally & Bernstein, 1994).  
Validity 
Confirmatory factor analysis (CFA) for the SF-12 and HADS measures was conducted in 
order to test whether the original scale construct was confirmed in this sample. No CFA was 
performed for EQ-5D since this measure does not include different theoretical constructs. The 
Weighted Least Squares Mean and Variance adjusted (WLSMV) estimation method was used 
for ordinal data. Multiple goodness of fit tests were used, including the Root Mean Square 
Error of Approximation (RMSEA), the Comparative Fit Index (CFI) and the Tucker–Lewis 
Index (TLI). Since it is well known that the overall χ² fit index is largely influenced by sample 
size, tending to over-reject models with large sample size, this index was not used in drawing 
conclusions (Hu et al, 1999). For CFI and TLI, a threshold value >0.9 was considered as a 
good fit (Bentler et al, 1980). Whereas for the RMSEA, a value <0.06 was considered as a 
good fit, a value <0.08 was considered as an acceptable fit and a value >0.1 led to rejection of 
the model (Brown et al, 1992; Hu et al, 1999). Factor loadings represent the correlation 
between observed variables and extracted components. Standardized factor loadings >0.5 
were perceived as good, loadings >0.4 indicated an acceptable correlation and those <0.4 
were perceived as not good. Discriminative validity was examined with the known-group 
method by assessing the relationship of the HRQoL constructs with age, gender and education. 
Non-parametric tests (Kruskall–Wallis) were used due to the skewed nature of the data. We 
hypothesized that HRQoL would decrease with age and lower education, and would be lower 
in female patients. Convergent validity was evaluated with the Spearman's correlations for 
theoretically correlated constructs. Constructs capturing similar functional or emotional 
characteristics were expected to highly correlate with one another. Correlations <0.3 were 
considered as negligible, a value between 0.3 and 0.5 as moderate and >0.5 as strong (Cohen, 
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1988). It was hypothesized that MCS-12 would correlate with HADS-A and HADS-D and 
that the two HADS scales would correlate with each other. Furthermore, it was expected that 
the EQ-5Dindex would correlate with PCS-12 and MCS-12. In addition, the EQ-VAS was 
considered as the criterion for overall health; hence, a correlation between EQ-VAS and PCS-
12, MCS-12 and EQ-5Dindex was expected. Likewise, the first question of the SF-12 
instrument (SF-12/1), asking about the general state of an individual's health, was also 
considered as a criterion of overall health. The SF-12/1 was hypothesized to correlate with 
EQ-5Dindex and the EQ-VAS. Similarly the EQ-5D anxiety/depression item and question 6c of 
the SF-12 item (SF-12/6c) “Have you felt downhearted and depressed?” were considered as 
an overall criterion for anxiety and depression. Therefore, these items were expected to 
correlate with both HADS-A and HADS-D. All the analyses were performed using IBM 
SPSS 19, except the CFA, which was conducted using M-plus version 6.11. 
3. Results 
General characteristics 
The patient characteristics are presented in Table 1. In total, data on 8745 patients from 22 
European countries are included in the psychometric analyses, ranging from 120 Greek 
patients to 550 patients from Germany. The majority of the patients were male (74.6%) and 
their mean age was 63.2 ±9.5 years. Regarding educational level, about a quarter (25.3%) of 
the patients had a primary education. More than half (56.7%) of the patients had a secondary 
education and 18.0% had a higher education. Mean values of the different HRQoL scales and 
subscales are shown in Table 2. Intraclass correlation coefficients (ICCs) were calculated for 
all HRQoL measures, in order to assess the proportion of variance due to the grouping 
structure on country-level. ICCs indicated a significant proportion of variance that could be 
assigned to the countries. Variation in HADS-A and HADS-D scores amounted to 5.70% and 
5.37% respectively. For EQ-5D and EQ-VAS, ICC values of 4.92% and 8.26% were observed 
respectively. Country grouping explained 8.44% and 5.67% in the variation of PCS-12 and 
MCS-12 scores respectively.  
Reliability 
The overall Cronbach's alpha for the EQ-5D self-classifier equals 0.73, indicating an 
acceptable internal consistency of the measure (see Table 3). The variation between countries 
ranged between 0.58 and 0.82. Ten countries had a value <0.70, indicating less acceptable 
internal reliability. The SF-12 subscales had higher Cronbach's alpha values with an overall 
value of 0.87 and 0.84 for PCS-12 and MCS-12 respectively. Country-specific values for 
PCS-12 ranged between 0.81 and 0.90, indicating good to excellent internal consistency. For 
MCS-12, Cronbach's alpha values ranged between 0.74 and 0.89, indicating acceptable to 
good internal consistency. In addition, for both HADS scales satisfying values were found 
overall, with a value of 0.82 and 0.74 for HADS-A and HADS-D respectively. For HADS-A 
Cronbach's alpha ranged between 0.73 and 0.86; for HADS-D, values fluctuated between 0.52 
and 0.82, with only 2 countries (Germany and Latvia) having a value <0.7. 
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Table 1: Patient characteristics of the EUROASPIRE population 
 
Number 
of patients 
Gender 
(%male) 
Age (mean 
±SD) 
Education level 
Primary (%) Secondary (%) High (%) 
All Countries 8745 74.6 63.2±9.5 25.3 56.7 18.0 
Belgium 281 85.4 62.4±8.8 16.3 61.6 22.1 
Bulgaria 538 69.5 64.8±10.4 3.6 63.1 33.3 
Cyprus 434 87.3 61.1±9.3 41.3 42.1 16.6 
Czech Rep. 475 79.2 62.9±8.6 3.0 80.3 16.7 
Germany 550 79.3 63.7±9.1 6.4 80.0 13.6 
Spain 505 74.7 62.0±9.7 70.3 23.9 5.8 
Finland 237 66.7 66.2±9.9 17.7 76.4 5.9 
France 303 78.3 62.2±10.4 44.9 45.9 9.2 
UK 322 73.6 63.0±9.8 8.5 66.3 25.2 
Greece 120 88.3 62.4±9.6 33.3 37.5 29.2 
Croatia 450 77.1 61.2±9.3 22.9 60.7 16.4 
Hungary 457 58.0 63.8±8.5 23.9 49.6 26.5 
Ireland 385 76.9 62.5±9.6 59.7 34.8 5.5 
Italy 377 79.3 65.2±9.1 39.9 53.2 6.9 
Lithuania 509 77.8 63.0±8.8 8.5 60.8 30.7 
Latvia 519 65.7 66.2±8.4 17.6 60.2 22.2 
Netherlands 223 81.6 64.8±8.9 26.3 67.2 6.5 
Poland 502 69.9 62.6±8.8 32.3 50.0 17.7 
Romania 521 72.6 61.7±9.8 10.4 74.4 15.2 
Russia 409 64.3 64.9±10.1 7.8 54.1 38.1 
Slovenia 293 73.0 64.8±9.7 32.1 57.7 10.2 
Turkey 335 80.6 59.8±10.1 56.7 31.4 11.9 
 
Validity 
CFA of the HADS 2-factor model suggested a good construct validity with the observed data 
fitting well with the theoretical model. The Bentler's CFI, TLI and RMSEA (0.96, 0.96 and 
0.06 respectively), indicated a good fit and factor loadings >0.55 were found, representing a 
good correlation between observed variables and extracted components. The CFA of the SF-
12 allowed for covariations between the error of the items that belong to one overall question 
(2a and 2b; 3a and 3b; 4a and 4b; 6a, 6b and 6c). Again, Bentler's CFI, TLI and RMSEA 
indices indicated acceptable to good fit (0.98, 0.98 and 0.09 respectively) and good 
correlation between observed variables and extracted components was seen with factor 
loadings ranging between 0.55 and 0.83. Known-group discriminative validity analyses 
confirmed that all HRQoL measures distinguished well between patient groups with a 
different age, gender or educational level (Table 2). Male patients had significantly lower 
HADS-A and HADS-D scores, and higher EQ-5Dindex, EQ-VAS, PCS-12 and MSC-12 scores 
compared to females. Significant differences for all measures were found between all three 
educational levels, with lower HRQoL values in lower educated patients. Higher anxiety, 
lower depression, higher EQ-5Dindex, EQ-VAS, PCS-12 and MCS-12 were found in younger 
patients compared to the older ones. On country-specific level, the above reported results 
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were roughly similar. A correlation matrix for the different constructs or items can be found 
in Table 4. All theoretically hypothesized correlations were confirmed. There was a strong 
correlation among the mental health scores HADS-A, HADS-D and MCS-12. Also, the 
overall health score EQ-5Dindex correlated strongly with PCS-12 and moderately with MCS-12. 
Table 2: Mean values of the different constructs 
 HADS-A  HADS-D  EQ-5Dindex EQ-VAS PCS-12 MCS-12 
All Countries 5.93 5.08 0.76 65.66 42.14 49.15 
Belgium 5.91 4.99 0.82 72.53 45.13 49.25 
Bulgaria 6.74 5.92 0.77 63.26 42.16 50.31 
Cyprus 4.68 3.68 0.81 69.97 47.49 52.85 
Czech Rep. 4.59 4.89 0.76 65.40 41.41 49.58 
Germany 5.29 5.64 0.76 67.66 42.47 51.37 
Spain 7.09 5.29 0.73 66.75 39.39 46.42 
Finland 4.87 4.32 0.78 74.03 38.01 53.62 
France 6.59 5.61 0.71 66.66 41.63 44.42 
UK 6.16 4.47 0.71 73.34 41.93 49.36 
Greece 6.44 4.90 0.80 68.85 46.51 50.82 
Croatia 6.64 5.22 0.73 63.74 41.21 48.21 
Hungary 6.66 5.45 0.70 66.30 - - 
Ireland 5.64 3.26 0.81 73.60 45.37 51.91 
Italy 5.10 4.23 0.86 75.08 47.08 51.43 
Lithuania 6.03 4.85 0.74 58.93 38.70 48.69 
Latvia 4.30 4.65 0.84 55.52 43.93 50.42 
Netherlands 4.28 3.40 0.85 75.74 47.08 52.77 
Poland 7.21 5.65 0.73 60.75 38.78 46.37 
Romania 5.78 4.86 0.75 69.32 41.13 49.39 
Russia 7.18 6.67 0.65 59.51 36.74 45.85 
Slovenia 7.01 6.49 0.66 62.93 40.21 46.91 
Turkey 5.96 6.01 0.77 69.13 45.73 44.08 
Significance * * * * * * 
Gender       
Men 5.48 4.75 0.78 67.85 43.20 49.93 
Women 7.24 6.01 0.69 62.22 38.82 46.75 
Significance * * * * * * 
Age       
<50 year 6.35 4.42 0.81 71.43 45.59 48.84 
50-59 years 6.12 4.73 0.77 67.48 43.31 48.94 
60-69 years 5.71 5.05 0.76 66.72 42.16 49.57 
>70 years 5.89 5.70 0.72 63.03 39.56 48.90 
Significance * * * * * * 
Education level       
Primary education 6.55 5.61 0.72 64.87 40.95 47.98 
Secondary 
education 
5.85 5.04 0.76 66.44 41.95 49.27 
High education 5.31 4.40 0.80 68.32 44.28 50.44 
Significance * * * * * * 
*  Kruskall Wallis p-value <0.0001 
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Criterion validity was confirmed for PCS-12, MCS-12 and EQ-5Dindex given the correlations 
with EQ-VAS as criterion for overall health perception. Likewise, EQ-5Dindex and EQ-VAS 
showed good correlations with the overall health criterion SF-12/1. Both HADS-A and 
HADS-D correlated moderate to strong with the individual mental health items EQ-5D 
anxiety/depression and SF-12/6c.  
Table 3: Internal consistency 
Cronbach's alpha  
  EQ-5Dindex SF-12 PCS SF-12 MCS HADS-A HADS-D 
All Countries 0.73 0.87 0.84 0.82 0.74 
Belgium 0.68 0.88 0.87 0.77 0.80 
Bulgaria 0.76 0.90 0.88 0.84 0.78 
Cyprus 0.67 0.85 0.84 0.83 0.77 
Czech Rep. 0.68 0.85 0.79 0.84 0.78 
Germany 0.67 -  -  0.80 0.52 
Spain 0.72 0.84 0.87 0.81 0.82 
Finland 0.67 0.88 0.82 0.77 0.72 
France 0.67 0.86 0.87 0.83 0.77 
UK 0.80 0.89 0.87 0.86 0.82 
Greece 0.75 0.86 0.89 0.79 0.76 
Croatia 0.75 0.87 0.84 0.82 0.77 
Hungary 0.71 -  -  0.84 0.80 
Ireland 0.67 0.86 0.80 0.81 0.72 
Italy 0.76 0.89 0.89 0.77 0.75 
Lithuania 0.66 0.87 0.80 0.77 0.70 
Latvia 0.58 0.84 0.74 0.73 0.62 
Netherlands 0.68 0.87 0.85 0.80 0.77 
Poland 0.73 0.84 0.82 0.82 0.72 
Romania 0.73 0.81 0.81 0.85 0.76 
Russia 0.74 0.88 0.85 0.79 0.70 
Slovenia 0.80 0.84 0.89 0.80 0.74 
Turkey 0.82 0.87 0.81 0.84 0.81 
 
4. Discussion 
Psychometric evaluations of the HADS, EQ-5D and SF-12 measures were performed in this 
study. Our study has the advantage that it comprises data on 8745 coronary patients, spread 
over 22 European countries. This is, to our knowledge, the largest study assessing the 
psychometric aspects of 3 different HRQoL questionnaires in a coronary population. Patients 
included were stable coronary patients, suffering from an event 6 months to 3 years prior to 
the interview. Data collection was organized in a standardized way by trained research staff, 
making the data suitable for comparison across patients and countries. Coding of the data and 
data analyses were performed in a systematic way.  
  
 
 
 
 
 
 
 
 
Table 4: Correlation between domains 
 HADS-D EQ-5Dindex EQ-5D anx/depr EQVAS PCS-12 MCS-12 SF12-1 SF12-6c 
HADS-A 0.60(0.36 to 0.73) -0.51(-0.31 to -0.61) 0.57(0.24 to 0.67) -0.36(-0.13 to -0.53) -0.34(-0.16 to -0.47) -0.59(-0.31 to -0.71) 0.36(0.11 to 0.52) -0.58(-0.32 to -0.70) 
HADS-D  -0.51(-0.22 to -0.63) 0.45(0.24 to 0.56) -0.45(-0.14 to -0.57) -0.41(-0.13 to -0.56) -0.57(-0.22 to -0.69) 0.44(0.26 to 0.56) -0.51(-0.13 to -0.63) 
EQ-5Dindex   -0.62(-0.44 to -0.81) 0.53(0.34 to 0.97) 0.64(0.48 to 0.72) 0.47(0.20 to 0.61) -0.51(-0.33 to -0.63) 0.50(0.32 to 0.56) 
EQ-5D anx/depr    -0.34(-0.25 to -0.42) -0.26(-0.10 to -0.39) -0.54(-0.42 to -0.63) 0.31(0.16 to 0.46) -0.55(-0.47 to -0.66) 
EQVAS     0.55(0.35 to 0.67) 0.41(0.23 to 0.57) -0.60(-0.48 to -0.73) 0.38(0.24 to 0.47) 
PCS-12      0.19(-0.14 to 0.44) -0.68(-0.51 to -0.75) 0.29(0.07 to 0.35) 
MCS-12       -0.38(-0.15 to -0.57) 0.76(0.63 to 0.86) 
SF12-1        -0.38(-0.24 to -0.47) 
EQ-5D anx/depr: EQ-5D anxiety/depression. All correlations are significant (p<0.05) 
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Previous studies often included analyses on only 1 single measure and in 1 specific region or 
country (Bjelland et al, 2002; Cosco et al, 2012; Ellis et al, 2005; Failde et al, 2010; 
Schweikert et al, 2006). Overall, favourable results were found, supporting the use of these 
HRQoL measures in a European coronary population. Internal consistency was confirmed for 
all the HRQoL measures with good to excellent Cronbach's alpha values for the PCS-12 scale, 
and moderate to good values for the MCS-12 scale and both HADS scales, across all 22 
countries. EQ-5Dindex Cronbach's alpha values were somewhat lower with about half of the 
countries having a value slightly below 0.70; this is possibly due to the heterogeneity of the 
questionnaire. In addition, the Cronbach's alpha is sensitive to the number of items, with a 
tendency to have a smaller value for scales with a limited number of items (Pallant, 2011). A 
good construct validity was shown for HADS and SF-12. For both HADS and SF-12, the TLI 
and CFI showed good fit. The RMSEA showed good fit for HADS and a borderline 
acceptable fit for SF-12. In addition, high factor loadings were observed, indicating a good 
correlation between observed variables and extracted components for both measures. 
Discriminative validity for all the HRQoL measures was confirmed. Higher HRQoL values as 
well as lower depression and anxiety scores were observed in men compared to women. 
These results support the findings previously reported in the literature (Berg et al, 2010; 
Cherepanov et al, 2010; Hinz et al, 2011; Johnson et al, 2000; Norris et al, 2008; Xie et al, 
2008). Likewise, in agreement with published papers, our study confirms HRQoL differences 
between groups with different educational levels, with higher EQ-VAS, PCS-12 and MCS-12 
scores among the higher educated ones (Failde et al, 2010). As expected, anxiety and 
depression scores were higher for the lower educated ones. In addition, it was shown that 
across all groups, age significantly influenced the perceived HRQoL. In general, younger 
persons had a higher anxiety score but a lower depression score. This is in line with the results 
reported by Spinhoven et al. (Spinhoven et al, 1997). Likewise, Hinz et al. reported similar 
results, with lower anxiety scores for older patients (Hinz et al, 2011). In contrast, as 
confirmed in the literature, older patients had lower EQ-5Dindex, EQ-VAS, PCS-12 and MCS-
12 scores (Berg et al, 2010; Johnson et al, 2000). Convergent validity was supported by the 
correlations found between the different constructs for which an association was theoretically 
expected. Moderate to strong correlations were observed between the SF-12 constructs and 
the EQ-5Dindex and EQ-VAS scores. Strengths were similar to the ones reported by Johnson 
and Pickard (Johnson et al, 2000). Likewise, a strong correlation was seen among both HADS 
scales and MCS-12. The strong correlation between SF-12/1 and both the EQ-5Dindex and EQ-
VAS confirmed good criterion validity for EQ-5Dindex and EQ-VAS. A similar correlation 
was seen in 2 previously published papers (Ellis et al, 2005; Schweikert et al, 2006). 
Furthermore, the EQ-VAS correlates well with the EQ-5Dindex and PCS-12 and correlates 
moderately with MCS-12. Correlations reported by Ellis et al., between EQ-VAS and the 
physical and mental components of SF-8 (a derivate from SF-36) were slightly higher (0.77 
and 0.55 respectively) (Ellis et al, 2005). The EQ-5Dindex anxiety component and the SF12-6c 
as criterion for anxiety and depression, correlated well with both HADS scales. The main 
limitation of the EUROASPIRE study is its cross-sectional design, making it impossible to 
compare HRQoL outcomes over a given period of time and to test responsiveness and test–
retest reliability. In addition, patients are not a representative sample of all patients with CHD 
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in each country, since they were identified from selected geographical areas and cardiac 
centres (Kotseva et al, 2009b). While the EQ-5D gives an overall view on a person's general 
health, the SF-12 clearly distinguishes between mental and physical health. Both measures 
can be used at any given time, whereas HADS is intended for use in the hospital setting, 
useful in screening for anxiety and depressive feelings in patients. In order to have an in-depth 
insight in a patient's HRQoL, it is advised to use a combination of general (e.g. EQ-5D, SF-
12), domain specific (e.g. HADS) and disease specific (e.g. McNew, Seattle Angina 
Questionnaire) HRQoL measures, and not to restrict to the use of a single instrument. The 
integrated HeartQol, a coronary heart disease specific, health-related HRQoL questionnaire, 
might be a good alternative (Oldridge et al, 2005). In conclusion, the results observed in our 
study confirm the validity and reliability of the EQ-5D, the SF-12 and the HADS for use in a 
stable coronary population, both on aggregate European level and on country-specific level. 
However, our results must be generalized with caution, because EUROASPIRE III patients 
might not be representative for all patients with stable coronary heart disease.  
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Abstract 
Background: The aim of our study was to compare EuroQoL-5D (EQ-5D) outcomes in 
Coronary Heart Disease (CHD) patients with those from the general population. We aimed to 
identify those dimensions mostly impaired.  
Methods: EQ-5D results - both the dimensions and the EuroQol Visual Analogue Scale (EQ-
VAS) - from a European sample (11 countries) of coronary patients were compared with 
published age- and gender-specific normative data.  
Results: EQ-5D outcomes differed across countries and gender. Overall, the age-adjusted EQ-
VAS scores were significantly lower in the coronary patients compared with the general 
populations, both in males (MD=-5.24[-7.59;-2.88]) and in females (MD=-8.32[-11.69;-
4.95]). Coronary patients had a significantly higher risk to report moderate or severe problems 
related to anxiety/depression (OR male=1.84[1.14;2.95]; OR female=3.20[2.32;4.40]). 
Furthermore, female coronary patients reported significantly higher problems on the mobility 
(OR=2.00[1.38;2.90]), usual activity (OR= 2.54[1.81;3.57]) and pain/discomfort dimension 
(OR=1.73[1.23;2.43]) whereas in males, a borderline significant OR was found on the 
mobility (OR=1.43[0.97;2.11]) and usual activity dimension (OR=1.44[0.94;2.20]). The 
difference between the general population and the CHD patients, attenuated as age increased. 
Conclusions: CHD  has a negative influence on patient’s self-reported health status, both the 
EQ-VAS as well as the EQ-5D dimensions (with the exception of self-care in both genders 
and pain/discomfort in males) were impaired. The relative impairment was the greatest in 
female patients and the differences in the proportion of reported problems diminished with 
increasing age. The EQ-5D instrument is appropriate in capturing problems related to 
anxiety/depression, pain/discomfort, mobility and usual activities. Within clinical practice, 
particular attention should be given to females and younger CHD patients. 
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1. Introduction 
Despite the emergence of several medical innovations during the past decades, coronary heart 
disease (CHD) remains a major health problem, responsible for one out of every five lives lost 
(Nichols et al, 2012). Furthermore, CHD is also associated with a large morbidity burden with 
health care expenses amounting to just under 20 billion euro in the European Union in 2009 
(Nichols et al, 2012). Conventional medicine is mainly focused on clinical measures and 
functional outcomes, however, morbidity and mortality rates do not reflect all aspects of 
health. Over the years patients’ self-perceived emotional, social and physical well-being has 
gained attention, especially in long-term chronic conditions, when full recovery is quite 
unlikely. Many patients consider the quality of the additional life years gained equally 
important as the length of life (Thompson et al, 2003). Furthermore, according to some 
studies self-perceived health is a significant predictor of mortality (Burstrom et al, 2001; Mols 
et al, 2009). Due to pain, physical and social restrictions, anxiety or depression, 
cardiovascular patients are particularly vulnerable to have an impaired self-perceived health 
status, often resulting in a reduced Health-Related Quality of Life (HRQoL) (Mols et al, 2009; 
Schweikert et al, 2009; Thompson et al, 2003; Xie et al, 2008). A number of measures are 
being used to assess the importance of disease symptoms and their effect on everyday life as 
perceived by the patient (Mayou et al, 1993; Swenson et al, 2000). In addition to more generic 
measures such as Euroqol-5D (EQ-5D) and the 36-Item Short Form Health Survey (SF-36), 
disease specific measures exist. 
Coronary patients often report an impaired health status, however interpretation of the results 
is difficult, if not impossible in the absence of reference values from the general population. 
Some studies have investigated the effect of CHD on patients’ self-perceived health status 
compared to normative values (Bradshaw et al, 2006; Brown et al, 1999; Djarv et al, 2012; 
Lalonde et al, 2001), with one single study making use of the EQ-5D instrument (Schweikert 
et al, 2009). This study by Schweikert et al., was based on 2950 German patients who had 
suffered from a myocardial infarction. At follow up (median time since event=7.4 years), the 
main impairments were seen in the pain/discomfort, usual activities and particularly 
anxiety/depression dimension. The purpose of our study was to investigate whether their 
findings could be appraised in a large European sample of coronary patients. EQ-5D 
information was gathered between 6 months and 3 years after their event (median time since 
event=1.24 years), allowing us to assess the impact more rapidly after an event.  
2. Methods  
EQ-5D measure 
In order to assess patients’ health status, the EQ-5D 3-level instrument was used. This is a 
cognitively undemanding, easy to complete standardized instrument to measure self-perceived 
health status. It is intended for self-completion and can be applied to various health conditions 
and treatments. The instrument comprises two parts: the EQ-5D descriptive system and the 
EQ-5D visual analogue scale (EQ-VAS). The former has 5 dimensions: mobility, self-care, 
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usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 response 
categories, i.e. 3 levels of severity: no problems, some problems or severe problems; from 
which a single index value, can be calculated. The EQ-VAS is a 20 cm vertical, visual 
analogue scale used to record the respondent’s self-rated health. The respondent is asked to 
indicate how good or bad his/her own health status is today. Zero is labelled as the worst 
imaginable health state and 100 as the best imaginable health state (Rabin et al, 2011; Rabin 
et al, 2001).  
Coronary population-EUROASPIRE III 
The EUROASPIRE III survey is a cross-sectional study (2006-07) to determine whether the 
European recommendations on cardiovascular disease prevention were being followed in 
everyday clinical practice (Kotseva et al, 2009b). Twenty-two European countries took part in 
this study, patients aged between 18 and 80 years, and hospitalized for coronary artery bypass 
graft (CABG), percutaneous coronary intervention (PCI), acute myocardial infarction (AMI) 
or myocardial ischemia were identified retrospectively from diagnostic registers, hospital 
discharge lists or other sources. At least 6 months and not later than 3 years after their hospital 
admission, patients were interviewed and examined in a standardized way by trained research 
staff.  To capture information from the index hospital admission, patients’ medical records 
were reviewed. Personal and demographic details as well as personal cardiovascular history, 
including stroke and transient ischaemic attack were extracted from the medical records. 
Furthermore, information on other medical history, including hypertension, hyperlipidaemia and 
diabetes were obtained. Recorded measurements of blood pressure, diabetes, lipids and smoking 
status and medication (generic name and total daily dose) were gathered if available. At 
interview, structured questionnaires were used to collect personal and demographic details; 
personal cardiovascular history, including stroke, transient ischaemic attack and peripheral artery 
disease; other medical history, including hypertension, hyperlipidaemia and diabetes; family 
history of CHD for patients with premature disease (men <55 years and women <65 years); 
reported lifestyle and other risk factor management in relation to smoking, diet (including weight 
reduction), exercise, blood pressure, lipids and glucose; medication (generic name and total daily 
dose); and level of education, school attendance and employment status. Furthermore patients 
were asked to complete validated self-administered questionnaires, among which the EQ-5D in 
order to assess their health status.  
Although the main objective of the EUROASPIRE III study was to describe the lifestyle, risk 
factor and therapeutic management in patients with coronary heart disease, the collected 
information allowed investigating the self-perceived health status in coronary patients. More 
detailed information on the EUROASPIRE III survey can be found elsewhere (Kotseva et al, 
2009b). 
Normative values-literature 
Age-, gender- and country-specific normative HRQoL values were gathered from the 
literature. An attempt was made to extract the normative data as much as possible from a 
single report in order to avoid between-study-heterogeneity due to the clinical and 
methodological variations. Countries for which normative EQ-5D information was not 
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available were excluded from the analyses. EQ-5D information for the general population was 
available in only half of the 22 EUROASPIRE III countries: Belgium, Finland, Germany, 
Greece, Hungary, Italy, the Netherlands, Poland, Slovenia, Spain and the United Kingdom. 
Data on the general population were extracted from a report published by the EuroQol Group 
(The EuroQol Group's International Task Force on Self-Reported Health, 2004). The 
publication provides population norms, which can be used as reference data. These age- and 
gender- specific reference data can be compared to the EQ-5D profiles of patients with 
specific conditions. Italian and Polish normative data are not included in the EuroQoL report, 
hence data were extracted from 2 published papers (Golicki et al, 2010; Savoia et al, 2006). 
More information on how the data was collected can be found in table 1. 
Table 1: Details of collected reference data 
Belgium Postal survey on a random sample of people from the Flemish speaking 
population of Belgium (July, August 2001) 
Finland Postal survey on a random sample of persons chosen from the Finnish 
computerized population registry (November 1992) 
Germany Postal survey and telephone interviews on a random sample households 
selected from the German telephone list (June 1994; April 1997; October to 
March 1998) 
Greece Face to face interviews on a sample individuals selected from the general 
population (March, April 1998) 
Hungary Interview of a random sample of people from the electoral registry (October 
to December 2000) 
Italy Postal survey on a random sample from the Registry of the North and South 
Health Authorities of the city of Bologna (2002) 
The Netherlands Postal survey on a random selection of  households based on postal area 
codes on the right bank of the River Maas in Rotterdam (district with over 
20% of immigrants were excluded) (January 1991) 
Poland Face‑to‑face interviews with the visitors of inpatients at 8 Polish medical 
centers: in Warsaw, Skierniewice, and Puławy forming a representative 
sample of the Polish adult population (first half 2008) 
Slovenia Postal survey on a randomized sample of people selected from the general 
population (April, May 2000) 
 Spain Face to face interviews on a random sample individuals selected from the 
general population of a primary health care district on the outskirts of 
Barcelona, covering 4 different socioeconomic areas (October 1996 to 
November 1997) 
United Kingdom Face to face interviews on a random sample of  individuals selected from the 
general population from England, Scotland and Wales (August, November 
1993). 
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Statistical analyses 
Due to the small sample sizes of coronary patients in younger age groups, only 4 age 
categories were included in the analyses: 40-49; 50-59; 60-69; 70-79 years. These gender 
specific age categories were matched with those from the general population. Country-
specific normative EQ-5Dindex values could not be calculated since we had no access to the 
raw data. Hence analyses are limited to the EQ-VAS and the EQ-5D dimensions. The latter 
was recoded into 2 categories: no problems reported and problems reported (both some 
problems or severe problems). Because the age structure in the general population differs 
from that of the EUROASPIRE III population, direct age standardization was performed 
(direct age standardization, 1984). For the EQ-VAS, mean differences (MD) between both 
groups were calculated. For all five EQ-5D dimensions the higher odds for reporting 
problems in CHD patients compared to the general population, presented as odds ratios (OR), 
were computed. Results were then summarized with a meta-analytic method using Review 
Manager 5.1 in order to pool the country-specific data into one overall result. A considerable 
heterogeneity was observed across countries (I² between 70% and 94%). Because the 
heterogeneity could not be readily explained, random-effect models were used. The default 
Mantel-Haenszel odd ratio for dichotomous outcomes and the inverse variance mean 
difference for continuous outcomes were applied. Additional analyses investigating the effect 
of age were performed in a similar way. 
3. Results 
Eleven European countries were included in the current analyses. Within the general 
population, 46.8% of the 11,765 persons with EQ-5D information were male. No information 
on disease history or education was provided. Furthermore, of the 3775 coronary patients 
included in the analyses, 74.1% were male. Table 2 shows the main characteristics of both the 
EUROASPIRE III population as well as the general population data used in our analyses. The 
main results are presented in table 3, providing a gender-specific comparison of EQ-5D 
outcomes between CHD patients and the general population. The more extensive graphs 
representing the proportion of reported problems on each dimension for each country included, 
are presented in appendix 1. A large variation in reported problems was found across 
countries and gender, both in the general as well as in the coronary population. Within 
coronary patients, the lowest proportion of reported problems was seen on the self-care 
dimension (8% in males and 11% in females) whereas the highest proportion of problems was 
seen in the pain/discomfort (49% and 66% in males and females resp.) and the 
anxiety/depression dimension (37% and 60% in males and females resp.). Furthermore 28% 
of the male CHD patients and 43% of female CHD patients reported problems on the usual 
activities dimension, and 32% of the male and 43% of the female patients reported problems 
on the mobility dimension.  
Overall, both male and female coronary patients were more likely to report problems 
regarding anxiety or depression (OR=1.84[1.14-2.95]; OR=3.20[2.32-4.40] resp.) compared 
with normative data.  In addition, female coronary patients had a significantly higher risk to 
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report problems on the pain/discomfort dimension (OR=2.00[1.38;2.90]), mobility dimension 
(OR= 2.54[1.81:3.57]) and usual activity dimension (OR=1.73[1.23;2.43]).  
Table 2: Characteristics of the populations included in this analysis. 
 EUROASPIRE III REFERENCE POPULATION 
Characteristics N % N % 
Country     
Belgium 278 7.4% 806 6.9% 
Finland 221 5.9% 1435 12.2% 
Germany 540 14.3% 546 4.6% 
Greece 116 3.1% 238 2.0% 
Hungary 452 12.0% 3265 27.8% 
Italy 362 9.6% 961 8.2% 
The Netherlands 500 13.2% 493 4.2% 
Poland 282 7.5% 200 1.7% 
Slovenia 496 13.1% 386 3.3% 
Spain 219 5.8% 1540 13.1% 
United Kingdom 309 8.2% 1895 16.1% 
Age categories     
40-49 years 295 7.8% 3426 29.1% 
50-59 years 969 25.7% 3058 26.0% 
60-69 years 1570 41.6% 2944 25.0% 
70-79 years 941 24.9% 2337 19.9% 
Gender     
Male 2798 74.1% 5503 46.8% 
Female 977 25.9% 6262 53.2% 
Recruiting event     
CABG 837 22.2% n.a.  
PCI 1600 42.4% n.a.  
AMI 605 16.0% n.a.  
Ischemia 733 19.4% n.a.  
Education      
Primary education 1084 29.0% n.a.  
Secondary education 2095 56.1% n.a.  
High education 556 14.9% n.a.  
Self-reported diabetes  1005 26.9% n.a.  
History of stroke 115 3.1% n.a.  
Recurrent CHD 505 13.4% n.a.  
CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; AMI, acute myocardial 
infarction; Recurrent CHD; Myocardial infarction, acute myocardial ischemia, CABG or PCI since recruiting 
diagnosis. 
 
Male coronary patients on the contrary, did not have a greater odds to report problems on the 
pain/discomfort dimension (OR=1.13[0.73;1.73]), but had a borderline significantly higher 
risk to report problems on the mobility dimension (OR=1.43[0.97;2.11]) and on the usual 
activity dimension (OR=1.44[0.94;2.20]. Furthermore, coronary patients did not have a higher 
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risk of reporting problems on the self-care dimension (OR=1.27[0.84-1.93]; OR=1.48[0.90-
2.46] in males and females resp.). Additional analyses of the reported problems within 
particular age groups, revealed more problems in older age groups. However, the difference 
between the general population and the CHD patients, attenuated as age increased (see 
appendix 2).  
Figure 1: Radar chart representing the differences in problems reported in the general population 
compared to coronary patients 
 
 
These graphs present the proportion of problems (some or severe problems) reported by the different groups. The 
further away from the origin, the more problems reported. CHD: Coronary Heart Disease 
Both male as well as female coronary patients had a significantly lower EQ-VAS compared to 
the general population (MD=-5.24[-7.59;-2.88]; MD=-8.32[-11.69;-4.95] resp.). In an 
additional analysis we compared the distribution of the EQ-VAS scores between both 
MOBILITY
SELF-CARE
USUAL ACTIVITIESPAIN/DISCOMFORT
ANXIETY/DEPRESSION
EQ-5D dimensions in males
CHD patients General population
CHD 
patients
General 
population
Mobility 32% 24%
Self-care 8% 7%
Usual activities 28% 20%
Pain/discomfort 49% 44%
Anxiety/depression 37% 24%
MOBILITY
SELF-CARE
USUAL ACTIVITIESPAIN/DISCOMFORT
ANXIETY/DEPRESSION
EQ-5D dimensions in females
CHD patients General population
CHD 
patients
General 
population
Mobility 43% 26%
Self-care 11% 7%
Usual activities 43% 21%
Pain/discomfort 66% 51%
Anxiety/depression 60% 34%
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populations. The 25
th
 percentile of the EQ-VAS scores in the general population  (25% of the 
EQ-VAS observations are smaller than this value) did not correspond with the first quartile of 
the EUROASPIRE population. The proportion of EUROASPIRE III patients having a value 
below the general population based 25
th
 percentile, exceeded the expected 25% in most 
countries. Similar results were seen when looking at the median and the 75
th
 percentile, 
indicating a shift of the EQ-VAS distribution in EUROASPIRE III patients to the left. 
Table 3: Comparison between the coronary patients and the general population 
EQ-5D dimension 
CHD patients General population 
OR [95% CI] / 
MD [95% CI] 
Number of patients 
reporting problems 
Total number 
of patients 
Number of patients 
reporting problems 
Total number 
of patients 
Males      
Mobility 848 2689 1323 5503 1.43[0.97,2.11] 
Self-care 221 2689 365 5503 1.27[0.84,1.93] 
Usual activities 763 2689 1109 5503 1.44[0.94,2.20] 
Pain/discomfort 1327 2689 2405 5503 1.13[0.73,1.73] 
Anxiety/depression 989 2689 1306 5503 1.84[1.14,2.95] 
EQ-VAS  2652  5474 -5.24[-7.59,-2.88] 
Females      
Mobility 404 930 1591 6087 2.00[1.38,2.90] 
Self-care 98 930 443 6087 1.48[0.90,2.46] 
Usual activities 403 930 1307 6087 2.54[1.81,3.57] 
Pain/discomfort 615 930 3122 6087 1.73[1.23,2.43] 
Anxiety/depression 557 930 2053 6087 3.20[2.32,4.40] 
EQ-VAS  928  6087 -8.32[-11.69,-4.95] 
CHD: Coronary Heart Disease, OR: odds ratio, MD: mean difference 
4. Discussion 
In order to interpret the EQ-5D scores in coronary patients, comparison with general 
population norms is warranted. Although many studies report on self-reported health status in 
cardiac patients (Dyer et al, 2010), only few reported on the comparison with reference 
values. To our knowledge only one study thoroughly compared the EQ-5D results of coronary 
patients with those from the general population (Schweikert et al, 2009). The study included 
2,950 German coronary patients who had suffered from their first MI, 9 months to 22 year 
ago (median time=7.4 years). Within their study, 79.3% of the respondents were male and 
their mean age amounted to 68 years. The aim of our study was to investigate whether these 
results could be confirmed in a similar sample of European coronary patients, suffering from a 
coronary event, between 6 months and 3 years ago (median time=1.24 years). Dividing the 
time since the recruiting diagnosis in 2 categories (<1 years and ≥1 year) revealed no 
significant difference in either EQ-5D dimension, hence the impact of the data collection 
period seemed limited. Furthermore, due to this shorter follow-up period the results were less 
likely to be biased by other unmeasured conditions. In accordance with the German study, 
most problems were reported on the anxiety/depression and pain/discomfort dimension. It 
should be noted however that this tendency of most frequently reported problem areas is also 
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seen across the general population (The EuroQol Group's International Task Force on Self-
Reported Health, 2004). Compared to the German data, the proportion of reported problems 
on each of the five EQ-5D dimensions was higher in the EUROASPIRE sample, with the 
exception of the self-care dimension were similar percentages were seen. Surprisingly, the 
EQ-VAS results reported by Schweikert et al. were slightly worse compared with our 
findings. 
Overall, our results confirm the previously published differences in self-reported health status 
between coronary patients and the general population. Similar to Schweikert et al, significant 
differences in reported problems in the pain/discomfort (in females), usual activities and 
anxiety/depression dimension were found. Likewise, both investigations revealed a significant 
difference in EQ-VAS scores, whereas no significant effect could be observed in the self-care 
dimension. In contrast to the German study, a higher proportion of mobility problems was 
reported in the EUROASPIRE III patients, compared to the general population. Although 
Schweikert and colleagues speculate that their result might in part be explained by effects of 
measures of secondary prevention such as higher physical activity, as well as possible 
selection or information bias, we hypothesize that the discrepancy with our results, is most 
probably caused by the duration of the follow-up time. Mobility problems are likely to 
decrease over time, due to partial or full recovery. 
In line with the literature, our analyses revealed worse EQ-5D results in females compared to 
males (Brink et al, 2005; Duenas et al, 2012; Emery et al, 2004; Norris et al, 2010; Phillips-
Bute et al, 2003). Despite the general consensus regarding worse self-perceived health 
outcomes in females, both in the general population as well as in coronary patients, research 
on the cause of this finding is still on-going. Some argue that women might perceive 
symptoms in a different way (Norris et al, 2010; Phillips-Bute et al, 2003; van Wijk et al, 
1997). Although the latest results indicate that male and female coronary patients experience 
the same symptoms, some studies found differences in the proportions of symptoms, with 
women reporting more angina, pain, nausea, fatigue, syncope, weakness, depression and loss 
of appetite (DeVon et al, 2002; DeVon et al, 2003; Kimble et al, 2003). Physiologic 
differences might be one of the reasons why women experience worse outcomes. Females for 
example, have smaller coronary arteries, which might increase ischemia (Lichtman et al, 
2008). Furthermore, the higher depression rates in women are strongly associated with poorer 
recovery rates possibly leading to impaired results (Lichtman et al, 2008). In addition, a lower 
sense of coherence (SOC) seems to be associated with worse self-perceived health outcomes 
(Bergman et al, 2012; Pragodpol et al, 2012). This concept assesses whether an individual 
experiences the world as comprehensible, meaningful and manageable. Among both genders, 
similar sources including the quality of the relationship with partner, social support, quality of 
work, and childhood living conditions, are predictors of SOC (Volanen et al, 2004). Both in 
the general population, as well as in coronary patients, women often have a worse SOC 
compared to men (Bergman et al, 2012; Eriksson et al, 2006). In accordance, Emery et al. 
identified perceived social support (meeting and talking regularly with friends and family) as 
an important predictor of self-perceived health outcome in cardiac women (Emery et al, 
2004).  
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Our results together with those of Schweikert and colleagues confirm the relationship between 
CHD and anxiety and depression, previously reported by others (Lane et al, 2002; Schweikert 
et al, 2009; Thombs et al, 2006). Depression and anxiety are common in coronary patients. 
Approximately 1 out of 5 hospitalized AMI patients suffer from major depression; at 1 year 
follow up, depression persisted in about half of these patients (Thombs et al, 2006). 
According to previous EUROASPIRE analyses, based on the Hospital Anxiety and 
Depression Scale (HADS), within our population the prevalence of depression varied from 
8.2% to 35.7% in males and from 10.3% to 62.5% in females; the prevalence of anxiety 
varied from 12.0% to 41.8% in males and from 21.5% to 63.7% in females (Pajak et al, 
2013). These findings suggest that the EQ-5D instrument is an appropriate tool for capturing 
problems related to anxiety and depression. 
Likewise, pain or discomfort are also commonly reported by CHD patients. According to a 
study by Brown et al (1999) only 43.7% of AMI survivors reported that they were free from 
chest pain symptoms (Brown et al, 1999). A study by Vetrovec et al (2004) - including  
patients diagnosed with chronic angina, of whom 56% had received revascularization 
procedures in the prior year -  revealed that 90% of patients had at least one episode of angina 
in the prior 6 months and more than one in three patients had multiple episodes per week 
(Vetrovec et al, 2004). Angina is inevitably associated with an impairment in self-perceived 
health status proportional to the number of angina attacks per week (Pepine et al, 1994). 
Within CHD patients, EQ-5D adequately captures problems related to pain and discomfort.  
Self-care showed to be a less severe problem in CHD patients. This is not surprising, since 
problems with self-care are more likely to occur during the acute phase of an event, e.g. 
shortly after a CABG. During this initial recovery period, patients can have more difficulties 
to wash or dress themselves. 
In line with Schweikert et al, the differences in self-reported health status outcomes between 
coronary patients and the general population, diminished with increasing age, which is 
probably caused by the increasing comorbidity associated with ageing in the normal 
population.  
It is worthwhile mentioning some strengths and weaknesses regarding this study. Although 
this study is the first to report on a European cross-country comparison, based on the raw data 
set of a large population of coronary patients, some limitations should be mentioned. A great 
variation in odd ratio’s and mean differences was seen across country-specific outcomes 
which can be partially explained by the variation in EQ-5D results across coronary patients 
from different geographical regions. As previously reported by our research group, the mean 
CHD-related EQ-5D outcomes vary across EUROASPIRE III countries (De Smedt et al, 
2013b). Furthermore, limited information is available on the validity of the reference data. 
Although the use of these reference data is being proposed by the EuroQol group, these data 
have not always been collected in the same standardized way, since they were extracted from 
individual substudies, each with their own specific data collection methods. Hence, some 
differences in sampling and data collection methods could have occurred in the EuroQol 
report, however according to the authors there is no reason to believe that these limitations 
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had a significant impact on the results since the EQ-5D is a rather simple and straightforward 
measure (The EuroQol Group's International Task Force on Self-Reported Health, 2004). In 
addition, the large time frame, ranging from 1993 until 2008, during which normative data 
was collected could have had an impact on our findings. Furthermore, information on the 
general population was only available for half of the EUROASPIRE III countries. Although 
an attempt was made to avoid heterogeneity between the collected data, by extracting 
country-specific information from one report as much as possible, considerable heterogeneity 
remained across the different countries, hence random effect model analyses were performed. 
Furthermore, we were not able to account for socioeconomic status, income and education 
since this information was not available for the general population data. 
In conclusion, our results have shown that the self-perceived health status in coronary patients 
is significantly worse compared to the general population, with the exception of self-care in 
both genders and pain/discomfort in males. We observed higher proportions of reported 
problems compared to the study performed by Schweikert et al., in which EQ-5D information 
was collected much later after the event, suggesting that impairments improve somewhat over 
time. The EQ-5D instrument appears to be an appropriate tool for capturing problems with 
regard to anxiety/depression, pain/discomfort, mobility and usual activities. Furthermore the 
tool differentiates significantly between women and men, with female CHD patients reporting 
a greater relative impairment. Within clinical practice particular attention should be given to 
the self-perceived health status of females and younger CHD patients. In addition to the 
individual burden on a patient’s live, self-perceived health status is also associated with future 
mortality and morbidity as well as with increased health care expenses, hence actions to tackle 
these impairments are needed (Burstrom et al, 2001; DeSalvo et al, 2006). Lifestyle changes 
are shown to be associated with better self-perceived outcomes, hence patients should be 
encouraged and supervised to change their behaviour in order to adopt a healthier lifestyle 
(De Smedt et al, 2013a). Future research should be aimed at investigating further 
interventions or treatment schemes  possibly associated with improvements in self-perceived 
health status. Furthermore, since country-specific normative EQ-5D information is rather 
scarce,  there is a need for a coordinated cross-country collection of EQ-5D information, with 
well-defined inclusion criteria and additional collection of covariates. This will allow easy 
comparison between the general population and several patient groups (not limited to CHD 
patients). 
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APPENDIX 1: Comparison between the coronary patients and the general population (age 
standardization) 
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ANXIETY/DEPRESSION  
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EQ-VAS 
MALES 
 
 
 FEMALES 
 
 
These tables give an overview of country and gender specific comparisons between the EUROASPIRE III 
patients and the general population. As can be seen from the tables a large variation exists between countries and 
between men and women. CHD: Coronary Heart Disease; events are defined as some or severe problems 
reported. 
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APPENDIX 2: Comparison between the coronary patients and the general population (age groups) 
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Abstract 
Background: Cardiovascular patients are likely to have an impaired Health-Related Quality of 
Life (HRQoL) due to functional and psycho-social limitations. The main objective of this 
study was to assess the distribution of HRQoL scores in coronary heart disease (CHD) 
patients across 22 European countries and to identify factors associated with the variation 
between patients. 
Methods: Data from the EUROASPIRE III survey (European Action on Secondary and 
Primary Prevention by Intervention to Reduce Events), on 8734 patients, were used. Patients 
with a diagnosis of CHD (coronary artery bypass graft (CABG), percutaneous coronary 
intervention (PCI), acute myocardial infarction (AMI) or myocardial ischemia) were 
interviewed and examined at least 6 months after their acute coronary event. HRQoL of each 
patient was measured using 2 standardized questionnaires: the EuroQoL-5D (EQ-5D) and the 
12-item short-form health survey (SF-12). 
Results: HRQoL values differed significantly across countries. Lower HRQoL estimates were 
found in women, older patients, less educated patients, patients with myocardial infarction or 
ischemia as recruiting diagnosis, patients with a history of stroke and patients who suffered 
from a recurring CHD event. In addition, HRQoL was significantly associated with current 
smoking, central obesity, lack of exercise and inappropriate HbA1c control in patients with 
diabetes. Furthermore the number of risk factors is inversely associated with HRQoL.  
Conclusion: Overall, a large heterogeneity was observed in HRQoL values between countries 
and patient groups. There seems to be a significant association between HRQoL and patient 
characteristics with lifestyle risk factors as important determinants of HRQoL. 
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1. Introduction 
Cardiovascular disease (CVD) remains the most common cause of disease burden in Europe, 
with coronary heart disease (CHD) being the single most important cause of death (Allender 
et al, 2008). Conventional treatment focuses mainly on functional outcomes, survival and 
extending life. However, morbidity and mortality rates are incomplete measures of outcome, 
since they do not reflect all aspects of health. Many patients consider the quality of the 
additional life years gained equally important as the length of life. Indeed, the goal of today's 
medicine should be to increase both patients' quantity and quality of life (Oldridge et al, 2005). 
In response, assessment of health-related quality of life (HRQoL) has been increasingly 
integrated in daily clinical practice. HRQoL is a subjective measure of overall well-being and 
reflects how a disease and its symptoms are perceived by a patient. Although there is no 
universal agreement on what constitutes HRQoL, current assessment focuses on the domains 
of social functioning, physical functioning and psychological functioning (Swenson et al, 
2000). CHD patients are known to have an impaired HRQoL (Xie et al, 2008). Recent studies 
have shown a significant influence of HRQoL on long-term outcomes. Poor HRQoL has been 
shown to predict morbidity and mortality in patients with CHD, even when controlling for 
standard risk factors (Grool et al, 2012; Rumsfeld et al, 1999; Spertus et al, 2002). The aim of 
our study was to examine the relationship between the cardiovascular profile of coronary 
patients and their HRQoL. Data were derived from the EUROASPIRE III (European Action 
on Secondary and Primary Prevention by Intervention to Reduce Events) survey wherein two 
commonly used instruments were employed to assess patient's HRQoL: the EQ-5D (EuroQol-
5D) and the SF-12 (12-item short-form health survey). 
2. Methods 
Study population and data collection 
The details of the EUROASPIRE III study have been reported elsewhere (Kotseva et al, 
2009b). In brief, EUROASPIRE III, performed in 2006-07 in patients with established CHD, 
was a cross-sectional study to determine whether the European recommendations on CVD 
prevention were being followed in everyday clinical practice. Patients aged between 18 and 
80 years, hospitalized for coronary artery bypass graft (CABG), percutaneous coronary 
intervention (PCI), acute myocardial infarction (AMI) or myocardial ischemia, hereafter 
referred to as the recruiting diagnosis, were retrospectively identified from diagnostic 
registers, hospital discharge lists or other sources at 76 different hospital centres across 22 
European countries: Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Poland, Romania, Russian 
Federation, Slovenia, Spain, The Netherlands, Turkey, and the United Kingdom (UK). Data 
collection was conducted by trained research staff using standardized methods and 
instruments. In total, 8966 patients (participation rate=73%) were interviewed and examined 
at least 6 months and not later than 3 years after their initial hospital admission (median 
time=1.24 years). Informed consent was obtained from each patient and the study protocol 
conforms to the ethical guidelines of the 1975 Declaration of Helsinki (Coats et al, 2011). 
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Patient characteristics and risk factors assessed  
The interview contained questions on personal and demographic details; medical and in 
particularly cardiovascular history (i.e. having a history of stroke or suffering from a recurrent 
coronary event between the recruiting diagnosis and the moment of interview); reported 
lifestyle and risk factor management related to smoking, exercise (regular exercise defined as 
20-60 min, 3 to 5 times a week), blood pressure, lipids, glucose and medication. In addition, 
height, weight and waist circumference were measured in light indoor clothes without shoes, 
as well as blood pressure, heart rate and breath carbon monoxide. Venous blood was tested for 
serum total cholesterol, HDL-cholesterol (HDL-C), triglycerides, plasma glucose and HbA1c, 
the latter two were only measured in patient with self-reported diabetes (Kotseva et al, 2009b). 
LDL-colesterol (LDL-C) was calculated according to the Friedewald formula. The risk factor 
targets used were based on the European guidelines on cardiovascular prevention (De Backer 
et al, 2003). A raised blood pressure was defined as systolic blood pressure (SBP)/diastolic 
blood pressure (DBP) ≥140/90 mm Hg (≥130/80 mm Hg in patients with diabetes). Raised 
total cholesterol was defined as total cholesterol ≥4.5 mmol/L. Raised LDL-C was defined as 
LDL-C ≥2.5 mmol/L and low HDL-C was defined as HDL-C <1/1.2 mmol/L for men/women. 
Raised fasting glucose was defined as fasting glucose ≥6.1 mmol/L among patients with self-
reported diabetes and raised HbA1c as HbA1c ≥6.5% among patients with self-reported 
diabetes. Low physical activity was defined as less than 20 min moderate physical activity, 
three times a week. Central obesity was defined as waist circumference >102/88 cm 
(men/women).  
Health-related quality of life assessment 
In order to assess patients' HRQoL, they were asked to fill out 2 self-administered 
questionnaires: EQ-5D and SF-12. In each country, the questionnaires were administered in 
the official language. Validity of these scales has been reported previously (De Smedt et al, 
2013b). The EQ-5D is an easy to complete brief instrument that contains a self-classifier (EQ-
5Dindex) covering 5 dimensions (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression) and a visual analogue scale (EQ-VAS). In the current analyses only the 
EQ-VAS was included. The EQ-VAS is a vertical scale, ranging from 0 (worst imaginable) to 
100 (best imaginable) on which the respondent is asked to indicate their current health state. 
The SF-12 consists of 12 Likert scale questions, covering 8 dimensions: general health, 
physical functioning, role-physical, bodily pain, vitality, social functioning, role-emotional 
and mental health. Both physical (PCS-12) and mental functioning (MCS-12) components can 
be assessed. The scores were standardized by a common scoring algorithm, ranging between 0 
and 100, with lower scores representing worse and higher scores representing better health 
(Ware et al, 2002). The SF-12 was not administered in Hungary. In Germany, the SF-36 was 
used instead of the SF-12 (Wee et al, 2008). 
Statistical analyses 
All analyses were based on generalized linear mixed models in order to account for the 
clustering of patients within countries. The association between patient characteristics and 
HRQoL was initially adjusted for gender, age and educational level. A further adjustment for 
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age, gender, educational level, recruiting diagnosis, diabetes, history of stroke, recurring 
coronary events, smoking, physical activity and central obesity was applied. To investigate 
the relation between uncontrolled risk factors and HRQoL, in patients being medically treated, 
adjustment for gender, age, recruiting diagnosis, educational level, diabetes and history of 
stroke and recurring events was performed. Likewise the relation between the number of risk 
factors and HRQoL was investigated. In an additional analysis the number of risk factors was 
considered as a continuous variable, hence a linear regression analysis was performed. In both 
analyses adjustment for patient characteristics was applied. Significance levels were set at p 
<0.05. All statistical analyses were performed using the IBM SPSS statistical software 
(version 20.0).  
3. Results 
HRQoL data (full information on at least 1 HRQoL instrument) were available for 8734 
patients (Table 1). About three quarters (74.6%) of patients included in our analyses were 
males (n=6516). The average age of patients was 63.2 years (SD=9.5). About 60% of patients 
included, had a cardiac revascularization as recruiting diagnosis, 19.5% was diagnosed with 
AMI. The overall mean PCS-12 and MCS-12 were 42.14 (SD=10.15) and 49.15 (SD=10.22) 
respectively. For the EQ-VAS a mean value of 66.42 (SD=18.84) was observed (Table 2).  
Comparison of the HRQoL scores across countries indicated substantial differences, even 
after adjustment for age, gender, education, recruiting diagnosis, diabetes, history of stroke 
and recurring events (p<0.001) (Fig. 1). There was a tendency towards a poorer HRQoL in 
patients residing in Eastern European countries.  
Likewise, gender, age and educational level were significantly associated with HRQoL, with 
men having a better self-perceived HRQoL compared to women, younger patients scoring 
higher on physical health and overall well-being, and those with lower education levels 
having worse HRQoL compared to those with higher levels of education (Tables 2 and 3). 
Furthermore, significantly lower HRQoL values were found in patients with self-reported 
diabetes and higher values in those having undergone cardiac surgery or angioplasty, except 
for MCS-12, where no significant differences were found between diagnostic categories. In 
addition, cardiovascular history was also significantly associated with lower HRQoL 
measures, except for MCS-12, on which recurring events did not have any impact. Finally, 
better control of lifestyle parameters (central obesity, smoking, physical activity) was 
significantly associated with HRQoL (except for MCS-12 in central obesity). Based on the 
regression coefficients from Table 3, these lifestyle parameters seem to be as important as 
cardiovascular history, gender or educational level. Furthermore, HRQoL was significantly 
associated with certain cardiovascular risk factors in those patients being medically treated 
(Table 4). Regarding blood pressure the associations with the different HRQoL measures 
were found to be non-significant or to go in the opposite direction, with worse HRQoL being 
associated with better blood pressure values. Regarding total cholesterol a significant 
association was seen with MCS-12. No significant relation was found with LDL-C and fasting 
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glucose, whereas HbA1c was significantly associated with all HRQoL measures in patients 
with diabetes. 
Table 1: Patient characteristics at the time of the interview (n=8734) 
 Men (n=6516) Women (n=2218) All (n=8734) 
Age in years, Mean (SD) 
 
Age categories 
<50 years 
50-59 years 
60-69 years 
≥70 years 
 
62.3 (9.5) 
 
 
10.6% (688/6516) 
29.5% (1924/6516) 
37.4% (2440/6516) 
22.5% (1464/6516) 
65.9 (8.9) 
 
 
5.0% (112/2218) 
19.9% (442/2218) 
40.1% (890/2218) 
34.9% (774/2218) 
63.2 (9.5) 
 
 
9.16% (800/8734) 
27.1% (2366/8734) 
38.1% (3330/8734) 
25.6% (2238/8734) 
Recruiting Diagnosis 
CABG 
PTCA 
AMI 
Ischemia 
 
 
20.5% (1339/6516) 
43.1% (2806/6516) 
19.2% (1248/6516) 
17.2% (1123/6516) 
 
17.1% (379/2218) 
35.3% (782/2218) 
20.7% (459/2218) 
27.0% (598/2218) 
 
19.7% (1718/8734) 
41.1% (3558/8734) 
19.5% (1707/8734) 
19.7% (1721/8734) 
Education 
Primary education 
Secondary education 
High education 
 
 
22.5% (1456/6480) 
57.3% (3714/6480) 
20.2% (1310/6480) 
 
33.4% (737/2207) 
54.9% (1211/2207) 
11.7% (259/2207) 
 
25.2% (2193/8687) 
56.7% (4925/8687) 
18.1% (1569/8687) 
Diabetes 
Raised fasting glucose 
Raised HbA1c 
 
22.6% (1459/6454) 
90.7% (943/1040) 
60.9% (592/972) 
29.8% (657/2203) 
87.4% (396/453) 
73.8% (321/435) 
24.4% (2116/8657) 
89.7% (1339/1493) 
64.9% (913/1407) 
History of stroke 4.1% (268/6500) 5.7% (127/2212) 4.53% (395/8712) 
Recurrent CHD after recruiting diagnosis 
 
14.1% (912/6483) 11.4% (251/2204) 13.4% (1163/8687) 
Central obesity 
Current smoker  
Low physical activity 
 
Raised total cholesterol 
On lipid lowering medication (LLM) 
Raised total cholesterol in treated patients 
Raised LDL-cholesterol 
Raised  LDL-cholesterol in patients on LLM 
 
Raised Blood pressure  
On antihypertensive medication 
Raised Blood Pressure in medically patients 
45.7% (2940/6433) 
19.0% (1234/6500) 
63.9% (3880/6073) 
 
47.7% (2936/6155) 
80.3% (5210/6487) 
41.4% (2035/4912) 
52.6% (2511/4770) 
46.5% (1797/3865) 
 
54.5% (3544/6503) 
67.1% (4350/6481) 
61.4% (2665/4341) 
73.4% (1609/2193) 
10.9% (242/2214) 
72.8% (1483/2038) 
 
62.0% (1309/2111) 
77.9% (1718/2205) 
56.8% (929/1637) 
61.3% (980/1598) 
55.0% (570/1267) 
 
60.8% (1347/2215) 
80.3% (1778/2215) 
66.3% (1176/1775) 
52.7% (4549/8626) 
16.9% (1476/8714) 
66.1% (5363/8111) 
 
51.4% (4245/8266) 
79.7% (6928/8692) 
45.3% (2964/6549) 
54.8% (3491/6368) 
48.6% (2638/5132) 
 
56.1% (4891/8718) 
70.5% (6928/8692) 
62.8% (3841/6116) 
 
 
 
 
 
  
 
 
Figure 1: Crude mean HRQoL outcomes across EUROASPIRE III countries 
 
 
* Adjusted for age, gender, educational level, recruiting diagnosis, diabetes, history of stroke and recurring events (p<0.001) 
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Table 2: Association between patient characteristics and different HRQoL instruments (Mean (SD)) 
 PCS-12  MCS-12  EQ-VAS  
All 42.14 (10.15) 49.15 (10.22) 66.42 (18.84) 
    
Gender    
Male 43.20 (10.02) 49.93 (9.96) 67.85 (18.59) 
Female 38.82 (9.84) 46.75 (10.64) 62.22 (18.84) 
 p<0.001* p<0.001 p<0.001 
Age     
< 50 yrs 45.59 (9.96)  48.84 (10.51)  71.43 (18.18)  
50-59 yrs 43.31 (10.1)  48.94 (10.22)  67.48 (18.73)  
60-69 yrs 42.16 (9.99)  49.57 (10.19)  66.72 (18.66)  
≥ 70 yrs   39.56 (9.89)  48.90 (10.13) 63.03 (18.9) 
 p<0.001 p=0.034 p<0.001 
Recruiting diagnosis    
CABG 42.53 (10.03)  50.23 (9.88)  66.85 (19.43)  
PTCA 43.03 (10.06)  49.27 (10.18)  67.92 (18.5)  
AMI 41.83 (10.13)  48.58 (10.24)  65.64 (18.56)  
ISCHAEMIA 40.04 (10.18) 48.47 (10.53) 63.63 (18.88) 
 p<0.001 p=0.214 p=0.011 
Educational level    
Primary 40.95 (10.36) 47.98 (10.89) 64.87 (20) 
Secondary 41.95 (10.04) 49.27 (10.08) 66.44 (18.55) 
High 44.28 (9.88) 50.44 (9.53) 68.32 (18) 
 p<0.001 p<0.001 p<0.001 
Diabetes     
No 42.94 (9.97) 49.48 (10.03) 67.34 (18.57) 
Yes 39.46 (10.27) 48.10 (10.76) 63.50 (19.43) 
 p<0.001 p<0.001 p<0.001 
Central Obesity    
No 43.53 (9.98) 49.67 (9.96) 68.33 (18.45) 
Yes 40.87 (10.11) 48.73 (10.44) 64.76 (18.99) 
 p<0.001 p=0.199 p<0.001 
Smoking    
No 42.04 (10.14) 49.37 (10.00) 66.56 (18.71) 
Yes 42.64 (10.17) 48.06 (11.18) 65.71 (19.40) 
 p=0.001 p<0.001 p<0.001 
Physical activity    
 <20min, 3x/week 40.79 (10.19) 48.69 (10.39) 64.39 (19.12) 
≥20 min, 3x/week 45.52 (9.28) 50.54 (9.58) 71.08 (17.22) 
 p<0.001 p<0.001 p<0.001 
History of stroke    
No 42.39 (10.08) 49.24 (10.16) 66.80 (18.77) 
Yes 36.92 (10.42) 47.17 (11.3) 58.43 (18.83) 
 p<0.001 p=0.001 p<0.001 
Recurring coronary event after IE    
No 42.34 (10.13) 49.26 (10.15) 66.76 (18.85) 
Yes 40.90 (10.19) 48.47 (10.59) 64.25 (18.64) 
 p<0.001 p=0.109 p<0.001 
*p-value adjusted for age, gender, educational level 
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Table 4: Association between uncontrolled cardiovascular risk factors different HRQoL instruments 
(mean (SE)) 
 PCS-12  MCS-12  EQ-VAS  
Raised blood pressure in  treated 
patients 
   
No 38.24 (0.80)* 47.04 (0.73) 62.17 (1.38) 
Yes 39.28 (0.78) 47.65 (0.71) 63.01 (1.35) 
 p<0.001** p=0.040 p=0.099 
Raised total cholesterol in  treated 
patients 
   
No 39.35 (0.79) 47.90 (0.71) 63.84 (1.42) 
Yes 39.11 (0.79) 47.22 (0.72) 62.96 (1.43) 
 p=0.329 p=0.011 p=0.056 
Raised LDL-cholesterol in  
treated patients 
   
No 39.40 (0.84) 47.30 (0.74) 63.08 (1.50) 
Yes 39.43 (0.84) 46.82 (0.74) 62.65 (1.50) 
 p=0.909 p=0.104 p=0.408 
Raised fasting glucose in diabetes 
patients 
   
No 37.75 (1.33) 44.50 (1.26) 58.43 (2.34) 
Yes 37.58 (1.10) 45.05 (0.95) 58.83 (1.84) 
 p=0.839 p=0.559 p=0.809 
Raised HbA1c in diabetes patients    
No 39.01 (1.18) 47.43 (1.17) 61.90 (2.04) 
Yes 37.55 (1.13) 45.62 (1.10) 59.15 (1.92) 
 p=0.013 p=0.006 p=0.013 
*adjusted mean 
**p-value adjusted for age, gender, educational level, recruiting diagnosis, diabetes, history of stroke and 
coronary recurring events 
 
Looking at the number of CVD risk factors (blood pressure, total cholesterol, smoking, 
physical activity, central obesity) revealed that an increase in the amount of risk factors was 
associated with a gradual decrease in HRQoL even after adjustment for patient characteristics 
(Table 5). Fitting a multiple linear model showed that each additional risk factor was 
associated with a 0.872 (p<0.001) decrease in PCS-12, a 0.326 (p=0.002) decrease in MCS-12 
and a 1.368 (p<0.001) decrease on the EQ-VAS. 
Table 5: HRQoL means (SD) in relation to the number of risk factors 
Number of risk factors PCS-12 MCS-12 EQVAS 
0 
1 
2 
3 
4 
5 
p-value 
 
46.11 (9.76) 
44.38 (9.79) 
42.15 (10.16) 
41.27 (10.07) 
39.73 (9.88) 
38.21 (9.73) 
<0.001* 
50.80 (9.22) 
50.01 (9.62) 
49.49 (10.16) 
48.62 (10.33) 
47.98 (10.76) 
46.85 (12.37) 
0.023 
72.85 (17.23) 
70.25 (18.07) 
66.68 (18.44) 
64.82 (18.90) 
61.99 (19.64) 
60.47 (18.06) 
<0.001 
*p-value adjusted for age, gender, educational level, recruiting diagnosis, diabetes, history of stroke and recurring 
coronary events.Risk factors included are: raised blood pressure, raised total cholesterol, current smoking, low 
physical activity and central obesity. 
 
  
 
 
Table 3: Results of multilevel linear regression analyses  for the association between patient characteristics and HRQOL 
 PCS-12 MCS-12 EQ-VAS 
Patient characteristics β  (SE)* p-value β  (SE)*  p-value β  (SE)*  p-value 
Intercept 56.709 (1.033) <0.001 50.347 (1.016) <0.001 84.60 (1.88) <0.001 
Age -0.153 (0.012) <0.001 0.011 (0.013) 0.407 -0.183 (0.023) <0.001 
Gender        
Male Reference  Reference  Reference  
Female -2.154 (0.267) <0.001 -2.749 (0.289) <0.001 -2.878 (0.499) <0.001 
Educational level       
Primary education -0.971 (0.293) 0.001 -0.570 (0.315) 0.071 -2.046 (0.549) <0.001 
Secondary education Reference  Reference   Reference  
High education 2.231 (0.296) <0.001 1.144 (0.320) <0.001 2.635 (0.558) <0.001 
Recruiting diagnosis       
CABG 0.518 (0.305) 0.090 0.604 (0.329) 0.067 0.999 (0.574) 0.082 
PTCA Reference   Reference  Reference  
AMI 0.115 (0.315) 0.714 0.681 (0.339) 0.045 1.677 (0.606) 0.006 
Ischemia -1.588 (0.337) <0.001 0.282 (0.363) 0.436 -0.210 (0.629) 0.739 
Diabetes       
No Reference  Reference  Reference  
Yes -2.535 (0.261) <0.001 -1.160 (0.281) <0.001 -2.911 (0.486) <0.001 
 History of stroke       
No Reference  Reference  Reference  
Yes -3.591 (0.520) <0.001 -1.456 (0.561) 0.009 -5.426 (0.979) <0.001 
Recurrent coronary event after 
recruiting diagnosis 
      
No Reference  Reference  Reference  
Yes -1.688 (0.319) <0.001 -0.580 (0.344) 0.093 -2.251 (0.604) <0.001 
Smoking       
No Reference  Reference  Reference  
Yes -0.917 (0.301) 0.002 -1.622 (0.325) <0.001 -2.062 (0.570) <0.001 
Physical activity       
≥20 min, 3x/week Reference  Reference  Reference  
<20min, 3x/week -3.094 (0.243) <0.001 -1.121 (0.262) <0.001 -4.384 (0.456) <0.001 
Central obesity       
No  Reference  Reference  Reference  
Yes -1.528 (0.228) <0.001 0.042 (0.246) 0.865 -1.887 (0.432) <0.001 
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4. Discussion 
In this study, including 8734 stabilized CHD patients from 22 European countries, we aimed 
to analyse the association between HRQoL and patient characteristics. As expected the overall 
HRQoL scores in our cohort of CHD patients were lower compared to the general population 
(König et al, 2009) and similar to previously reported results (Xie et al, 2008). Our analyses 
revealed that patient characteristics were significantly associated with HRQoL. Firstly, 
patients from Eastern European countries were more likely to have an impaired HRQoL. 
Similar findings have been previously reported in the general population with lower overall 
subjective well-being scores in less prosperous countries (The EuroQol Group's International 
Task Force on Self-Reported Health, 2004). Secondly, in accordance with the literature, CHD 
women reported lower HRQoL results than men (Agewall et al, 2004; Brink et al, 2005; 
Duenas et al, 2011; Emery et al, 2004; Phillips-Bute et al, 2003; Pragodpol et al, 2012; 
Schweikert et al, 2006; Xie et al, 2008), an observation which was also seen in the general 
population (Franco et al, 2012; Xie et al, 2008). With regard to age, a significant association – 
with younger patients reporting a better HRQoL – was observed with the PCS-12 and the EQ-
VAS. Likewise other research groups found higher HRQoL values in younger CHD patients 
(Brink et al, 2005; Lee et al, 2012; Pragodpol et al, 2012; Schweikert et al, 2006). Xie and 
colleagues reported similar results regarding the physical score; however, for the mental score 
and the EQ-5D, better values were found in older CHD patients (Xie et al, 2008). Patients 
with self-reported diabetes were more likely to have a worse HRQoL. Similarly Xie et al. 
reported significantly lower HRQoL outcomes on both the SF-12 and the EQ-5D in these 
patients whereas Peterson et al. reported a 3 point lower score on PCS-12 in patients with 
diabetes (Peterson et al, 2006; Xie et al, 2008). In addition, similar to the results reported by 
Lee et al., lower educated patients had significantly lower HRQoL outcomes (Lee et al, 2012). 
Analyses also revealed significantly higher HRQoL scores in patients undergoing 
revascularization as recruiting diagnosis, confirming previous studies (Kim et al, 2005; 
Lukkarinen et al, 2006; Sevinc et al, 2010; Weintraub et al, 2008). Other significant predictors 
of impaired HRQoL were: having a history of stroke or suffering from a recurring coronary 
event. Several studies have shown a negative influence of stroke on HRQoL (Leach et al, 
2011; Paul et al, 2005; Saarni et al, 2006; Schwander et al, 2009; Xie et al, 2008). Recurring 
cardiovascular events are also known to cause a decrease in HRQoL, although to a smaller 
extent than the HRQoL reduction associated with initial events (Schwander et al, 2009). 
Lifestyle risk factors were significantly associated with HRQoL. In line with the literature, 
central obesity was associated with a decrease in HRQoL (Jarvinen et al, 2007; Lee et al, 
2012; Oreopoulos et al, 2010). In addition, we found an association between HRQoL and 
physical activity, with better HRQoL outcomes in physically active persons. Similarly, Sevinç 
et al. reported a higher HRQoL in coronary patients who are active or exercise regularly, 
compared to sedentary patients (Sevinc et al, 2010). Finally, a significant association between 
HRQoL and current smoking was seen (Haddock et al, 2003; Taira et al, 2000). In contrast to 
some authors stating that smoking cessation does not improve HRQoL significantly, we have 
found significantly higher HRQoL in quitters, similar to non-smokers (data not shown) 
(Hoogwegt et al, 2010; Quist-Paulsen et al, 2006; Wiggers et al, 2006). These results stress 
the importance of promoting healthy lifestyle changes in coronary patients, not only to 
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prevent recurrent events but also to increase patients' HRQoL. Our findings are in line with 
the latest European recommendations on CVD prevention, promoting multimodal, 
behavioural interventions in CHD patients (Perk et al, 2012). The interventions should include 
promotion of healthy lifestyle based on cognitive–behavioural strategies, through behavioural 
change including nutrition, exercise, smoking cessation, coping with the illness and 
improving medication adherence. When looking at the relation between HRQoL and CVD 
risk factors in patients being treated, less pronounced differences were seen across different 
risk groups. A negative association was found between SF-12 and raised blood pressure, 
which was eliminated after adjustment for medication intake. Indeed about 28% of the 
EUROASPIRE III patients were taking nitrates and 30% were taking diuretics at the time of 
the interview, medications which are often given in patients with angina and heart failure 
respectively, two conditions that are associated with a substantial decrease in HRQoL (Herlitz 
et al, 2005; Pragodpol et al, 2012). Some previous studies did find a correlation between 
HRQoL and blood pressure, with worse HRQoL in hypertensive patients whereas others did 
not find any association (Carvalho et al, 2012; Herlitz et al, 2005; Sevinc et al, 2010; Soini et 
al, 2010). Uncontrolled total cholesterol was significantly associated with a worse MCS-12, 
whereas no association was found with LDL-cholesterol. Similarly, Sevinç et al. found no 
significant association between HRQoL and cholesterol (Sevinc et al, 2010). HbA1c but not 
fasting glucose was significantly associated with HRQoL with worse health outcomes in those 
with a lower HRQoL. The latter observation was in accordance with published literature (Lee 
et al, 2012). Khanna et al. found a significant association between HbA1c and diabetes-
specific HRQoL whereas Lau et al. only found an effect on the mental score of SF-12 
(Khanna et al, 2012; Lau et al, 2004). Furthermore, in accordance with the literature, the 
number of risk factors was inversely associated with HRQoL (Li et al, 2008). These results 
reaffirm the high importance of a holistic approach regarding risk factor prevention. Overall, 
the greatest association was seen with physical functioning. This is in line with the review by 
Smith et al. (1999) stating that physical health has a much greater impact on health status than 
mental health.  Our analyses did not include the EQ-5Dindex since country-specific weights to 
calculate the EQ-5Dindex were not available for all 22 countries. However, when performing 
the analyses using the UK weights for all the countries, similar results as reported were found 
(data not shown). The EUROASPIRE III study is one of the largest surveys throughout 
Europe assessing patients' subjective HRQoL in a stable coronary population. Data collection 
was organized in a standardized way and HRQoL was measured by means of 2 different 
widely used HRQoL instruments. In order to account for HRQoL differences inherent to the 
centre, multilevel analyses were used. The major limitation of our study is its cross-sectional 
design; therefore no statement about causality, only about the association between HRQoL 
and different characteristics, can be made. Furthermore, results should be interpreted with 
caution since most of the data were self-reported. Additionally, results are not country 
representative as the survey was carried out in selected geographical areas in each country. In 
conclusion, patient characteristics such as age, gender, educational level, physical activity, 
smoking status, central obesity and comorbidities seem to be significantly associated with 
HRQoL in coronary patients. In addition HRQoL, especially the physical health components 
and the EQ-VAS, seems to decrease significantly with an increasing number of risk factors.
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Abstract 
Background: Patients with coronary heart disease often suffer from an impaired health-related 
quality of life (HRQoL) and psychological distress. A healthier lifestyle not only extends 
individuals’ lengths of life but might also improve their HRQoL/psychological distress. The 
aim of this study was to explore the relation between self-reported lifestyle changes and 
HRQoL/psychological distress in European coronary patients.  
Methods: Data on 8745 coronary patients, from 22 countries, participating in the 
EUROASPIRE III survey (2006–2007) were used. These patients hospitalized for coronary 
artery bypass graft, percutaneous coronary intervention, acute myocardial infarction, or 
myocardial ischemia were interviewed and examined at least 6 months and no later than 3 
years after their hospital admission to gather information on their EQ-5D, SF-12, HADS, self-
reported lifestyle changes, and risk factors.  
Results: Significantly better HRQoL/psychological distress scores were found in ex-smokers 
compared to current smokers. Patients who made an attempt to increase their physical activity 
level had a better HRQoL/psychological distress compared to those who had not made an 
attempt. Furthermore dietary changes were associated with HRQoL/psychological distress, 
with better outcomes in patients who tried to reduce fat and salt intake and increase fish, fruit, 
and vegetable intake. The intention to change behaviour was not associated with 
HRQoL/psychological distress.  
Conclusions: Better HRQoL/psychological distress scores were found in those coronary 
patients who adopted a healthier lifestyle. The actual lifestyle changes – smoking cessation, 
increasing physical activity, and adopting a healthy diet – and not the intention to change are 
associated with better HRQoL/psychological distress outcomes. 
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1. Introduction 
Even though cardiovascular disease (CVD) mortality rates have fallen rapidly in many 
European countries in the latest decades, CVD continues to be the number one cause of 
morbidity and mortality (Nichols et al, 2012; Perk et al, 2012). Many risk factors contribute to 
the development of CVD. In addition to unchangeable risk factors such as age, family history, 
gender, and geographical area, the progress of CVD is driven by several modifiable risk 
factors (Yusuf et al, 2004). Unhealthy lifestyle habits such as smoking, physical inactivity, 
and unhealthy eating habits have a major influence on the development of CVD; hence, 
guidelines on CVD prevention have stressed the importance of adopting a healthy lifestyle 
both in high-risk patients as well as in CVD patients (Pearson et al, 2002; Perk et al, 2012; 
Vanhees et al, 2012; World Health Organisation, 2007). According to several studies in the 
general population, the uptake of a healthier lifestyle – such as ceasing smoking, becoming 
physically active, and developing healthy eating habits – will not only extend the length of 
life but also improve the health-related quality of life (HRQoL) (Anokye et al, 2012; 
Henriquez Sánchez et al, 2012; Piper et al, 2012). HRQoL is a comprehensive concept 
referring to the individual’s physical, emotional, and social wellbeing (Thompson et al, 2003). 
Coronary patients often suffer from an impaired HRQoL; hence, many of them consider 
HRQoL equally important as the length of life. Patients and their caregivers as well as policy 
makers have a particular interest in finding ways to improve patients’ overall wellbeing 
(Thompson et al, 2003). However, evidence regarding the direct association between lifestyle 
changes and HRQoL or psychological well-being in coronary patients is scarce. Some studies 
report on the association with smoking cessation, weight loss, or physical activity; however, 
to our knowledge, no study has investigated the association of lifestyle changes in coronary 
patients with various HRQoL/psychological distress measures in a systematic manner 
(Haddock et al, 2003; Oreopoulos et al, 2010; Quist-Paulsen et al, 2006; Schweikert et al, 
2009; Sevinc et al, 2010; Taira et al, 2000). The aim of our study was to explore the relation 
between several self-reported lifestyle changes and HRQoL/psychological distress in coronary 
patients using data from a large European cohort. Knowledge about this association may lead 
to an increased motivation in patients to change their behaviour. Moreover, the outcomes of 
this study can be important for decision makers in defining priorities related to their 
prevention policy. We hypothesized that coronary patients who have not made an attempt to 
change their behaviour in order to adopt a healthier lifestyle would have worse 
HRQoL/psychological distress. 
2. Methods 
Study population and data collection 
This study is based on data collected during the EUROASPIRE III survey (European Action 
on Secondary and Primary Prevention through Intervention to Reduce Events). Details of the 
study have been described extensively elsewhere (Kotseva et al, 2009b). Briefly,  the 
EUROASPIRE III survey, conducted during 2006–07 under the auspices of the European 
Society of Cardiology Euro Heart Survey Programme, was a cross-sectional study to 
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determine whether the European recommendations on CVD prevention were being followed 
in everyday clinical practice across 22 European countries (76 hospital centres): Belgium, 
Bulgaria, Croatia, Cyprus, Czech Republic, Finland, France, Germany, Greece, Hungary, 
Ireland, Italy, Latvia, Lithuania, Poland, Romania, Russian Federation, Slovenia, Spain, The 
Netherlands, Turkey, and the UK. Patients aged between 18 and 80 years, hospitalized for 
coronary artery bypass graft, percutaneous coronary intervention, acute myocardial infarction, 
or myocardial ischemia but without evidence of myocardial infarction – hereafter referred to 
as the recruiting diagnosis – were retrospectively identified from diagnostic registers, hospital 
discharge lists or other sources. In total, 8966 patients (participation rate 73%) were 
interviewed and examined at least 6 months and no later than 3 years after their initial hospital 
admission. The present study included only those patients for which HRQoL/psychological 
distress information was available (n=8745). Data collection was conducted by trained 
research staff using standardized methods and instruments. Patient medical records from the 
initial hospital admission were reviewed, to collect – among others – information on their 
initial diagnosis, waist circumference, body weight, and height. At the time of interview and 
examination (median time= 1.24 years after the recruiting diagnosis), physical measurements 
were performed in light indoor clothes without shoes using calibrated measuring equipment. 
In addition, information was obtained on risk factors and adopted lifestyle changes. During 
the interview, data were gathered on smoking history and smoking cessation attempts 
undertaken since the initial hospital admission. Likewise, information on dietary steps 
(reducing salt intake, reducing fat intake, increasing fish intake, increasing fruit and vegetable 
intake) taken since the initial hospital admission to eat healthier and to reduce their body 
weight were collected. Additionally, several questions were asked regarding patients’ physical 
activity level and the attempts undertaken to increase their physical activity level. Patient 
were asked to describe their self-perceived physical activity level on the following scale: no 
physical activity; light physical activity; vigorous physical activity for 20 minutes, 2 or 3 
times a week; or vigorous physical activity for 20 minutes ≥3 times a week. Furthermore, they 
completed the short form International Physical Activity Questionnaire (IPAQ) allowing the 
categorization of patients according to their physical activity score. In addition, information 
about their future intention to change was gathered. The questions as asked during the 
interview can be found in the Appendix. Body mass index (BMI) was calculated as the 
patient’s weight in kilograms divided by the squared height in meters. The WHO classes were 
used for classification: normal range was defined as BMI <24.9 kg/m²; overweight was 
defined as BMI 25–29.9 kg/m², and obesity as BMI ≥30 kg/m² (World Health Organization, 
1995). Central obesity was defined as waist circumference 102 cm in men and 88 cm in 
women (Lean et al, 1995). Smokers were those who reported to be a current smoker or who 
had a carbon monoxide in breath value exceeding 10 ppm at the time of the interview. IPAQ 
classes were calculated according to the guidelines for data processing and analysis (IPAQ 
core group, 2005). A low IPAQ score was defined as no activity or some activity reported but 
not enough to meet the other categories. A moderate IPAQ score was defined as 3 or more 
days of vigorous-intensity activity of at least 20 minutes per day, or 5 or more days of 
moderate intensity activity and/or walking of at least 30 minutes per day, or 5 or more days of 
any combination of walking, moderate-intensity, or vigorous-intensity activities achieving a 
minimum total physical activity of at least 600 MET-minutes/week. Metabolic equivalent 
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(MET) is a common outcome measure used to express the energetic expenditure of different 
physical activities (Ainsworth et al, 2000). A high IPAQ score was defined as vigorous-
intensity activity on at least 3 days and accumulating at least 1500 MET-minutes/week or 7 or 
more days of any combination of walking, moderate- or vigorous- intensity activities 
accumulating at least 3000 MET-minutes/ week. To assess patients’ HRQoL/psychological 
distress, three self-administered questionnaires were given to the patients during the interview: 
the EuroQoL-5D (EQ-5D), the 12-item short form health survey (SF-12), and the Hospital 
Anxiety and Depression Scale (HADS). The former two are health status measures, whereas 
the latter assesses psychological well-being. Questionnaires were administered in the 
countries’ official language. Validity of these scales in this sample has been reported 
previously (De Smedt et al, 2013b). The EQ-5D contains a self-classifier using five 
dimensions, with three response categories each, to assess patients’ health status: mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression; from which an EQ-5Dindex 
score can be calculated (with 1 representing perfect health, 0 representing death, and <0 
representing a health state perceived worse than death). In addition, patients were asked to 
indicate their current health status on a visual analogue scale (EQ-VAS) ranging from 0 
(worst imaginable) to 100 (best imaginable) (Rabin et al, 2001). The current analysis only 
makes use of the VAS, as the normality assumptions for the EQ-5Dindex were not met. The 
SF-12 is a shortened version of the SF-36 consisting of 12 Likert scale questions, covering 
eight dimensions: general health, physical functioning, role physical, bodily pain, vitality, 
social functioning, role emotional, and mental health. Both physical (PCS-12) and mental 
functioning (MCS-12) component scores, ranging between 0 and 100, were calculated using a 
common scoring algorithm, with lower scores representing worse and higher scores 
representing better health (Ware et al, 2002). The SF-12 was not administered in Hungary. 
The HADS contains seven items related to anxiety and seven to depression, each with a 4-
point response scale. Item scores can be added to obtain the summary scores on anxiety 
(HADS-A) and depression (HADS-D) separately. The total score on each subscale ranges 
between 0 and 21 with higher scores representing worse outcomes (Zigmond et al, 1983). 
Statistical analysis 
All analyses are based on generalized linear mixed models in order to account for the 
clustering of patients within countries. HRQoL differences between groups were tested using 
multiple linear regression models. Potential confounding caused by differences in age, gender, 
diagnostic category, education, cardiovascular history, and diabetes was adjusted for all 
models. Results are shown for men and women together, since the interaction term with the 
different items was non-significant. Significance levels were set at p <0.05. All statistical 
analyses were performed using the IBM SPSS statistical software (version 20.0).  
3. Results  
The main characteristics of the patients included are shown in Table 1. Data on 6523 men 
(74.6%) and 2222 women (25.4%) were available for analysis. Patients’ age (mean ± SD) was 
63.2 ± 9.5 years. At the time of the recruiting diagnosis, patients’ BMI was 28.3 ± 4.4 kg/m2, 
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30.5% of patients were obese, 44.9% were central obese, and 30.2% reported smoking. At the 
time of the interview, patients’ BMI was 28.9 ± 4.5 kg/m2, 35.4% were obese, 16.9% were 
still smoking, and 11.7% reported no physical activity. In those patients being overweight or 
obese at the time of the recruiting diagnosis, 77.0 % reported ever being offered weight advice 
by a doctor or health professional, 68.2% of all patients reported having ever received 
personal advice on increasing physical activity, 92.0% had been ever advised on a healthy diet, 
and 87.7% of patients smoking at the time of the recruiting diagnosis had been ever offered 
smoking advice. Since the recruiting diagnosis, 81.8% of smokers made an attempt to quit 
smoking in order to reduce their risk of recurrent coronary heart disease, 90.2% of patients 
tried to eat healthier by reducing salt, sugar, or fat intake and increasing fish, fruit, and 
vegetable intake, and 58.6% of patients took steps to increase their physical activity level.  
Smoking 
HRQoL scores were significantly worse in smokers compared to non-smokers, with ex-
smokers (both patients who stopped smoking before or after the recruiting diagnosis) having 
HRQoL values leaning towards the scores of never smokers (Table 2). Patients who had made 
an attempt to quit smoking since the recruiting diagnosis, had a better HRQoL score (HADS-
D, EQ-VAS, PCS-12) compared to those who did not undertake an attempt to quit. However, 
as can bee seen from Table 2 the smoking status at the time of interview was responsible for 
these HRQoL differences. Indeed, whether or not a cessation attempt was made had no impact 
on the HRQoL outcomes in those still smoking at the time of the interview. A closer look into 
the quitters’ HRQoL indicated that the time since smoking cessation (<6 months vs. >6 
months) did not have an influence on their self-perceived mental, physical, and overall 
wellbeing. Patients still smoking at the interview, who had the intention to quit smoking in the 
following 6 months did not differ in HRQoL scores from those who did not consider smoking 
cessation.  
Physical activity 
A better HRQoL was reported in patients who had made an attempt to increase their physical 
activity compared to those who had not made such an attempt (Table 3). The actual physical 
activity level reported during the interview was significantly associated with HRQoL. A 
positive relation between HRQoL outcomes and the amount of exercise was seen both with 
the results of the validated IPAQ instrument as well as with the results of a single question, 
asking about the patients’ self-perceived physical activity level.  
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A combined parameter including IPAQ class and increasing physical activity revealed 
significant differences across groups, with the lowest HRQoL reported in patients in the 
lowest IPAQ class who have not made any attempt to become physically active, whereas 
those having a moderate or high IPAQ level who declared to have made an attempt to 
increase their physical activity reported the highest HRQoL. 
Table 1: Patient characteristics 
 Men (n=6523) Women (n=2222) All (n=8745) 
Age in years, Mean (SD) 62.3(9.5) 65.9(8.9) 63.2(9.5) 
Recruiting Diagnosis (%) 
CABG  
PTCA 
AMI  
Ischemia 
 
20.6%(1343/6523) 
43.1%(2809/6523) 
19.1%(1248/6523) 
17.2%(1123/6523) 
 
17.1%(380/2222) 
35.3%(784/2222) 
20.7%(460/2222) 
26.9%(598/2222) 
 
19.7%(1723/8745) 
41.1%(3593/8745) 
19.5%(1708/8745) 
19.7%(1721/8745) 
Education (%) 
Primary education  
Secondary education  
High education  
 
22.5%(1459/6487) 
57.3%(3717/6487) 
20.2%(1311/6487) 
 
33.5%(740/2211) 
54.8%(1212/2211) 
11.7%(259/2211) 
 
25.3%(2199/8698) 
56.7%(4929/8698) 
18.1%(1570/8698) 
Diabetes (%) 22.6%(1461/6461) 29.9%(659/2207) 24.5%(2120/8668) 
History of stroke (%) 4.1%(268/6507) 5.7%(127/2216) 4.5%(395/8723) 
Recurrent CHD after recruiting diagnosis (%) 14.1%(912/6490) 11.4%(251/2208) 13.4%(1163/8698) 
At time of recruiting diagnosis 
BMI, Mean (SD) 
Obesity (%) 
Central obesity (%) 
Smoking (%) 
 
28.2(4.2) 
28.5%(789/2764) 
38.6%(468/1211) 
33.8%(2201/6508) 
 
28.87(4.84) 
36.1%(352/974) 
61.3%(284/463) 
19.6%(434/2215) 
 
28.3(4.4) 
30.5%(1141/3738) 
44.9%(752/1674) 
30.2%(2635/8723) 
At time of interview 
BMI, Mean (SD) 
Obesity (%) 
Central obesity (%) 
Smoking (%) 
Self-reported PA 
No PA weekly (%) 
Light PA in most weeks (%) 
Vigorous PA, ≥20 min, once or twice/week (%) 
Vigorous PA, ≥20 min, ≥3 times a week (%) 
IPAQ moderate/high (%) 
Low 
Moderate 
high 
 
28.6(4.2) 
32.2%(2093/6500) 
41.6%(2681/6440) 
19%(1236/6507) 
 
10.8%(696/6428) 
56.3%(3618/6428) 
17.5%(1122/6428) 
15.4%(992/6428) 
 
22.3%(774/3476) 
38.8% (1350/3476) 
38.9%(1352/3476) 
 
29.70(5.19) 
44.8%(990/2210) 
70.4%(1546/2196) 
10.9%(242/2218) 
 
14.4%(316/2193) 
63.0%(1381/2193) 
13.3%(291/2193) 
9.3%(205/2193) 
 
31.9%(360/1129) 
39.1%(442/1129) 
29.0%(327/1129) 
 
28.9(4.5) 
35.4%(3083/8710) 
48.9%(4227/8636) 
16.9%(1478/8725) 
 
11.7%(1012/8621) 
58.0%(4999/8621) 
16.4%(1413/8621) 
13.9%(1197/8621) 
 
24.6%(1134/4605) 
38.9% (1792/4605) 
36.5% (1679/4605) 
Lifestyle advice on (%) 
Smoking cessation (in prior smokers) 
Diet 
Weight (if prior BMI>25)  
Physical activity 
 
88.3%(1935/2191) 
92.4%(5989/6479) 
75.7%(1607/2122) 
69.2%(4467/6457) 
 
84.5%(364/431) 
90.9%(2011/2213) 
80.5%(616/765) 
65.3%(1439/2204) 
 
87.7%(2299/2622) 
92.0%(8000/8692) 
77.0%(2223/2887) 
68.2%(5906/8661) 
Lifestyle changes to reduce risk of heart disease (%) 
Trying to stop smoking (in prior smokers) 
Trying to eat healthier 
Trying to increase physical activity 
 
81.2%(1713/2110) 
89.7%(5645/6291) 
59.9%(3792/6327) 
 
84.9%(348/410) 
91.6%(1963/2143) 
54.9% (1175/2142) 
 
81.8%(2061/2520) 
90.2%(7608/8434) 
58.6%(4967/8469) 
HRQoL/psychological distress at interview, Mean (SD) 
HADS-A 
HADS-D 
EQ-5Dindex 
EQ-VAS 
PCS-12 
MCS-12 
 
5.48(3.80) 
4.75(3.54) 
0.78(0.23) 
67.85(18.59) 
43.20(10.02) 
49.93(9.96) 
 
7.24(4.16) 
6.01(3.86) 
0.69(0.25) 
62.22(18.94) 
38.82(9.84) 
46.75(10.64) 
 
5.93(4.0) 
5.07(3.67) 
0.76(0.24) 
66.42(18.84) 
42.14(10.15) 
49.15(10.22) 
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At interview, in patients with a normal weight not yet exercising regularly, no significant 
difference was found in HRQoL (except for PCS-12) between those willing to become 
physically active, versus those not willing to become physically active. In contrast, patients 
being overweight or obese at interview with the intention to exercise regularly in the near 
future reported a higher HRQoL compared to those with no intention to become regularly 
physically active.  
Body weight and healthy diet  
BMI was significantly associated with HRQoL, with obese patients having inferior HRQoL 
outcomes (Table 4). At interview, among patients who were still overweight or obese, those 
with the intention to lose weight in the upcoming months did not differ significantly in 
HRQoL (except for PCS-12) from those who did not have any intention to lose weight. With 
regard to actual weight change, no significant difference was found in HRQoL outcomes 
(except for PCS-12) between those who had lost weight (5% weight loss), maintained their 
weight level (± 5% weight change), or gained weight (5% weight gain) between the recruiting 
diagnosis and the interview. HRQoL differed significantly between those who had taken steps 
to adopt a healthier diet, compared to those who did not. Patients reducing fat intake, reducing 
salt intake, increasing fish intake, or increasing fruit and vegetable intake had higher HRQoL 
values; however, the effects on the psychological dimensions was sometimes non significant 
(MCS-12, HADS-A).  
4. Discussion 
The aim of the current study was to investigate the relationship between self-reported lifestyle 
changes and HRQoL in coronary patients, using a large cohort originating from 22 European 
countries. Higher HRQoL scores were found in coronary patients who adopted a healthier 
lifestyle – by ceasing smoking, developing healthier eating habits, or increasing their physical 
activity – even after adjustment for other patient characteristics. Furthermore, no significant 
differences were found in HRQoL outcomes between patients considering smoking cessation 
versus those not intending to quit. It is thus unlikely that those willing to quit smoking had a 
higher initial HRQoL allowing them to find the motivation to quit. Nonetheless, it remains 
possible that ex-smokers differ from current smokers in several unmeasured characteristics, so 
these results should be interpreted with caution. In patients with a normal body weight, no 
differences were found between those intending to become more regularly physically active 
versus those without this intention. Likewise, overweight and obese patients considering 
weight loss did not differ in HRQoL compared with the non-intenders (except PCS-12), 
whereas overweight and obese patients intending to become physically active reported a 
higher HRQoL compared to those without this intention. Not surprisingly, the greatest 
HRQoL differences were found in the items capturing the current physical health status (PCS-
12). After all, physical activity constitutes a component of HRQoL. Patients experiencing 
problems with their physical health, due to pain/discomfort for instance, may be less likely to 
become physically active. 
  
 
 
Table 2: Association between HRQoL and SMOKING CESSATION  
 HADS-A HADS-D EQ-VAS PCS-12 MCS-12 
COMPLETE SAMPLE      
Smoking history†      
Ever smoker (n=3058) 6.72 ± 0.22 5.68± 0.22 62.62± 1.36 38.52± 0.78 47.99± 0.67 
Prior smoker (n=1279) 6.73± 0.24 5.78± 0.24 62.26± 1.41 38.77± 0.81 48.05± 0.71 
Smoker (n=1478) 7.21± 0.24 6.48± 0.24 60.73± 1.41 37.81± 0.80 46.32± 0.71 
Never smoker (n=2896) 6.70± 0.22 5.85± 0.22 63.68± 1.35 39.58± 0.77 47.37± 0.67 
 p<0.000 p<0.001 p=0.003 p<0.001 p<0.001 
SMOKING AT TIME OF RECRUITING DIAGNOSIS      
Smoking cessation attempt       
Yes (n=2061) 7.01± 0.34 6.12± 0.31 62.11± 1.64 39.89± 0.96 46.84± 0.93 
No (n=459) 7.30± 0.38 6.54± 0.34 59.77± 1.83 38.41± 1.05 45.75± 1.03 
 p=0.160 p=0.030 p=0.018 p=0.004 p=0.054 
Smoking status at interview      
Still smoking – no cessation attempt (n=376) 7.32± 0.38 6.65± 0.35 60.61± 1.85 38.59± 1.07 45.38± 1.05 
Still smoking – cessation attempt (n=915) 7.38± 0.34 6.54± 0.31 60.91± 1.68 39.22± 0.99 45.69± 0.95 
Prior smoker† (n=1279) 6.83± 0.34 5.83± 0.31 62.22± 1.65 40.05± 0.97 47.38± 0.93 
 p=0.004 p<0.001 p=0.177 p=0.021 p<0.001 
PRIOR SMOKERS†      
Quit time       
<6 months before interview (n=173) 6.75± 0.50 6.00± 0.45 62.39± 2.49 39.60± 1.34 49.22± 1.31 
>6 months before interview (n=1077) 7.02± 0.42 6.15± 0.38 62.26± 2.14 40.48± 1.17 48.21± 1.11 
 p=0.392 p=0.620 p=0.930 p=0.264 p=0.223 
SMOKING AT THE TIME OF INTERVIEW      
Intention to quit smoking       
Yes (n=652) 7.70± 0.50 6.37± 0.43 59.04± 2.20 37.48± 1.30 45.22± 1.36 
No (n=354) 7.18± 0.53 6.25± 0.46 61.08± 2.34 38.67± 1.38 46.38± 1.45 
 p=0.064 p=0.629 p=0.120 p=0.073 p=0.126 
Values are mean ± SE adjusted for age, gender, diagnostic category, education, diabetes, recurrent coronary heart disease, and history of stroke.; † Ever 
smoker, patients who have ever smoked but who where former smokers at the time of the recruiting diagnosis; prior smoker, patients who where smoking at the 
time of the recruiting diagnosis, but were former smokers at the time of the interview; smoker, patients still smoking at the time of interview; never smokers, 
patients who have never smoked.; EQ-VAS, EuroQoL visual analogue scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety; 
HADS-D, HADS depression; MCS-12, SF-12 mental functioning; PCS-12, SF-12 physical functioning; SF-12, the 12-item short form health survey. 
  
 
 
Table 3: Association between HRQoL and PHYSICAL ACTIVITY CHANGES  
 HADS-A HADS-D EQ-VAS PCS-12 MCS-12 
COMPLETE SAMPLE      
Attempt to increase physical activity      
Yes (n=4967) 6.57± 0.22 5.56± 0.22 64.17± 1.33 39.90± 0.75 48.02± 0.66 
No (n=3502) 7.14± 0.22 6.31± 0.22 60.69± 1.34 37.50± 0.75 46.82± 0.67 
  p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
Physical activity level based on single question†      
No physical activity (n=1012) 7.62± 0.24 7.22± 0.24 55.53± 1.43 34.01± 0.84 44.93± 0.70 
Light physical activity in most weeks (n=4999) 6.83± 0.22 5.90± 0.22 62.53± 1.34 38.81± 0.80 47.57± 0.64 
Vigorous PA ≥20 min, ≤ 2x/week (n=1413) 6.20± 0.24 5.14± 0.24 67.21± 1.41 41.75± 0.83 48.71± 0.69 
Vigorous PA ≥20 min, ≥3x/week (n=1197) 6.02± 0.24 4.90± 0.24 68.36± 1.43 42.44± 0.83 49.33± 0.70 
 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
IPAQ      
Low (n=1134) 7.21± 0.29 6.67± 0.29 57.21± 2.09 35.99± 1.02 46.20± 0.86 
Moderate (n=1792) 6.24± 0.29 5.48± 0.29 63.65± 2.09 39.64± 1.02 49.31± 0.85 
High (n=1679) 6.01± 0.30 5.09± 0.30 67.94± 2.10 41.03± 1.03 50.90± 0.87 
 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
Change in physical activity according to IPAQ classes      
Change in PA + low IPAQ (n=515) 7.02± 0.32 6.49± 0.31 58.55± 2.10 37.57± 1.03 46.56± 0.90 
No change in PA + low IPAQ (n=591) 7.51± 0.32 6.95± 0.31 54.93± 2.09 33.90± 1.03 45.71± 0.90 
Change in PA + moderate/high IPAQ (n=2093) 5.90± 0.30 5.09± 0.29 66.74± 2.01 40.83± 0.99 50.23± 0.84 
No change in PA + moderate/high IPAQ (n=1264) 6.59± 0.30 5.66± 0.30 62.74± 2.04 38.82± 1.00 49.39± 0.86 
 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
PHYSICALLY INACTIVE PATIENTS‡      
Intention to become PA (if normal weight)      
Yes (n=200) 7.32± 0.49 5.80± 0.44 63.63± 2.43 41.12± 1.22 47.04± 1.25 
No (n=736) 7.05± 0.42 6.30± 0.38 62.36± 2.14 37.87± 1.07 46.85± 1.07 
 p=0.399 p=0.096 p=0.409 p<0.001 p=0.834 
Intention to become PA (if overweight or obese)      
Yes (n=1098) 6.69± 0.29 6.00± 0.26 63.69± 1.47 39.10± 0.82 47.63± 0.79 
No (n=3315) 7.01± 0.27 6.28± 0.25 60.29± 1.40 37.65± 0.79 46.64± 0.74 
 p=0.025 p=0.035 p<0.001 p<0.001 p=0.009 
Values are mean ± SE adjusted for age, gender, educational level, recruiting diagnosis, diabetes, history of stroke, and coronary recurring events.; † Which of 
the following four best describes your level of activity outside work?; ‡Physically inactive <3–5 times/week, 20–60 min/session.; EQ-VAS, EuroQoL visual 
analogue scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety; HADS-D, HADS depression; IPAQ, International Physical Activity 
Questionnaire; MCS-12, SF-12 mental functioning; PCS-12, SF-12 physical functioning; SF-12, the 12-item short form health survey. 
  
 
 
Table 4: Association between HRQoL and DIETARY CHANGES  
 HADS-A HADS-D EQ-VAS PCS-12 MCS-12 
COMPLETE SAMPLE      
BMI at interview      
Normal (n=1572) 6.84± 0.23 5.92± 0.23 62.89± 1.38 39.45± 0.78 47.13± 0.69 
Overweight (n=4055) 6.68± 0.22 5.72± 0.22 63.53± 1.34 39.59± 0.76 47.80± 0.66 
Obese (n=3083) 6.90± 0.22 6.04± 0.22 61.89± 1.34 37.92± 0.76 47.39± 0.66 
 p=0.052 p=0.001 p=0.001 p<0.001 P=0.056 
Weight changes between recruiting diagnosis and 
interview 
     
≥5% weight loss (n=763) 6.78± 0.26 6.01± 0.25 62.87± 1.55 39.08± 0.84 46.91± 0.76 
-5% <weight change <+5% (n=4066) 6.66± 0.23 5.77± 0.23 63.23± 1.45 39.46± 0.79 47.61± 0.69 
≥5% weight gain (n=1496) 6.71± 0.25 5.95± 0.24 61.93± 1.50 38.56± 0.82 47.67± 0.73 
 p=0.746 p=0.115 p=0.070 p=0.012 p=0.209 
Attempt to eat healthier      
Change in fat intake      
Yes (n=7376) 6.77± 0.22 5.83± 0.22 62.94± 1.33 38.99± 0.76 47.57± 0.65 
No (n=1285) 6.99± 0.24 6.24± 0.24 61.04± 1.42 37.95± 0.80 47.02± 0.70 
 p=0.070 p<0.001 p=0.001 p=0.001 p=0.083 
Reduction in salt intake      
Yes (n=6150) 6.77± 0.22 5.79± 0.22 63.19± 1.35 39.08± 0.76 47.58± 0.65 
No (n=2417) 6.93± 0.23 6.08± 0.23 61.74± 1.39 38.44± 0.78 47.25± 0.68 
 p=0.108 p=0.001 p=0.002 p=0.010 p=0.202 
Increase in fish intake      
Yes (n=5818) 6.67± 0.22 5.73± 0.22 63.73± 1.35 39.12± 0.76 47.71± 0.65 
No (n=2815) 7.08± 0.22 6.21± 0.23 60.90± 1.37 38.33± 0.77 47.09± 0.67 
 p<0.001 p<0.001 p<0.001 p=0.001 p=0.012 
Increase in fruit and vegetable intake      
Yes (n=6765) 6.73± 0.22 5.78± 0.22 63.18± 1.34 39.10± 0.76 47.55± 0.65 
No (n=1886) 6.95± 0.23 6.19± 0.23 61.24± 1.39 38.32± 0.79 47.36± 0.68 
 p=0.034 p<0.001 p<0.001 p=0.003 p=0.492 
OVERWEIGHT AND OBESE PATIENTS      
Intention to lose weight      
Yes (n=3226) 6.90± 0.23 5.92± 0.22 62.21± 1.33 38.35± 0.79 47.66± 0.68 
No (n=3524) 6.78± 0.23 5.91± 0.22 62.31± 1.33 39.16± 0.79 47.39± 0.68 
 p=0.233 p=0.915 p=0.835 p=0.001 p=0.313 
Values are mean ± SE adjusted for age, gender, educational level, recruiting diagnosis, diabetes, history of stroke, and coronary recurring events.; EQ-VAS, 
EuroQoL visual analogue scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety; HADS-D, HADS  depression; MCS-12, SF-12 
mental functioning; PCS-12, SF-12 physical functioning; SF-12, the 12-item short form health survey. 
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These findings support the hypothesis of a vicious circle, where overweight and obese people 
who often experience difficulties in walking or climbing stairs, for example, are less inclined 
to become physically active, thus leading to an increase in weight, which again leads to less 
exercise (Bauman et al, 2012). Therefore, implementing multimodal interventions, focusing 
both on exercise, diet, and weight may be necessary. Lower HRQoL scores were found in 
smokers compared to non-smokers (both never smokers and former smokers). These results 
confirm the observations found in several studies conducted in the general population; 
however, for coronary patients, conflicting results have been found (Haddock et al, 2003; 
Piper et al, 2012; Quist-Paulsen et al, 2006; Schweikert et al, 2009; Taira et al, 2000). Even 
though patients who made an attempt to quit smoking had a higher HRQoL compared to those 
who did not, no significant difference could be found between attempters and non-attempters 
still smoking at interview, suggesting that only successful smoking cessation attempts will 
lead to a HRQoL increase. Furthermore, our results imply that HRQoL outcomes rapidly 
improve once patients stop smoking, because time since smoking cessation did not have an 
influence on HRQoL. Likewise, a study in the general population by Piper et al. showed that 
HRQoL improved quickly (1 year) after smoking cessation and that this improvement was 
sustained for at least 3 years (Piper et al, 2012). Within the Nurses’ Health Study, HRQoL 
scores improved gradually with longer time since quitting (Sarna et al, 2008). In complete 
agreement with past research both in the general population as well as in coronary patients, 
our results have shown that, based on both subjective as well as standardized measures 
(IPAQ), low physical activity levels are associated with worse HRQoL scores (Bize et al, 
2007; Sevinc et al, 2010). Conform the observations made by Martin et al. (Martin et al, 
2009), our findings suggest that the improvements in HRQoL outcomes are associated with 
the amount of physical activity; however, the largest increase was seen between low and 
moderate IPAQ scores and a significant but lower effect was found between moderate and 
high IPAQ. Actions related with an increase in physical activity as well as the actual physical 
activity levels were associated with better HRQoL outcomes. These components seem to 
reinforce one another, with the highest HRQoL scores seen in patients residing in the highest 
IPAQ class, who had, moreover, made an attempt to increase their physical activity. In 
accordance with the literature, BMI was inversely associated with HRQoL (Oreopoulos et al, 
2010; Schweikert et al, 2009). In contrast, regarding weight changes (≥5% weight loss; ± 5% 
weight change; ≥5% weight gain) between recruiting diagnosis and interview, no significant 
between-group differences were observed. In the general population, similar results were 
found, allowing us to conclude that the act of exercising and healthy eating behaviour 
themselves, and not merely losing weight, are aligned with a better HRQoL (Martin et al, 
2009). Finally, dietary changes are associated with better HRQoL outcomes. Results from the 
SUN project have also found an important association between adherence to Mediterranean 
diet (consumption of fruit, vegetables, and fish and olive oil and reduction of meat and dairy 
intake) and better SF-36 scores (Henriquez Sánchez et al, 2012). Little is know about the 
clinical relevance of these differences in HRQoL, since no general consensus is available on 
what is perceived as a meaningful difference. Some authors have suggested half a standard 
deviation as the minimal important difference (MID) (Norman et al, 2003), while others have 
proposed a 3–5-point change for the SF-12 (Samsa et al, 1999), a MID of 0.074 for EQ-5D 
(Walters et al, 2005), and a MID of 1.5 for HADS (Puhan et al, 2008). When applying these 
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rules, no clinical relevance could be found for most associations, with the exception of 
physical activity, with several items exceeding the MID. The limitations of our study have to 
be acknowledged in order to interpret the results correctly. Potential for recall bias exists, 
since most data were self-reported. Furthermore, there is potential confounding by social 
desirability bias. Patients may have overestimated their behavioural changes in order to 
present a more social acceptable image of themselves. Also, the included questions did not 
allow assessment of the degree to which an attempt was made to alter their behaviour. The 
questions included in the questionnaire were formulated as ‘steps taken to reduce your risk of 
CHD’. We have no information about when the patient has taken these steps, how many times, 
and whether or not the patient is still continuing with the action.  Also, the cross-sectional 
study design does not allow assessment of the directionality of the association between 
HRQoL and lifestyle changes. However, the lack of association between the intention to 
accept a healthier lifestyle and patients’ HRQoL most likely indicates that the lifestyle 
changes induce better HRQoL outcomes and not the other way round. A longitudinal 
assessment as well as a more detailed questionnaire in order to gather further information on 
the ‘stage of change’ is needed in order to better understand the complex relationship between 
lifestyle changes and HRQoL. According to the transtheoretical model, behavioural changes 
can be divided in five different stages of change: the precontemplation stage, the 
contemplation stage, the preparation stage, the action stage and the maintenance stage 
(Prochaska et al, 1983; Romain et al, 2012). Furthermore, it is unclear whether these benefits 
in HRQoL are sustained over time or whether the gains are associated with a one-time benefit 
inherent to the change itself; hence, further research should focus on the long-term gains in 
HRQoL. In addition, patients included are not always representative for a country’s coronary 
patients, since data from selected geographical areas were used. The main strengths of our 
study are its large sample, including patients across Europe, and its ability to control for 
various confounders. Notwithstanding the limitations, out results reveal HRQoL gains 
associated with adopting a healthier lifestyle. The actual self-reported lifestyle changes – 
ceasing smoking, increasing physical activity, and adopting a healthy diet – and not the 
intention to change are associated with better HRQoL outcomes.  
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APPENDIX  
Risk factor: Smoking 
Have you ever smoked?  1 Yes                   2 No 
Were you smoking in the month prior to the hospital admission for the index event or 
procedure? 
 1 Yes                   2 No 
Do you smoke now?  1 Yes                   2 No 
If not smoking now, did you quit within the last 6 months?  1 Yes                   2 No 
If not smoking now, did you quit more than 6 months ago?  1 Yes                   2 No 
If smoking now, are you seriously thinking of quitting smoking?  1 Yes, within the next 30 days                  
 2 Yes, within the next 6 months 
 3 No, not thinking of quitting 
 4 Don’t know/ Unsure 
Risk factor: Diet and Body Weight    
Are you seriously considering trying to lose weight to reach your goal in the next 
month? 
 1 Yes                   2 No  3 Don’t know/ Unsure 
Are you seriously considering trying to lose weight to reach your goal in the next 6 
months? 
 1 Yes                   2 No  3 Don’t know/ Unsure 
Risk factor: Physical Activity  
Which of the following four best describes your level of activity outside work? 
(Please continue getting to and from work, sporting activity and other physical effort 
during your leisure time, like gardening or dancing. Vigorous activity causes 
shortness of breath, a rapid heart rate, and sweating.) 
 1 No physical activity weekly                  
 2 Only light physical activity in most weeks 
 3 Vigorous physical activity at least 20 minutes 
once or twice a week 
 4 Vigorous physical activity for at least 20 
minutes three or more times a week  
 5 Don’t know/ Unsure 
Regular Exercise is any PLANNED physical activity (e.g., brisk walking, aerobics, 
jogging, bicycling, swimming, rowing, etc.) performed to increase physical fitness. 
(Such activity should be performed 3 TO 5 TIMES per week for 20-60 MINUTES per 
session.  Exercise does not have to be painful to be effective but should be done at a 
level that increases your breathing rate and causes you to break a sweat.)  Do you 
exercise regularly according to that definition? 
 1 Yes, I have been for MORE than 6 months                  
 2 Yes, I have been for LESS than 6 months                  
 3 No, but I intend to in the next 30 days 
 4 No, but I intend to in the next 6 months 
 5 No, and I do NOT intend to in the next 6 
months 
 6 Don’t know/ Unsure 
Which one of the following steps did you take SINCE THE INDEX EVENT OR PROCEDURE to reduce your risk of heart disease? 
Stop smoking     
Abstinence  1 Yes                   2 No  3 Don’t know/ Unsure 
Reduction  1 Yes                   2 No  3 Don’t know/ Unsure 
smoking cessation clinic  1 Yes                   2 No  3 Don’t know/ Unsure 
nicotine replacement therapy  1 Yes                   2 No  3 Don’t know/ Unsure 
Bupropion  1 Yes                   2 No  3 Don’t know/ Unsure 
Other  1 Yes                   2 No  3 Don’t know/ Unsure 
Healthy diet     
reduction of fat intake  1 Yes                   2 No  3 Don’t know/ Unsure 
eating more fruits and vegetables  1 Yes                   2 No  3 Don’t know/ Unsure 
eating more fish  1 Yes                   2 No  3 Don’t know/ Unsure 
reducing sugar  1 Yes                   2 No  3 Don’t know/ Unsure 
Increase physical activity     
following specific exercise advice from a health or exercise professional  1 Yes                   2 No  3 Don’t know/ Unsure 
attending a fitness club or leisure centre  1 Yes                   2 No  3 Don’t know/ Unsure 
trying to do more general everyday physical activities  1 Yes                   2 No  3 Don’t know/ Unsure 
joining a community walking group  1 Yes                   2 No  3 Don’t know/ Unsure 
Other  1 Yes                   2 No  3 Don’t know/ Unsure 
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Chapter 7. 
Association HRQoL/psychological 
distress and risk factor level awareness 
in coronary patients 
 
Based on:  
De Smedt D, Clays E, Annemans L, Pardaens S, Kotseva K, De Bacquer D, On behalf of the EUROASPIRE 
Study Group 
Risk factor awareness in a coronary population is associated with better health-related quality of life 
outcomes. 
International Journal of Public Health. Submitted 
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Abstract 
Purpose: The purpose of this study was to investigate the risk factor level awareness in 
coronary patients and to assess its associations with health-related quality of life 
(HRQoL)/psychological distress.  
Methods: Data from EUROASPIRE III (European Action on Secondary and Primary 
Prevention by Intervention to Reduce Events) was used. 8743 coronary patients from 22 
European countries were interviewed and examined at least 6 months after their acute event. 
Patients were asked to complete EQ-5D, SF-12 and HADS instruments. Furthermore risk 
factor level awareness was assessed during interview. 
Results: 81.7% of patients indicated to be aware of their own blood pressure level, whereas 
only 46.6% of patients indicated to be aware of their cholesterol level. Furthermore, 43.7% of 
patients were aware of their blood glucose level, whereas in diabetes patients blood glucose 
level awareness reached 81.8%. Risk factor level awareness was significantly associated with 
HRQoL/psychological distress, with patients being unaware of their risk factor levels having 
worse outcomes. The relationship between awareness and HRQoL/psychological distress 
seemed to be partly mediated by the attempt of patients to adopt a healthier behaviour, 
nevertheless, there was also a direct link between awareness and HRQoL/psychological 
distress. 
Conclusion: Insufficient risk factor level awareness in coronary patients is associated with 
worse HRQoL/psychological distress, independent from patients’ risk factor profile. Health 
care workers should be encouraged to inform their patients about the importance of their 
coronary risk factors, the actual level and their personal target. 
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1. Introduction 
The major causes responsible for developing coronary heart disease (CHD) in addition to 
increasing age and genetic predisposition are elevated cholesterol level, high blood pressure, 
smoking, obesity, diabetes, physical inactivity and psychosocial stress (Perk et al, 2012). 
Therefore, in addition to optimized medical treatment, behavioural changes towards a 
healthier lifestyle are recommended. Smoking cessation, a healthy diet and an increase in 
physical activity are known to have a positive influence on CHD risk factors and 
consequently help to reduce the risk for a coronary event (Perk et al, 2012). Many coronary 
patients however, are unable to list the risk factors associated with CHD (Redfern et al, 2007). 
According to a study by Karthik et al. about half of coronary artery disease (CAD) patients 
identify smoking (53.6%) and high cholesterol (55.3%) as a risk factor. Blood pressure and 
family history were identified as a risk factor by only two in five patients (43% and 42.5% 
respectively) and no more than 14.5% and 13.6% of patients know that diabetes and obesity 
are risk factors for CHD  (Karthik et al, 2006). Furthermore, they observed that only one in 
two patients taking CHD medication have knowledge about its role in their treatment (Karthik 
et al, 2006). Moreover, few CHD patients are aware about their own risk factor profile. Cheng 
et al. found that two thirds of CAD patients were aware of their own blood pressure level and 
only 45.3% of patients reported to be aware of their cholesterol level (Cheng et al, 2005b; 
Cheng et al, 2005a). Similar results were found in the general population, with only 51% of 
US citizens being aware of their own cholesterol level (Nash et al, 2003).  
This lack of patient awareness could result in low adherence to lifestyle changes and 
prescribed medication. A better knowledge and understanding of CHD risk factors as well as 
patients' knowledge about their own coronary heart disease risk factors correlates with 
improved patient behaviour, both concerning self-reported lifestyle changes as well as 
medication adherence, which can lead to better cardiovascular outcomes (increase in survival, 
decrease in cardiac events) (Alm-Roijer et al, 2004, Alm-Roijer et al, 2006).  According to 
Grover et al (2007) discussing the coronary risk profile with the patient is associated with a 
small but measurable improvement in the efficacy of lipid therapy (Grover 2007). Recently 
however, in addition to the more objective clinical measures, many patients consider the 
health-related quality of life (HRQoL) equally important. HRQoL is a multidimensional 
concept assessing the effect of a disease, its treatment and symptoms on patients’ physical, 
emotional and social well-being. Prior studies have found an association between impaired 
HRQoL, anxiety, depression and worse long-term cardiovascular outcomes (Kurdyak et al, 
2011; Spertus et al, 2002; Thombs et al, 2008).  
The purpose of the current study is twofold. Firstly, we wanted to investigate the risk factor 
awareness in a large European sample of coronary patients. Secondly, we hypothesized that 
risk factor awareness in CHD patients will be associated with an improved HRQoL and with 
less psychological distress. Furthermore, we wanted to examine whether such an association 
is mediated by lifestyle changes or yet another mechanism. This issue has not yet been 
addressed previously.  
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2. Methods 
Data collection 
Data were extracted from the EURopean Action on Secondary and Primary Prevention by 
Intervention to Reduce Events (EUROASPIRE III) study, a cross-sectional survey performed 
in 2006-2007 across 22 European countries: Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, 
Poland, Romania, Russian Federation, Slovenia, Spain, The Netherlands, Turkey, and the 
United Kingdom (UK). More details on this survey can be found elsewhere (Kotseva et al, 
2009b). Briefly, patients aged between 18 and 80 years, hospitalized for coronary artery 
bypass graft (CABG), percutaneous coronary intervention (PCI), acute myocardial infarction 
(AMI) or myocardial ischemia, were retrospectively identified from diagnostic registers, 
hospital discharge lists or other sources.  
Patients were invited for interview and physical examination. Data collection was organized 
in a standardized way by trained research staff. In total, 8,966 patients (participation 
rate=73%) were interviewed and examined at least 6 months and not later than 3 years after 
their initial hospital admission (median=1.24 years). 
The following information was obtained: personal and demographic details, medical and in 
particular cardiovascular history, family history of CHD, reported lifestyle, lifestyle changes 
and risk factor management related to exercise, diet, smoking and medical treatment. Patients 
were also asked “Whose care are you currently (in the last three months) under for your 
cardiac condition”. Weight, height, waist circumference, blood pressure (BP), heart rate, 
breath carbon monoxide, serum total cholesterol (TC), high-density lipoprotein cholesterol 
(HDL-C), triglycerides, low-density lipoprotein cholesterol (LDL-C), blood glucose and 
glycated haemoglobin (HbA1c) in patients with diabetes, were measured. The risk factor 
targets used, were based on the European guidelines on cardiovascular prevention (Perk et al, 
2012). Raised BP was defined as systolic blood pressure (SBP)/ diastolic blood pressure 
(DBP) ≥140/90 mm Hg (≥130/80 mm Hg in patients with diabetes). Raised TC was defined 
as TC ≥4.5 mmol/L. Raised blood glucose was defined as blood glucose ≥6.1 mmol/L. Low 
physical activity was defined as less than 20 min moderate physical activity, three times a 
week. Central obesity was defined as waist circumference >102/88 cm (men/women).  
In addition, patients were asked to complete 3 validated self-administered measures to assess 
their HRQoL and psychological distress: the EuroQoL-5D (EQ-5D), the 12-item short form 
health survey (SF-12), and the Hospital Anxiety and Depression Scale (HADS) (De Smedt et 
al, 2013b). The EQ-5D is a commonly used, easy to complete, standardized instrument to 
measure health status, containing a descriptive part (EQindex) and a visual analogue scale (EQ-
VAS). The former covers 5 dimensions: mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression, with three response categories each (no problems, some problems, or 
severe problems). The answers on these dimensions provide a simple descriptive profile from 
which an index score can be calculated, with 1 representing perfect health, 0 representing 
death, and <0 representing a health state perceived worse than death. The EQ-VAS  a 20 cm 
vertical scale on which the patient is asked to indicate how good or bad their current health 
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status is  from 0 (worst imaginable) to 100 (best imaginable) (Rabin et al, 2011). The SF-12 
(second version) emerges from the SF-36, but includes only 12 Likert scale questions, 
covering eight dimensions: general health, physical functioning, role physical, bodily pain, 
vitality, social functioning, role emotional, and mental health. Both a physical (PCS-12) and 
mental functioning (MCS-12) component score, ranging between 0 and 100, can be calculated 
using a norm-based scoring algorithm. Lower scores represent worse and higher scores 
represent better self-perceived HRQoL outcomes (Ware et al, 2002). The SF-12 was not 
administered in Hungary. The HADS instrument finally, merely covers psychological issues, 
and it is useful in assessing the mental health status of patients. It contains seven items related 
to anxiety and seven related to depression, each with a 4-point response scale. Item scores can 
be added to obtain the summary scores on anxiety (HADS-A) and depression (HADS-D) 
separately. The total score on each subscale ranges between 0 and 21 with higher scores 
representing worse outcomes (Zigmond et al, 1983).  
Furthermore, risk factor level awareness were assessed during interview. Patients were asked 
the following questions: “Are you aware of your latest blood pressure/ total cholesterol/ 
blood glucose level? YES/NO” 
Statistical analyses 
Risk factor level awareness variables were investigated both as separate items and as a 
combination of variables. The combined variable incorporated BP, TC and blood glucose 
level awareness. Hence patients could be aware on 0, 1, 2 or 3 risk factor levels. The first was 
labelled as unaware whereas the latter three were categorized as aware of at least one risk 
factor. Descriptive analyses were performed in order to gain knowledge about gender and 
country specific risk factor level awareness rates. Chi² tests and the Kruskal-Wallis tests were 
used to assess characteristics associated with awareness. Furthermore, a multilevel linear 
model, with HRQoL as continuous outcomes was used in order to account for the clustering 
of patients within countries (random effect). No interaction with gender was seen, hence 
instead of performing the analyses separately for males and females, gender was included as 
covariate in the analyses. Initial adjustment for age, gender, education and country was 
carried out and further adjustment for lifestyle changes was applied (fixed effect). Analyses 
were performed using IBM SPSS version 21. Significance levels were set at p <0.05. 
3. Results 
Of the 8966 eligible patients, 8743 patients provided valid HRQoL and awareness 
information. Their mean age was 63.2 years (SD=9.5), 74.6% were male, and 25.3% had only 
received a low education. At the time of the interview 24.5% had diabetes, 35.4% was obese 
and 49.0% was central obese, 16.9% were smoking, 69.7% reported a low physical activity 
level, 51.3% had a raised TC and 56.1% had a raised BP, 79.7% and 70.5% were taking lipid 
lowering and antihypertensive medication respectively. 
According to the patients, risk factors measurement since index hospitalization was not 
always done: 96.6% of patients have indicated that their BP was measured, 87.4% of patients 
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stated that their TC was measured and 80.1% and 94.4% of the complete sample and the 
diabetes patients respectively, reported that their blood glucose was measured since their 
index hospitalization. 
Risk factor level awareness among patients was highest with regard to BP, with 81.7% of 
patients indicating to be aware of their own level. With regard to cholesterol only 46.6% of 
patients indicated to be aware of their own TC level. Furthermore, 43.7% of the complete 
sample was aware of their blood glucose level, whereas in diabetes patients blood glucose 
level awareness reached 81.8% (Table 1). 
Table 1: Risk factor level awareness in coronary patients, stratified by age and gender 
 ALL , % aware(n) MALE , % aware(n) FEMALE , % aware(n) 
  ≤65 year >65 year p-value* ≤65 year >65 year p-value* 
TC level 46.6(4076/8743) 48.0(1826/3803) 44.8(1217/2719) 0.009 49.9(471/943) 44.0(562/1278) 0.005 
BP level 81.7(7143/8743) 80.7(3069/3803) 83.0(2257/2719) 0.019 81.8(771/943) 81.8(1046/1278) 0.989 
BG level 43.7(3824/8743) 40.3(1532/3803) 45.2(1229/2719) <0.001 46.9(442/943) 48.6(621/1278) 0.433 
BG level (if 
diabetes) 
81.8(1734/2120) 82.9(655/790) 82.3(552/671) 0.745 84.6(225/266) 76.8(302/393) 0.015 
TC: total cholesterol; BP: blood pressure; BG:  blood glucose  
* Significance between age groups 
In bold: significant difference between gender,  categorized by age 
 
 
No consistent distinction in awareness rates could be observed across age groups. 
Furthermore, in those patients aged 65 years or younger, risk level awareness did not differ 
substantially between males and females, except for blood glucose. In those patients above 65 
years, females were more likely to be aware of their blood glucose level, except in diabetes 
patients were males were more aware about their level (table 1).  
Furthermore, a great variation in awareness can be seen across countries (table 2). The lowest 
patient awareness was seen in Ireland and the UK with the proportion of patients being aware 
on at least one out of three risk factor levels amounting to 61.3% and 63.4% respectively. 
Only 2.9% of Irish and 8.1% of UK patients were perfectly aware on all three risk factors. In 
contrast, more than half of the Russian (62.8%), Greek (56.7%) and Cypriot (52.3%) patients 
were fully aware on all three risk factors. 
Additionally, a within country variation is observed with great awareness on some risk factors 
and very low awareness on others. In Belgium for example, a high proportion of patients was 
aware of his/her own blood pressure level (87.1%), whereas a minority of patients were aware 
of their blood glucose level (18.9%). Similarly, the blood pressure awareness in Spanish 
patients (84.2%) is high whereas less than 1 in 4 patients is aware on their total cholesterol 
level (23.6%). Likewise, although  the awareness on blood pressure and blood glucose in Irish 
(23.1% and 15.3% resp.) and UK patients (34.8% and 22.0% resp.) is very low the proportion 
of patients being aware on their total cholesterol level is rather average (47.8% and 46.3%). 
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Table 2: Risk factor level awareness in coronary patients across Europe 
COUNTRY TC-level, % 
aware(n) 
BP-level, % 
aware(n) 
BG-level, % 
aware(n) 
Perfectly aware, % 
aware(n) 
Belgium 39.6 (111/280) 87.1 (244/280) 18.9 (53/280) 8.9 (25/280) 
Bulgaria 25.1 (135/538) 78.4 (422/538) 33.3 (179/538) 15.8 (85/538) 
Croatia 35.1 (158/450) 84.4 (380/450) 43.8 (197/450) 23.1 (104/450) 
Cyprus 59.9 (260/434) 86.4 (375/434) 66.6 (289/434) 52.3 (227/434) 
Czech Republic 48.0 (228/475) 87.4 (415/475) 45.3 (215/475) 30.7 (146/475) 
Finland 60.3 (143/237) 75.5 (179/237) 41.8 (99/237) 30.8 (73/237) 
France 56.4 (171/303) 94.7 (287/303) 54.5 (165/303) 40.9 (124/303) 
Germany 38.5 (212/550) 80.4 (442/550) 31.5 (173/550) 16.0 (88/550) 
Greece 78.3 (94/120) 74.2 (89/120) 64.2 (77/120) 56.7 (68/120) 
Hungary  42.5 (194/457) 91.5 (418/457) 63.5 (290/457) 33.5 (153/457) 
Ireland 47.8 (184/385) 23.1 (89/385) 15.3 (59/385) 2.9(11/385) 
Italy 50.9 (192/377) 97.1 (366/377) 49.9 (188/377) 34.7 (131/377) 
Latvia 57.6 (299/519) 91.1 (473/519) 47.8 (248/519) 39.3 (204/519) 
Lithuania 53.7 (273/508) 95.7 (486/508) 38.8 (197/508) 25.6 (130/508) 
Poland 48.8 (245/502) 92.0 (462/502) 52.6 (264/521) 36.1 (181/502) 
Romania 53.0 (276/521) 91.2 (475/521) 49.5 (258/521) 39.7 (207/521) 
Russian Federation 66.7 (273/409) 94.4 (386/409) 68.0 (278/409) 62.8 (257/409) 
Slovenia 57.0 (167/293) 93.5 (274/293) 57.3 (168/293) 41.0 (120/293) 
Spain 23.6 (119/505) 84.2 (425/505) 37.8 (191/505) 11.1 (56/505) 
The Netherlands 47.1 (105/223) 66.8 (149/223) 22.0 (49/223) 11.2 (25/223) 
Turkey 26.3 (88/335) 58.2 (195/335) 34.6 (116/335) 16.7 (56/335) 
United Kingdom 46.3 (149/322) 34.8 (112/322) 22.0 (71/322) 8.1 (26/322) 
     
Male 46.7 (3043/6523) 81.6 (5326/6523) 42.3 (2761/6523) 27.9 (1820/6523) 
Female 46.5 (1033/2222) 81.8 (1817/2222) 47.8 (1063/2222) 30.5 (677/2222) 
≤65 years 48.4 (2297/4746) 80.9 (3840/4746) 41.6 (1974/4746) 28.0 (133/4746) 
>65 years 44.5 (1779/3999) 82.6 (3303/3999) 46.3 (1850/3999) 29.2 (1167/3999) 
TC: total cholesterol; BP: blood pressure; BG: fasting glucose; Perfectly aware= aware on TC, BP and FG level 
 
Information on the patient characteristics in relation to their awareness can be found in table 3. 
A greater proportion of revascularization (PCI and CABG) is seen in those patients more 
aware.  Patients with diabetes, obesity, a raised TC or raised BP were more aware of their 
own levels. Similarly, patients taking antihypertensive medication or lipid lowering 
medication were more aware of their own levels. Patients not aware of their own levels were 
more likely to be lower educated, to be smokers and to be low physically active.  
Multilevel analyses revealed a significant association between awareness and HRQoL (table 
4). Patients not aware of their own risk factor levels reported lower HRQoL outcomes 
compared to those being partially or fully aware. Especially the mental components seem to 
be significantly associated with awareness, whereas no gradual effect was seen on the 
physical component (PCS-12). Analyses on the individual HRQoL dimensions produced 
similar results with better HRQoL outcomes in those more aware. 
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Table 3: Characteristics of awareness 
 Unaware  
n=1081 
Aware on 1 risk 
factor level 
n=2778 
Aware on 2 risk 
factor levels 
n=2387 
Aware on 3 risk 
factor levels 
n=2497 
 
Male, %(n) 73.9(799/1081) 76.9 (2136/2778) 74.0 (1767/2387) 72.9 (1820/2497) P=0.007 
Age, mean (SD) 63.1(10.6) 62.9 (9.7)  63.3 (9.0)  63.5 (9.2)  P=0.406 
Recruiting diagnosis: 
revascularization, %(n) 
54.8(592/1081) 59.1 (1642/2778) 63.4 (1514/2387) 62.7 (1566/2497) P<0.001 
Low education, %(n) 35.8(385/1074) 28.2 (778/2759) 23.9 (567/2374) 18.8 (469/2490) P<0.001 
Diabetes, %(n) 12.1(129/1069) 12.4 (342/2750) 35.8 (850/2376) 32.3 (799/2472) P<0.001 
Blood glucose, mean (SD) 6.6 (2.0) 6.69 (1.78)  7.41 (2.66)  7.23 (2.37)  P<0.001 
BMI, mean (SD) 28.6(4.6) 28.7 (4.4)  29.2 (4.5) 28.9 (4.4)  P=0.003 
Obese, %(n) 32.6(351/1077) 34.4 (952/2766) 37.3 (886/2375) 35.9 (894/2490) P=0.030 
Central obesity, %(n) 45.2(483/1068) 47.5 (1300/2738) 53.1 (1255/2364) 48.3 (1189/2464) P<0.001 
Low physical activity level, %(n) 75.5(793/1051) 68.6 (1882/2742) 67.3 (1585/2355) 70.8 (1750/2472) P<0.001 
TC, mean (SD) 4.6(1.3) 4.7 (1.2)  4.7 (1.2)  4.7 (1.2)  P=0.097 
Raised TC, %(n) 47.9(487/1016) 52.1 (1369/2627) 50.6 (1132/2239) 52.7 (1260/2393) P=0.056 
Lipid lowering medication, %(n) 75.4(807/1071) 75.7 (2089/2761) 81.0 (1925/2377) 84.8 (2115/2493) P<0.001 
SBP, mean (SD) 138.3(21.0) 140.5 (21.4)  141.7 (20.7)  139.6 (19.6)  P<0.001 
DBP, mean (SD) 81.7(12.0) 82.9 (12.2)  83.1 (11.7)  82.7 (11.0)  P=0.004 
Raised BP, %(n) 50.0(539/1079) 53.3 (1478/2773) 60.6 (1445/2383) 57.5 (1434/2492) P<0.001 
Antihypertensive medication, %(n) 57.1(609/1067) 71.4 (1976/2768) 72.7 (1731/2382) 73.2 (1821/2489) P<0.001 
Smoking, %(n) 24.9(268/1078) 20.1 (555/2766) 13.9 (332/2384) 12.9 (323/2496) P<0.001 
Cardiac rehabilitation, %(n) 59.9(276/461) 73.1 (934/1277) 81.3 (943/1158) 80.9(792/979) P<0.001 
Under cardiologist care, %(n) 61.4(662/1079) 67.9(1883/2773) 69.5(1657/2385) 76.9(1919/2494) P<0.001 
Under GP care, %(n) 54.9(592/1079) 54.3(1507/2773) 54.5(1299/2385) 48.5(1209/2494) P<0.001 
Under no care, %(n) 5.4(58/1079) 2.7(76/2773) 2.3(55/2385) 1.3(33/2494) P<0.001 
RD: recruiting diagnosis; TC: total cholesterol; BP: blood pressure; GP: general practitioner 
 
Table 4: Association awareness and HRQoL/psychological distress 
  MCS-12 PCS-12 EQVAS HADSA HADSD 
 Mean (SE) p-value Mean (SE) p-value Mean (SE) p-value Mean (SE) p-value Mean (SE) p-value 
Unaware 47.74(0.69)a REFc 41.37(0.80) REF 64.92(1.42) REF 6.26(0.21) REF 5.76(0.24) REF 
1 aware 48.29(0.62) 0.186 42.35(0.74) 0.014 66.98(1.30) 0.006 5.82(0.21) 0.001 5.28(0.22) 0.001 
2 aware 48.92(0.63) 0.006 41.95(0.74) 0.156 66.46(1.31) 0.045 5.79(0.21) 0.001 5.01(0.22) <0.001 
3 aware 49.27(0.63) 0.001 42.00(0.74) 0.133 67.25(1.31) 0.003 5.74(0.24) 0.001 4.91(0.22) <0.001 
 P<0.001b P=0.083 P=0.019 P=0.004 P<0.001 
a Adjusted means 
b P-values adjusted for age, gender, education,  country 
c Post hoc paired comparison 
 
More detailed analyses of individual awareness variables revealed a significant association 
between HRQoL/psychological distress and TC level awareness both in patients with an 
elevated TC (≥4.5mmol/L) as well as in patients on cholesterol target (<4.5mmol/L), with 
better outcomes in patients who are aware about their cholesterol level. Likewise a significant 
association was found between HRQoL/psychological distress and BP level awareness, with 
the exception of MCS-12, PCS-12 and HADS-A in patients with an elevated BP. Blood 
glucose awareness did not seem to be associated with HRQoL/psychological distress, neither 
in those on target or above target. In diabetes patients however a significant association 
between blood glucose awareness and the EQ-5D index, MCS-12, HADS-D was found (table 
5).  Additional analyses for lifestyle changes resulted in a reduction of the mean effect size; 
however significant associations remained mostly significant except for the EQ-VAS.  
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Table 5: association between HRQoL/psychological distress and risk factor level awareness stratified by risk 
profile (mean (SE)) 
 % (N) EQ-VAS MCS-12 PCS-12 HADSA HADSD 
Complete sample       
TC < 4.5       
Not aware TC level 54.3(2187/4028) 66.292(1.325)a 48.227(0.576) 42.738(0.699) 5.906(0.219) 4.714(0.207) 
Aware TC level 45.7(1841/4028) 68.204(1.328) 49.608(0.578) 41.552(0.698) 6.375(0.218) 5.335(0.206) 
  P=0.002b P<0.001 P<0.001 P<0.001 P<0.001 
  p=0.357c p=0.032 p=0.039 P=0.029 P=0.006 
TC ≥ 4.5       
Not aware TC level 52.4(2228/4249) 65.339(1.351) 47.718(0.699) 41.576(0.773) 6.557(0.220) 5.568(0.219) 
Aware TC level 47.6(2021/4249) 66.882(1.351) 48.978(0.698) 42.158(0.773) 6.310(0.220) 5.018(0.219) 
  P=0.008 P<0.001 P=0.058 P=0.043 P<0.001 
  P=0.130 P<0.001 P=0.214 P=0.028 P=0.003 
BP <140/90 (130/80)       
Not aware BP level 20.1(769/3832) 65.527(1.521) 47.547(0.709) 41.712(0.827) 6.744(0.269) 5.720(0.265) 
Aware BP level 79.9(3063/3832) 67.880(1.381) 48.974(0.616) 42.536(0.755) 6.099(0.233) 4.835(0.235) 
  P=0.005 P=0.002 P=0.065 P<0.001 P<0.001 
  P=0.193 P=0.044 P=0.255 P=0.014 P=0.003 
BP ≥140/90 (130/80)       
Not aware BP level 16.9(830/4897) 64.294(1.431) 48.102(0.737) 41.148(0.811) 6.467(0.246) 5.668(0.253) 
Aware BP level 83.1(4067/4897) 66.112(1.287) 48.806(0.651) 41.744(0.741) 6.251(0.210) 5.190(0.223) 
  P=0.021 P=0.109 P=0.155 P=0.181 P=0.002 
  P=0.309 P=0.789 P=0.789 P=0.296 P=0.267 
BG <6.1mmol/L       
Not aware FG level 67.1(1380/2057) 67.723(1.464) 48.382(0.672) 43.065(0.857) 6.355(0.282) 5.111(0.235) 
Aware FG level 32.9(677/2057) 67.343(1.542) 48.964(0.727) 41.989(0.896) 6.356(0.301) 4.912(0.255) 
  P=0.668 P=0.249 P=0.024 P=0.995 P=0.265 
  P=0.511 P=0.574 P=0.029 P=0.766 P=0.851 
BG ≥6.1mmol/L       
Not aware FG level 50.2(2224/4434) 66.263(1.302) 48.05(0.642) 42.197(0.715) 6.198(0.222) 5.372(0.222) 
Aware FG level 49.8(2210/4434) 65.554(1.305) 48.545(0.644) 41.408(0.717) 6.342(0.222) 5.313(0.223) 
  P=0.587 P=0.126 P=0.008 P=0.228 P=0.592 
  P=0.190 P=0.519 P=0.012 P=0.286 P=0.199 
If diabetes       
BG <6.1mmol/L        
Not aware FG level 22.5(29/129) 60.268(4.335) 44.241(2.303) 42.034(2.520) 6.601(0.822) 6.998(0.742) 
Aware FG level 77.5(100/129) 64.714(2.694) 46.810(1.361) 39.760(1.823) 6.326(0.501) 5.330(0.417) 
  P=0.293 P=0.276 P=0.297 P=0.743 P=0.037 
  P=0.584 P=0.468 P=0.158 P=0.642 P=0.154 
BG ≥6.1mmol/L       
Not aware FG level 17.6(241/1367) 61.507(1.863) 44.840(0.918) 39.082(1.055) 6.885(0.325) 6.584(0.309) 
Aware FG level 82.4(1126/1367) 62.658(1.480) 47.728(0.662) 39.475(0.881) 6.473(0.226) 5.739(0.215) 
  P=0.411 P=0.000 P=0.584 P=0.153 P=0.002 
  P=0.104 P=0.000 P=0.370 P=0.047 P=0.005 
TC: total cholesterol; BP: blood pressure; BG: Blood glucose 
a Adjusted means (for age, gender, education and country) 
b p-values adjusted for age, gender, education and country  
c p-values adjusted for age, gender, education, attempt to increase physical activity, attempt to quit smoking, attempt to eat 
healthier and country 
4. Discussion  
The importance of lifestyle changes and medication compliance is well-known in 
cardiovascular prevention (Perk et al, 2012; Rasmussen et al, 2007). In order to change 
behaviour, knowledge of CHD risk factors is essential (Nash et al, 2003) and improved illness 
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understanding and risk factor awareness have been shown to correlate with increased 
compliance to lifestyle changes and medication intake (Alm-Roijer et al, 2004; Alm-Roijer et 
al, 2006; Baroletti et al, 2010; Grover et al, 2007). Patients who are involved in their medical 
care report less discomfort, greater alleviation of symptoms, more improvement in their 
general medical condition, less concern with their illnesses, a greater sense of control of their 
illnesses, and more satisfaction with their physicians (Brody et al, 1989). Hence patients 
should be empowered to take charge of their own health, also known as ‘patient 
empowerment’. Empowerment in patients with long term conditions has been defined as: “an 
enabling process or outcome arising from communication with the health care professional 
and a mutual sharing of resources over information relating to illness, which enhances the 
patient’s feelings of control, self-efficacy, coping abilities and ability to achieve change over 
their condition”(Small et al, 2013). Four milestones can be considered in the evolution to 
patient empowerment. The first step is to make patients aware of their condition and to inform 
them. There is a change from passive to active participation in the disease treatment. When 
the patient is aware about his/her own health status, proper action plans and guidance can 
result in better adherence to treatment plans and consequently better health outcomes 
(Calvillo et al ,2013). 
Our study results have shown insufficient risk factor level awareness among coronary patients, 
especially with regard to their own TC and blood glucose level and target. Those patients not 
aware about any of their risk factor levels, were more likely to have a lower education, to be 
low physically active or to be a smoker, whereas those aware on some or all of their own risk 
factor levels were more likely to have diabetes, to be obese, to have a raised TC, to have a 
raised BP or to have a high blood glucose. Hence, according to our results, patients with 
increased risk factor levels are more likely to be aware of their TC, BP or blood glucose level. 
Furthermore, risk factor level awareness was associated with HRQoL and psychological 
distress, independent from patients’ risk factor profile. In patients on target as well as in 
patients above target, awareness was associated with better outcomes. The relationship 
between awareness and HRQoL seems to be partly mediated by the attempt of patients to 
adopt a healthier behaviour. Patients with a greater awareness are more likely to have made 
attempts in order to improve their lifestyle. And lifestyle improvements have been shown to 
improve patients’ HRQoL/psychological distress outcomes (De Smedt et al, 2013a; Ludt et al, 
2011). Nevertheless, there also seems to be a direct association between awareness and 
HRQoL, particularly with the mental component. Patients more aware, report less anxiety and 
depression and score better on their mental and emotional well-being regardless of whether 
they change their lifestyle behaviour. Due to the cross-sectional design of the EUROASPIRE 
III survey, the causality of this association could not be explored. Awareness of their own risk 
factor levels might result in less mental distress and a better self-perceived health status. One 
possible explanation for this hypothesis, might be that patient involvement in their care and 
awareness of their risk factor profile could possibly affect their illness perception and sense of 
control. Poor illness perception and low sense of control have been associated with worse 
physical and mental HRQoL (Lau-Walker et al, 2009; Stafford et al, 2009). Hence, in addition 
to improved adherence to lifestyle changes, a better sense of control might also lead to a 
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decrease in anxiety (French et al, 2005). However, there could just as well exist a reverse 
causality, with better HRQoL/psychological distress ensuring a greater interest of patients in 
their own risk factor profile. Most likely, some interplay exists between the above described 
pathways reinforcing one another. 
Within our knowledge this is the first study to assess the association between awareness and 
HRQoL/psychological distress in coronary patients. Some studies have already investigated 
risk factor awareness in the general population, however various definitions of awareness 
have been used making comparison difficult. In the general population, where hypertensive 
patients who were aware of their elevated BP had worse HRQoL outcomes, compared to 
those persons unaware of their hypertension (Korhonen et al, 2011; Mena-Martin et al, 2003). 
This result can be largely attributed to the labelling effect, which can induce anxiety and 
depression because of the awareness of the elevated coronary and mortality risks associated 
with hypertension (Mena-Martin et al, 2003). Likewise, a higher sick leave is reported in 
persons aware of their hypertension status (Leynen et al, 2006). In the current analyses 
however, there was no labelling effect, since all patients included in EUROASPIRE III were 
already aware of their coronary condition.  
Although the EUROAPSIRE survey is a unique database with information collected in a 
standardized way from a large sample of coronary  patients across 22 European countries, our 
study also has some noteworthy limitations. First of all, as already mentioned, it is not 
possible to assess causality due to the study design, hence longitudinal studies are needed in 
order to draw conclusions about the directionality between risk factor level awareness and 
HRQoL/psychological distress. Secondly, those patients participating in the study are most 
likely those patients interested in their own health. Whether or not patients are interested in 
their own health is likely to be a determinant in the awareness of risk factor levels and targets. 
Therefore the above reported insufficient risk factor level awareness rates might be an 
underestimation. We were not able to adjust for the time since last measurement, hence this 
could potentially have had an influence on the result. Adjusting for the time since 
hospitalization however, did not alter the results significantly. In addition, it could be 
questioned whether awareness was measured in the best possible way. The question was 
translated in different languages, potentially resulting in small differences causing variation in 
interpretation across different patients. Further research should focus on how awareness can 
be assessed adequately. Furthermore, we were not able to adjust for income or socio-
economic status, since these variables were not collected. Likewise, the organisation of the 
health care system in a given country, will have a substantial influence on the risk factor level 
awareness rates. Finally, it should be mentioned that patients are not a representative sample 
of all patients with CHD in each country, since they were identified from selected 
geographical areas and cardiac centres, hence caution is required when generalizing these 
results. 
In conclusions, risk factor awareness among coronary patients is still suboptimal. An 
important finding, since this has been shown to be associated with worse compliance with 
medication and lifestyle changes. Furthermore risk factor level awareness seems to be 
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associated with improved HRQoL and psychological distress. Future research should aim to 
investigate the directionality of this association using longitudinal follow up studies. Are 
patients with a better health status and less emotional distress, more interested in their risk 
factor profile. Or does knowledge about their own risk factor profile result in improved 
HRQoL outcomes.  
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Abstract 
Objectives: The aim of the current study was to compare EQ-5D and SF-6D (based on SF-12) 
utility scores using a large European sample of stable coronary heart disease (CHD) patients. 
Special attention was given to country-specific results. 
Methods: Data from the EUROASPIRE III (EURopean Action on Secondary and Primary 
Prevention by Intervention to Reduce Events) survey were used. Patients hospitalized for a 
coronary artery bypass graft, percutaneous coronary intervention, acute myocardial infarction 
or myocardial ischemia were interviewed and examined at least 6 months after their acute 
event. Health-related quality of life (HRQoL) was assessed using the EQ-5D and the SF-12. 
SF-12 outcomes were converted to SF-6D utility values, allowing comparison between both 
measures. 
Results: Both EQ-5D and SF-6D results were available for 7,472 CHD patients from 20 
European countries. The measures were significantly correlated (ICC=0.536), however, large 
differences between the two measures remain. 28.8% of patients reported a ceiling effect on 
the EQ-5D instrument, whereas only 4.2% of patients reported full health based on the SF-6D. 
Especially the mental component does not seem to be completely captured by the EQ-5D 
instrument. Furthermore, patients with worse EQ-5D outcomes were more likely to have 
better SF-6D results, whereas patients with better EQ-5D outcomes were more likely to have 
worse SF-6D results. 
Conclusions: Both measures are not interchangeable. Whereas the main disadvantage of the 
EQ-5D is its ceiling effect, the potential advantages of SF-12 might disappear when 
converting the outcomes into an SF-6D utility, due to the small differences between patients. 
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1. Introduction 
Patients’ self-reported health-related Quality of Life (HRQoL) is increasingly considered an 
important outcome of medical treatment, especially in chronic conditions, such as coronary 
heart disease (CHD), where patients are being monitored for a considerable period of time. 
CHD is often a cause of pain, increased anxiety, and functional and social limitations, hence 
coronary patients are likely to have an impaired HRQoL (Mols et al, 2009; Thombs et al, 
2006; Xie et al, 2008). Many different disease-specific as well as general measures exist to 
assess HRQoL in CHD patients such as: the MacNew Heart Disease Health-related Quality of 
Life Questionnaire (MacNew); the Seattle Angina Questionnaire (SAQ); the Myocardial 
Infarction Dimensional Assessment Scale (MIDAS); the 36-Item Short Form Health Survey 
(SF-36); the 12-Item Short Form Health Survey (SF-12); the Health Utility Index (HUI); the 
EuroQol-5D (EQ-5D); etc. However, few of these HRQoL measures generate a single 
preference based utility measure of health.  Utilities are particularly useful in the calculation 
of cost-effectiveness ratio’s (ICER), for computing health benefits expressed in quality 
adjusted life years (QALYs). The results of such evaluations enable decision makers to set 
priorities with regard to the reimbursement of health care, hence the validity of utilities is of 
great importance. EQ-5D is the most commonly used instrument to calculate utilities for cost-
effectiveness analysis purposes. However, an algorithm developed by Brazier et al. in 2004 
made it possible to calculate a utility score based on SF-12 by converting the measure in a 6-
dimensional health state classification (SF-6D) (Brazier et al, 2004b; Kharroubi et al, 2007; 
McCabe et al, 2006). Some concern exists regarding the comparability between the utility 
score calculated from EQ-5D and the one based on SF-12 (Bharmal et al, 2006; Brazier et al, 
2004a; Bryan et al, 2005; Ferreira et al, 2008). A recent study by Joore et al. (2010) reported 
remarkable differences in cost-effectiveness results, depending on the instrument used. 
Patients with mild health conditions had higher EQ-5D scores, whereas patients with severe 
conditions had higher SF-6D scores (Joore et al, 2010). This leads to better or worse cost-
effectiveness outcomes, depending on the HRQoL instrument used. The incomparability of 
the results using different instruments poses a real threat on the usefulness and credibility of 
cost-effectiveness analyses . 
Existing literature regarding the comparison of the EQ-5D and SF-6D in coronary patients is 
scarce. Only one study reported on this comparison, however the SF-6D scores were based on 
SF-36 outcomes and the sample size was relatively small (n=561) (van Stel et al, 2006). They 
concluded that in coronary patients EQ-5D and SF-6D are quite different from each other. 
The aim of the current study was to compare the EQ-5D and the SF-6D (based on SF-12) 
utility scores using a large European sample of coronary patients, with an additional focus on 
country-specific results.  
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2. Methods 
Coronary Sample 
Analyses were based on EUROASPIRE III (EURopean Action on Secondary and Primary 
Prevention by Intervention to Reduce Events) data, a cross-sectional survey performed in 
2006-2007 across Europe. More details on this survey can be found elsewhere (Kotseva et al, 
2009b). Briefly, patients aged between 18 and 80 years, hospitalized for coronary artery 
bypass graft (CABG), percutaneous coronary intervention (PCI), acute myocardial infarction 
(AMI) or myocardial ischemia, were retrospectively identified from diagnostic registers, 
hospital discharge lists or other sources. In total, 8966 patients (participation rate=73%) were 
interviewed and examined at least 6 months and not later than 3 years after their initial 
hospital admission (median time=1.24 years). During interview, EQ-5D and SF-12 
information was collected. HRQoL information was available for 20 EUROASPIRE III 
countries: Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, France, Greece, 
Ireland, Italy, Latvia, Lithuania, Poland, Romania, Russian Federation, Slovenia, Spain, The 
Netherlands, Turkey, and the United Kingdom (UK). Furthermore, self-reported demographic 
details as well as disease information were collected by trained research staff. 
 
HRQoL instruments 
EQ-5D is a commonly used, easy to complete, standardized instrument containing a 
descriptive part (EQindex) and a visual analogue scale (EQ-VAS). The former covers 5 
dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with 
three response categories each (no problems, some problems, or severe problems). The 
answers on these dimensions provide a simple descriptive profile, with 243 possible health 
states, from which an index score can be calculated. Within the current analyses we have 
chosen to use the UK algorithm for all countries included. Conform with the EuroQoL 
guidelines we used this most robust valuation set, since country specific algorithms were not 
available for each individual country included. Theoretically, the index score can range 
between -0.594 (worst health state) and 1 (full health) (Rabin et al, 2001). The algorithm is 
based on the time trade off (TTO) technique developed by Torrance et al (Torrance, 1976). 
With this method, the subject can chose between two alternatives: a state of illness during a 
given period followed by death, versus a state of perfect health for a shorter time period, 
followed by death. The time period is varied until the subject is indifferent between the two 
alternatives. 
The SF-12v2 is a shortened version of the SF-36, including 12 questions, with three to five 
answer categories each (Likert scale). The instrument  covers eight dimensions: general health, 
physical functioning, role physical, bodily pain, vitality, social functioning, role emotional, 
and mental health. Both a physical (PCS-12) and mental functioning (MCS-12) component 
score, ranging between 0 and 100, can be calculated using a scoring algorithm. Lower scores 
represent worse and higher scores represent better self-perceived HRQoL outcomes (Ware et 
al, 2002). Using an algorithm (UK version) by Brazier et al. (2004), the SF-6D can be 
calculated from the SF-12. The SF-6D is based on 11 SF-12 questions and combines them 
into 6 dimensions (physical functioning, role limitations, bodily pain, vitality, social 
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functioning, mental health); 7500 different health states can be defined, from which an index 
score can be calculated. The score can range between 0.296 and 1 (Brazier et al, 2004b; 
Kharroubi et al, 2007; McCabe et al, 2006). The algorithm to calculate this score is based on 
the standard gamble (SG) technique, first described by von Neumann and Morgenstern (Von 
Neumann & Morgenstern, 1994). It is based on a paired comparison in which subjects can 
chose between two alternatives. The first alternative has two possible outcomes, either the 
subject returns to perfect health with probability p, or the subject dies with probability 1-p. 
The second alternative leads to a certain disease state for life. The probability p can be varied 
until the subject is indifferent between the two alternatives. Due to the high number of 
different health states, many of them are not explicitly evaluated but estimated based on their 
proximity to those states which are tested. 
Statistical analyses 
Only patients with both EQ-5D and SF-12 information were included in the analyses. 
Analyses were performed both on European as well as on country-specific level. A Wilcoxon 
signed rank test was performed in order to test whether the EQ-5D results differ significantly 
from the SF-6D values. Furthermore, the spearman correlation and the intraclass correlation 
coefficient between EQ-5D and SF-6D outcomes, and the spearman correlation between the 
different dimensions of the EQ-5D and SF-6D were calculated. The ceiling effect of both 
measures was assessed by estimating the proportion of patients who reported to be in full 
health (no problems on either dimension). Analyses were performed using IBM SPSS version 
21. 
3. Results 
A total of 7,472 coronary patients completed the SF-12 as well as the EQ-5D instrument. 
Their mean age was 63.1 (9.2) years. Three quarter of patients were male, and one in four 
patients had received a low education. Almost 60% had a cardiac revascularization as 
recruiting diagnosis; 23.2% of patients reported to suffer from diabetes; 4.5% reported to have 
a history of stroke and 13.3% reported to have suffered a recurrent coronary event since the 
recruiting diagnosis. Table 1 gives an overview of the utility outcomes based on the patient 
characteristics. Country specific results are presented in table 2. The median EQ-5D values 
range between 0.66 (Russia) and 1.00 (Italy) depending on the country. The lowest EQ-5D 
value reported was -0.59 and the highest value was 1.00. About 1.8% of patients had EQ-5D 
outcomes below 0, reflecting health states that are perceived worse than death. The median 
SF-6D values ranged between 0.66 (Spain, France, Croatia, Lithuania, Poland, Russia, 
Slovenia, Turkey) and 0.80 (Cyprus, Italy, the Netherlands), the lowest SF-6D value was 0.35 
and the highest was 1.00. 
The EQ-5D and SF-6D seemed to be significantly correlated with an overall spearman 
correlation coefficient of 0.695. The intraclass correlation coefficient, although significant, 
was somewhat lower with an overall value of 0.536. The correlation between the different 
HRQoL dimensions is reported in table 3. All dimensions were significantly correlated with 
each other. The highest correlations are seen between related dimensions such as physical 
CHAPTER 8 
 
100 
 
functioning-mobility (r=0.446); physical functioning-usual activities (r=0.504); role 
limitation-usual activities (r=0.390); social functioning-usual activities (r=0.403); pain-
pain/discomfort (r=0.630); mental health-anxiety/depression (r=0.551). 
Overall 28.8% (2149/7472) of patients reported no problems on the EQ-5D instrument, 
whereas only 4.2% (311/7472) of patients reported full health on the SF-6D instrument. 
Table 1: Utility outcomes by patient characteristics 
 EQ-5D (Median (IQR)) SF-6D (Median (IQR)) 
All 0.80(0.69-1.00) 0.70(0.62-0.82) 
Gender   
Male 0.80(0.69-1.00) 0.72(0.63-0.86) 
Female 0.73(0.62-0.85) 0.66(0.58-0.74) 
Age   
<50 years 0.85(0.73-1.00) 0.72(0.64-0.86) 
50-59 years 0.80(0.69-1.00) 0.72(0.62-0.86) 
60-69 years 0.80(0.69-1.00) 0.70(0.62-0.83) 
≥70 years 0.73(0.62-0.85 0.66(0.61-0.78) 
Recruiting diagnosis   
CABG 0.80(0.69-1.00) 0.72(0.63-0.96) 
PCI 0.80(0.69-1.00) 0.72(0.62-0.86) 
AMI 0.78(0.66-1.00) 0.66(0.62-0.80) 
Ischemia 0.73(0.62-0.88) 0.66(0.60-0.80) 
Educational level   
primary 0.74(0.62-1.00) 0.66(0.606-0.80) 
Secondary 0.80(0.69-1.00) 0.69(0.62-0.80) 
High 0.81(0.73-1.00) 0.72(0.66-0.86) 
Diabetes   
No 0.80(0.69-1.00) 0.72(0.62-0.86) 
Yes 0.73(0.62-0.85) 0.66(0.60-0.78) 
Central obesity   
No 0.81(0.69-1.00) 0.72(0.63-0.86) 
Yes 0.74(0.64-0.85) 0.66(0.62-0.80) 
Smoking   
No 0.80(0.69-1.00) 0.70(0.62-0.82) 
Yes 0.80(0.66-1.00) 0.69(0.62-0.86) 
Physical activity   
<20min, 3x/week 0.73(0.62-0.85) 0.66(0.60-0.78) 
≥20min, 3x/week 0.80(0.69-1.00) 0.72(0.63-0.86) 
History of stroke   
No 0.80(0.69-1.00) 0.70(0.62-0.82) 
yes 0.69(0.52-0.85) 0.66(0.57-0.74) 
Recurring coronary event after recruiting 
diagnosis 
  
No 0.80(0.69-1.00) 0.71(0.62-0.82) 
yes 0.78(0.66-1.00) 0.66(0.62-0.80) 
All EQ-5D and SF-6D outcomes are significantly different (p<0.001), except for patient with a history of stroke. 
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Again some variation was seen across countries, with the proportion of full health on the EQ-
5D instrument ranging from 10.4% (Russia) to 50.9% (Italy); on the SF-6D instrument full 
health was seen in 0.0% (Russia) to 15.7% (Cyprus) of patients depending on the country. In 
those patients with full health on the EQ-5D, a median SF-6D of 0.86 (IQR: 0.74-0.92) was 
found. Moreover 15.6% of patients with a full health on the EQ-5D still reported a SF-6D 
value below the overall median. Patients reporting no limitations on the EQ-5D still reported 
substantial problems on the SF-6D role limitation and vitality dimension. 
Table 2: Country specific utility outcomes 
 
EQ-5D  SF-12 Wilc 
test 
Spearman 
correlation 
ICC 
EQ-5D Full 
health 
SF-12 Full 
health Wilc  
test 
Median (IQR) % (n) 
Overall  (n=7472) 0.80 (0.31) 0.70 (0.20) ** 0.665** 0.536** 28.8 (2149/7472) 4.2 (311/7472) ** 
Belgium (n=246) 0.81 (0.27) 0.72 (0.14) ** 0.595** 0.438** 39.0 (96/246) 2.0 (5/246)  
Bulgaria (n=538) 0.80 (0.34) 0.72 (0.25) ** 0.688** 0.593** 30.3 (163/538) 7.1 (38/538) ** 
Cyprus (n=420) 0.85 (0.27) 0.80 (0.26) ** 0.621** 0.528** 37.6 (158/420) 15.7 (66/420) ** 
Czech Rep (n=475) 0.76 (0.19) 0.72 (0.18) ** 0.636** 0.515** 24.8 (118/475) 1.3 (6/475) ** 
Spain (n=473) 0.76 (0.34) 0.66 (0.20) ** 0.679** 0.512** 25.4 (120/473) 3.8 (18/473) ** 
Finland (n=237) 0.80 (0.31) 0.72 (0.24) ** 0.644** 0.518** 29.1 (69/237) 3.0 (7/237) ** 
France (n=269) 0.73 (0.18) 0.66 (0.14) ** 0.572** 0.430** 17.8 (48/269) 0.7 (2/269)  
UK (n=277) 0.80 (0.31) 0.72 (0.25) ** 0.720** 0.583** 29.6 (82/277) 2.2 (6/277) * 
Greece (n=119) 0.85 (0.31) 0.72 (0.20) ** 0.605** 0.513** 35.3 (42/119) 7.6 (9/119) ** 
Croatia (n=437) 0.73 (0.23) 0.66 (0.17) ** 0.670** 0.518** 22.7 (99/437) 2.5 (11/437) ** 
Ireland (n=370) 0.85 (0.27) 0.78 (0.21) ** 0.713** 0.620** 39.2 (145/370) 4.6 (17/370) ** 
Italy (n=377) 1.00 (0.2) 0.80 (0.26) ** 0.634** 0.519** 50.9 (192/377) 4.5 (17/377) ** 
Lithuania (n=505) 0.74 (0.19) 0.66 (0.18) ** 0.583** 0.464** 20.4 (103/505) 1.8 (9/505) * 
Latvia (n=518) 0.85 (0.27) 0.74 (0.23) ** 0.503** 0.422** 39.6 (205/518) 8.1 (42/518) ** 
Netherlands (n=199) 0.85 (0.27) 0.80 (0.25) ** 0.664** 0.607** 42.2 (84/199) 10.1 (20/199) ** 
Poland (n=461) 0.73 (0.23) 0.66 (0.14) ** 0.651** 0.489** 20.4 (94/461) 0.7 (3/461) ** 
Romania (n=521) 0.76 (0.19) 0.68 (0.18) ** 0.649** 0.504** 24.6 (128/521) 3.3 (17/521) ** 
Russia (n=405) 0.66 (0.15) 0.66 (0.14) * 0.698** 0.494** 10.4 (42/405) 0.0 (0/521)  
Slovenia (n=292) 0.69 (0.33) 0.66 (0.15) * 0.688** 0.485** 14.7 (43/292) 2.7 (8/292) ** 
Turkey (n=333) 0.81 (0.31) 0.66 (0.13) ** 0.689** 0.456** 35.4 (118/333) 3.0 (10/333) ** 
Wilc test: Wilcoxon Signed rank test 
*p-value <0.05; **p-value<0.01 
 
Furthermore, of those patients reporting full health on the EQ-5D, 15.5% of patients had a 
PCS-12 value below the overall median, and 23.0% had a MCS-12 value below the overall 
median. In contrast, in those patients with full health on the SF-6D only 4.2% of patients 
reported an EQ-5D value below the overall median. Patients with an EQ-5D value below 0, 
had SF-6D values ranging between 0.35 and 0.68. Only 1 patient reported severe problems on 
all the EQ-5D dimensions, whereas none of the patients reported the worst possible SF-6D 
health state. 
Figure 1 compares the EQ-5D utilities with the SF-6D utilities according to patient’s EQ-5D 
health profile. According to these data, patients with worse EQ-5D outcomes were more 
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likely to have better SF-6D outcomes, whereas patients with better EQ-5D outcomes were 
more likely to have worse SF-6D results. 
 
Figure 1: Comparison between EQ-5D and SF-6D utilities 
  
 
4. Discussion 
Similar to previous studies in various populations, the EQ-5D outcomes in coronary patients 
are significantly correlated with the SF-6D values, with ICC’s indicating moderate agreement 
between the instruments (Brazier et al, 2004a; Ferreira et al, 2008; Kontodimopoulos et al, 
2011). Moderate correlations were also found between related dimensions. Correlations found 
in our study were slightly lower (with the exception of those related to pain and mental health) 
than those reported by Brazier et al (Brazier et al, 2004a), but stronger than those seen by Van 
Stel et al (van Stel et al, 2006). However, there remain significant differences between the 
EQ-5D and SF-6D utility outcomes. In all EUROASPIRE III countries, the utility values 
differed significantly from each other with median SF-6D utility scores being systematically 
lower than EQ-5D outcomes, both at country specific level, as well as after stratification by 
patient characteristics. Due to the small sample sizes on country specific level, and the 
variability in disease severity and comorbidities, caution is required when interpreting the 
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Table 3: Correlation between EQ-5D and SF-12 (SF-6D) dimensions 
 Physical 
functioning 
Role 
limitation 
Social 
functioning 
Pain  Mental 
health 
Vitality 
Mobility 0.446 0.338 0.346 0.459 0.268 0.325 
Self care 0.318 0.223 0.313 0.321 0.230 0.247 
Usual activities 0.504 0.390 0.403 0.474 0.321 0.371 
Pain/discomfort 0.415 0.395 0.390 0.630 0.354 0.343 
Anxiety/depression 0.281 0.405 0.410 0.338 0.551 0.324 
All correlations are significant (p<0.001) 
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results at country level. It should be noted also, that EQ-5D utility outcomes are based on UK 
preference weights, since country-specific weight were not available for all included countries.  
Furthermore, a ceiling effect was observed in the EQ-5D instrument, but no floor effect was 
seen on either instrument (although a slight proportion of patients reported EQ-5D outcomes 
below zero). These results are similar to previously reported outcomes (Joore et al, 2010; van 
Stel et al, 2006). One study reported on full health in the general population, with 47% of 
patients having no problems on the EQ-5D and 5.8% of patients reporting no problems on the 
SF-6D (Bharmal et al, 2006). According to a study by Joore et al. (2010) 40% to 54% of 
hypertensive patients (depending in the treatment modality) report full health on the EQ-5D, 
whereas only 1% to 2% reported no problems on the SF-6D (Joore et al, 2010). A study in 
coronary patients found a ceiling effect on the EQ-5D in 13.5%, whereas only 0.4% of 
patients reported full health on the SF-6D (van Stel et al, 2006). Brazier et al. acknowledge a 
possible ceiling effect of the EQ-5Dindex tool and a possible floor effect of the SF-6D 
instrument (Brazier et al, 2004a). Subanalyses in the EUROASPIRE III population revealed 
that patients reporting no problems on the EQ-5D still reported substantial problems on the 
SF-6D role limitation and vitality dimensions. This is in line with the lower correlations 
between the EQ-5D dimensions and the SF-6D role limitation and vitality dimension. 
Furthermore, within our population, especially mental problems are not completely captured 
by the EQ-5D instrument. Likewise, in the study by Brazier et al. (2004), based on 7 patient 
groups, it was observed that those patients in full health on the EQ-5D may still experience 
problems in physical functioning, mental health and vitality (Brazier et al, 2004a).  
As mentioned by others, some of the differences between the instruments might be explained 
by the theoretical construction of the measures (Brazier et al, 2004a; Bryan et al, 2005; van 
Stel et al, 2006). First of all, EQ-5D contains only 5 dimensions, whereas SF-6D captures 6 
dimensions. In addition, the recall period is different: ‘today’ versus ‘past four weeks’, 
however we agree with Van Stel et al. (2006), that the influence of the recall period in the 
utility differences might be non-significant, since HRQoL was measured in stable CHD 
patients (6 months to 3 years after the recruiting diagnosis) (van Stel et al, 2006). Furthermore, 
the EQ-5D covers only 5 dimensions with each 3 answer categories, whereas the SF-6D is 
based on 11 SF-12 questions with each 3 to 5 response categories. An increase in number of 
questions and answers automatically leads to a more descriptive and sensitive tool with a 
higher amount of possible outcomes. A patient who has sometimes frightened feelings, might 
for example indicate that he/she is not anxious or depressed on the EQ-5D whereas on the SF-
12 he/she would indicate ‘a little of the time’ on the question whether he/she has felt 
downhearted and depressed. This is only one example indicating the more refined answer 
options of the SF-12. However, conversion from SF-12 to SF-6D is associated with some 
sensitivity loss, particularly due to the small range of possible utility scores. The SF-6D 
outcomes range between 0.296 and 1 which is almost half of the possible EQ-5D range, hence 
SF-6D outcomes are more centred to the middle and the potential difference between health 
states is larger using the EQ-5D utility scores. This was also reported in a paper by 
McDonough et al. (2007), concluding that cost-effectiveness analyses using the SF-6D give 
less favourable cost-effectiveness results (McDonough et al, 2007). The EQ-5D however, is 
very much skewed to the right, hence the probability of having worse outcomes is rather low, 
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and therefore the room for improvement is limited especially in patients with a mild or largely 
asymptomatic condition. In contrast, the impairments associated with a mild condition might 
be better recognized by the SF-6D, hence the SF-6D might be more sensitive for smaller 
impairments, leading to better cost-effectiveness outcomes. Indeed, the change in utility score 
rather than the absolute value of the score is of most importance in cost-effectiveness analyses. 
In agreement with the literature, EUROASPIRE III results have indicated that patients with 
worse EQ-5D outcomes were more likely to have better SF-6D results, whereas patients with 
better EQ-5D outcomes were more likely to have worse SF-6D results (Joore et al, 2010). 
Furthermore, our results indicate that disease severity or patient characteristics are not always 
captured by both instruments equally. In patients with diabetes, a history of stroke or a 
recurrent coronary event, the proportion of patients reporting full health is lower, both using 
the EQ-5D as well as the SF-6D. However, patients who are categorized as having a CABG 
or PCI, were more likely to report full health on the EQ-5D but not on the SF-6D compared to 
patients having AMI or ischemia. Likewise, smokers and obese patients were less likely to 
report full health on the SF-6D but not on the EQ-5D compared to non-smokers and patients 
with a normal weight. 
Medicine has changed tremendously during the last century. New scientific insights have led 
to the development of several innovations regarding medication, technical procedures and 
diagnostic tools. Today’s society strives to provide the best possible health care, however 
financial resources are limited. Therefore, the use of cost-effectiveness analyses is becoming 
increasingly important. Current recommendations from NICE promote the use of the EQ-5D 
instrument for the calculation of QALYs (National Institute for Health and Care Excellence, 
2013). However, it is important to recognize the advantages and disadvantages of both the 
EQ-5D and SF-6D instrument. Whereas the main disadvantage of the EQ-5D is its ceiling 
effect, the potential advantages of SF-12 might disappear when converting the outcomes into 
an SF-6D utility score. The new EQ-5D five level (EQ-5D-5L) might overcome some of the 
above reported problems by increasing sensitivity and reducing the ceiling effects, however 
further research is needed in order to investigate these issues (Herdman et al, 2011).  
Furthermore, as both the EQ-5D as well as the SF-12 might be insufficiently sensitive to 
capture small differences in coronary patients, a disease-specific instrument from which a 
utility outcome can be calculated should be developed. Such a tool can significantly improve 
the reliability of health economic evaluations. 
In conclusion, our study results have indicated that both utility tools are not interchangeable.  
In addition to the different theoretical construction of the instruments as well as the unequal 
utility range, differences in outcome can also be explained by patient characteristics and 
disease severity. Knowledge of these inconsistencies is required when using utility values, in 
order to avoid comparison of values derived from different instruments. 
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Abstract 
Aims: The EUROASPIRE III survey indicated that the guidelines on cardiovascular disease 
prevention are poorly implemented in patients with established Coronary Heart Disease 
(CHD). The purpose of this health economic project was to assess the potential clinical 
effectiveness and cost-effectiveness of optimizing cardiovascular prevention in eight 
EUROASPIRE III countries (Belgium, Bulgaria, Croatia, Finland, France, Italy, Poland, and 
the UK). 
Methods and results: The individual risk for subsequent cardiovascular events was estimated, 
using published Framingham equations. Based on the EUROASPIRE III data, the type of 
suboptimal prevention, if any, was identified for each individual, and the effects of optimized 
tailored prevention (smoking cessation, diet and exercise, better management of elevated 
blood pressure and/or LDL-cholesterol) were estimated. Costs of prevention and savings of 
avoided events were based on country-specific data. A willingness to pay threshold of € 
30,000/quality-adjusted life year (QALY) was used. The robustness of the results was 
validated by sensitivity analyses. Overall, the cost-effectiveness analyses for the eight 
countries showed mainly favourable results with an average incremental cost-effectiveness 
ratio (ICER) of € 12,484 per QALY. Only in the minority of patients at the lowest risk for 
recurrent events, intensifying preventive therapy seems not cost-effective. Also, the single 
impact of intensified cholesterol control seems less cost-effective, possibly because their 
initial 2-year risk was already fairly low, hence the room for improvement is rather limited.  
Conclusion: These results underscore the societal value of optimizing prevention in most 
patients with established CHD, but also highlight the need for setting priorities towards 
patients more at risk and the need for more studies comparing intensified prevention with 
usual care in these patients. 
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1. Introduction 
In 2008, >4.58 million people died in Europe due to cardiovascular diseases (CVD) (World 
Health Organisation, 2011). CVD continues to be the main cause of morbidity and mortality, 
with >30% of life-years lost and nearly half of all deaths (Allender et al, 2008). Consequently, 
CVD adds significantly to the increasing healthcare costs. According to Leal et al. the 
economic burden of CVD in the EU amounts to € 169 billion annually; 62% of these costs are 
healthcare-related. Per 1000 people, 2.4 working-years are lost due to mortality and 591 days 
are lost because of morbidity; representing a total EU cost (in 2003) of € 24,384 million and € 
10,768 million, respectively. In addition, informal care of CVD patients was estimated to cost 
€ 29,050 million yearly (Leal et al, 2006). During the previous decades several guidelines on 
cardiovascular prevention have been published. The first Joint European guidelines on the 
prevention of CVD in clinical practice were published in 1994 with regular updates since (De 
Backer et al, 2003; Graham et al, 2007; Pyorala et al, 1994; Wood et al, 1998). Within the 
European Society of Cardiology (ESC), secondary prevention was given the highest priority. 
Therefore, the ESC conducted three surveys (European Action on Secondary and Primary 
Prevention by Intervention to Reduce Events-EUROASPIRE) to ascertain whether the 
guidelines are being implemented in clinical practice (Kotseva et al, 2009b; EUROASPIRE 
Study Group, 1997; EUROASPIRE II Study Group, 2001). In the latest survey 
(EUROASPIRE III) many coronary patients still did not achieve the targets for CVD 
prevention, indicating that the integration of the guidelines in routine clinical care is still 
substandard. Hence there is considerable room for improvement to raise the standards of 
prevention in these patients through more effective lifestyle interventions, control of risk 
factors, and appropriate use of cardio protective medication. Optimizing the management of 
these coronary heart disease (CHD) patients would decrease the occurrence of subsequent 
CVD events, hence increasing their quality of life and extend their survival. Many studies 
already reported on the cost-effectiveness of single prevention strategies (Chen et al, 2009; 
Heeg et al, 2007; Lindgren et al, 2007; Lowensteyn et al, 2000; Soini et al, 2010; Taylor et al, 
2009; Wilson et al, 2011). However, none conducted an integrated tailor-made cost-
effectiveness analysis on secondary cardiovascular prevention targeting different intervention 
strategies simultaneously, adapted to the current prevention status of patients. This paper 
reports on the cost-effectiveness of such optimized prevention in cardiovascular patients in 
eight European countries, using the EUROASPIRE III data.  
2. Methods 
European cardiovascular disease prevention model  
An individual-based state-transition model was designed to quantify the clinical and cost-
effectiveness of optimizing secondary prevention. Opposed to common Markov models, 
based on a cohort with an average risk profile and average transition probabilities, the current 
model allows simulating the health and economic outcomes of individual patients taking into 
account their individual characteristics and their prevention status. The model makes use of 6-
month cycles and includes three disease states, two post-event states, and a death state, and 
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was developed after exploring the literature  (Figure 1) (Heeg et al, 2007; Soini et al, 2010). 
All EUROASPIRE III patients start in the initial state. The model predicts their likelihood to 
develop fatal and non-fatal CVD or to die from other causes. Every cycle, patients can suffer 
a coronary event, a stroke, or heart failure and move to the CHD state, CVD state, or 
congestive heart failure (CHF) state, respectively. Once in one of these subsequent event 
states, patients enter a post-event state after one cycle.  
Figure 1: Markov model. 
 
All patients start in the coronary artery bypass graft (CABG)/percutaneous transluminal coronary angioplasty 
(PTCA)/myocardial infarction (MI)/angina disease state. Patients suffering a MI will move to the coronary heart 
disease state (CHD). Patients suffering a stroke will move to the cardiovascular disease state (CVD), patients 
suffering a heart failure will progress to the congestive heart failure state (CHF). 
EUROASPIRE III survey  
The design and the principal findings of the EUROASPIRE III survey have been reported 
extensively elsewhere (Kotseva et al, 2009b). In brief, the study aimed to determine whether 
the joint European guidelines on CVD prevention are being implemented in CHD patients at 
that time (De Backer et al, 2003). The survey was conducted in 22 European countries during 
2006–07. Patients were aged 18–80 years and admitted to a hospital for an acute coronary 
event or a cardiac procedure [i.e. coronary artery bypass graft (CABG); percutaneous 
transluminal coronary angioplasty (PTCA), myocardial infarction (MI), or acute myocardial 
ischemia]. EUROASPIRE patients from eight countries were included in our analysis 
(Bulgaria, Belgium, Croatia, Finland, France, Italy, Poland, and the UK). Depending on the 
country only 3–43% of patients are meeting all targets, i.e. achieving blood pressure (BP) 
target, cholesterol target, physical activity target, and smoking target. In total 2693 patients 
not on target on at least one of the risk factors were included in our study. 
Base case risk and risk reductions  
Performing a tailor-made analysis necessitates the calculation of individuals’ future 
cardiovascular risk. From all available risk prediction algorithms, such as SCORE, QRISK, 
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PROCAM, ASSIGN, LIPID, reynolds risk score, UKPDS etc. The Framingham risk 
equations were used to calculate the different CVD outcomes since these allow risk estimation 
based on individual patient risk factors, collected within the EUROASPIRE III survey 
(D'Agostino et al, 2000; Kannel et al, 1999; Wolf et al, 1991). However, evidence indicates 
that the Framingham risk calculators might overestimate CVD risk; in addition the 
Framingham population differs in characteristics from the EUROASPIRE population. 
Therefore, in order to use the Framingham risk calculators, calibration was applied based on 
mean CHD, stroke, and CHF risk figures available in the literature (Alberts et al, 2009; Hense 
et al, 2003; Kober et al, 1995; Pedersen et al, 2005). If the figures in the literature differed 
from our calculated risk, based on the mean of the individual patient calculations, then our 
individual patient calculations were multiplied with a correction factor in order to have the 
same overall risk figure as those reported in a typical European CHD population.  
Optimizing prevention  
Optimizing prevention was based on the 2003 joint European guidelines (De Backer et al, 
2003). In those patients not on target, several strategies were theoretically applied in order to 
improve their risk factors and consequently their cardiovascular risk. Hence their future risk 
was calculated assuming optimized risk target treatment. About 17% of the patients included 
in our analyses were smokers. Optimal smoking cessation was installed through counselling 
and pharmacotherapy [varenicline or nicotine replacement therapy (NRT)]. Fifty-two per cent 
of the patients had a total cholesterol not on target. Simvastatine 20 mg per day was initiated 
in patients with an elevated total cholesterol of ≥4.5 mmol/L and not yet receiving cholesterol 
treatment. It was assumed that in those ≤6% above target it was an issue of improving 
compliance. In patients with a cholesterol level between 6 and 12% above target, the statin 
dose was doubled if possible and atorvastatine 40 mg/day was given if patients were already 
on the maximum dose of a weaker statin (type fluvastatin, lovastatin, pravastatin, or 
simvastatin). Ezetimibe was added in patients already on a maximum dose of a strong statin 
(type atorvastatin or rosuvastatin). This was based on the literature indicating a 6% additional 
fall in the risk factor level by doubling the dose (Weng et al, 2010). An elevated BP was 
found in 60% of patients. Those with a raised BP (BP >140/90 mmHg and BP >130/80 
mmHg for CHD patients without diabetes, and with diabetes, respectively) and not yet on 
treatment were placed on one inexpensive antihypertensive drug, (e.g. beta-blocker or 
diuretic). For those with a slightly increased BP (BP >140/90 and <150/95 mmHg for non-
diabetics and BP >130/80 and <140/90 mmHg for diabetics), but already on treatment, a 
compliance problem was assumed. When the BP exceeded 150/95 and 140/90 mmHg, 
respectively, in non-diabetics and diabetics already on treatment, a combination therapy was 
installed with a maximum of four different BP-lowering drugs. Regarding physical activity a 
lifestyle intervention was implemented in 77% of patients because they were not regularly 
physical active. 
Calculation of the risk reduction  
Optimizing the preventive actions in coronary patients leads to a reduction in cardiovascular 
events. Relative risks (RRs) related with these preventive actions were gathered from meta-
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analyses or large clinical trials (Table 1) (Clark et al, 2005; Critchley et al, 2003; Frey et al, 
2011; Kjekshus et al, 1997; Mills et al, 2011b; Mills et al, 2011a; Shah et al, 2010; Spector et 
al, 2011; Turnbull et al, 2005). Note that the risk reduction associated with smoking cessation 
was based on the effect of the smoking cessation therapy, accounting for the willingness to 
quit and the yearly relapse rates (Wetter et al, 2004). 
Table 1: Relative risks associated with different interventions to optimize prevention 
Intervention CHD Stroke CHF 
Smoking cessation  
0.68 (0.57-0.82) 
(Critchley et al, 2003) 
0.68 (0.54-0.85) 
(Frey et al, 2011) 
0.68 (0.47-0.99) 
(Critchley et al, 2003) 
Cholesterol-
lowering 
medication  
Standard vs. 
no therapy  
0.82 (0.75-0.91) 
(Mills et al, 2011b) 
0.86 (0.78-0.95) 
(Mills et al, 2011b) 
0.79 (0.63-0.95) 
(Kjekshus et al, 1997) 
Intensive vs. 
standard 
therapy  
0.9 (0.84-0.96) (Mills et 
al, 2011a) 
0.85 (0.76-0.97) 
(Spector et al, 2011) 
0.9 (0.84-0.96) 
(Mills et al, 2011a) 
Blood 
pressure-
lowering 
medication 
Standard vs. 
no therapy  
0.8 (0.73-0.88) 
(Turnbull et al, 2005) 
0.72 (0.62-0.83) 
(Turnbull et al, 2005) 
0.82 (0.69-0.98) 
(Turnbull et al, 2005) 
Intensive vs. 
standard 
therapy  
0.95 (0.78-1.16) 
(Turnbull et al, 2005) 
0.76 (0.58-1) 
(Turnbull et al, 2005) 
0.82 (0.55-1.22) 
(Turnbull et al, 2005) 
Physical activity  
0.62 (0.44-0.87) 
(Clark et al, 2005) 
0.55 (0.39-0.77) 
(Clark et al, 2005) 
0.62 (0.44-0.87) 
(Clark et al, 2005) 
 
These RRs indicate the effect of targeting one risk factor; however, in reality many patients 
have multiple risk factors not on target. Within our cohort, 41.3% of patients included in the 
analyses had two risk factors, 26.2% had three risk factors and 4.2% had all four risk factors 
not on target. Optimizing prevention implies addressing these risk factors simultaneously. 
Adding up the individual risk reduction would result in an overestimation of the total risk 
reduction, therefore, when multiple interventions are initiated a correction was made: 1 - ((1 - 
RR1 × RR2) × 0.8). The equation was formulated by comparing the effect of controlling 
multiple risk factors simultaneously vs. controlling individual risk factors separately 
(Dagenais et al, 2006). Country, age, and gender-specific general mortality probabilities were 
derived from WHO data (World Health Organisation, 2011). Cardiovascular mortality rates 
were based on data published by Vaartjes et al (Vaartjes et al, 2010).  
Cost of optimized prevention  
Optimizing prevention involves additional country-specific treatment costs for the health-care 
sector (Table 2). For smoking cessation, the cost of a 12 week drug treatment was considered, 
supplemented with the cost of two cardiologist visits and three motivational support visits. 
Regarding cholesterol and BP treatment daily medication and two yearly cardiologist visits 
were accounted for. These visits were assumed to increase adherence with the treatment. The 
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lifestyle intervention to increase physical activity included individual sessions, group sessions, 
and a fitness programme (Jacobs-van der Bruggen MA et al, 2007).  
Cost of avoided events  
Effective prevention should lead to a decrease in the number of cardiovascular events and 
therefore the health-care costs associated with these events will decrease. Country-specific 
data were gathered by the national coordinators to estimate these costs (Table 3). 
Quality of life  
The main outcome is expressed as quality-adjusted life years (QALYs). QALYs combine the 
quantity and quality of life, whereby the latter is represented by a utility value varying 
between 0 (death) and 1 (perfect health). To calculate the total QALYs associated with a 
given condition, the utility value is multiplied with the expected number of life years spent in 
that condition. The EUROASPIRE III database contains utility values for each patient during 
his initial disease state. A subsequent coronary event was assigned a penalty value of 0.0578 
for the remainder of the model, whereas stroke and CHF are appointed the penalty value 
0.2743 and 0.1372, respectively (Saarni et al, 2006; Schwander et al, 2009). 
Table 2: Country-specific intervention cost (€) 
 Cholesterol 
treatment/day (range)  
Blood pressure 
treatment /day (range) 
Smoking cessation treatment 
/year (NRT/varenicline) 
Lifestyle 
intervention /year 
f
 
Belgium 0.19-1.59
 a
 0.18-0.30
 a
 384/407
 a
 329  
Bulgaria 0.03-0.96 0.03-0.24 265/- 121 
Croatia 0.07-1.34 0.07-0.15 154/907 168 
Finland 0.49-1.45 0.15-0.49 466/571 319 
France 0.32-1.82 0.17-0.44 370/509 298 
Italy 0.07-1.84
 b
 0.17-0.42 
b
 312/560 
c
 279 
Poland 0.05-1.48 
d,e
 0.05-0.15 
d
  67/301
d
 173
 d
 
UK 0.81-1.87 0.05-0.81 662/718 309 
a Gecommentarieerd Geneesmiddelenrepertorium. http://www.bcfi.be/; b Regione Emilia Romagna. 
http://www.saluter.it/documentazione/ptr/elaborati/129_ace_inibitori.pdf; c Federazione nazionale unitary di farmacia. 
http://www.federfarma.it; d Medycyna Praktyczna. http://www.mp.pl; e National Health Fund Poland. http://www.nfz.gov.pl; f (Jacobs-van 
der Bruggen MA et al, 2007); Bulgaria: IMS retail data; Croatia: Croatian National Health Insurance Institute data; Finland: Official Finnish 
medical agency prices. 
Cost-effectiveness  
An incremental cost-effectiveness ratio (ICER) defined as the ratio between the net total costs 
and the net effects expressed in QALYs was calculated: 
(Cost optimi ed prevention – Cost current prevention)
(Effectiveness optimi ed prevention – Effectiveness current prevention)
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Sensitivity analyses 
Health economic modelling entails uncertainty around the input parameters, therefore 
sensitivity analyses were performed. Each input parameter is assumed to vary within a range 
of possible values defined by their probability distribution, based on standard error estimates 
from the literature (if not available a ±30% range was used). Moreover, different scenarios 
were tested such as the use of NRT vs. varenicline, Framingham calibration vs. no calibration 
and applying an adjustment when combining the individual risk reduction vs. no adjustment. 
In addition, a cost-effectiveness acceptability curve estimating the probability that the results 
are cost-effective at different willingness to pay thresholds was calculated.  
Table 3: Country-specific cost of diseases (€) 
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CHD (acute cost) 6178 
a
 2108 4000 6400 4337 6200 
c
 2077 
e
 1599 
f
 
CHD (first 6 months after the event) 2660 
a
  442 3000 3215 1850 4200 
c
 501 
e
 1333 
g
 
CHD (Second and further 6 months 
after acute event) 
1197 
a
  442 1250 708 1850 1800
 c
 430
 e
 1333 
g
 
Stroke (acute cost) 7366 
a
  1423 2500 6500 5029 3926 
d 
 1365
 e
 2830 
f
 
Stroke (first 6 months after the event) 3712 
a
  220 4530 8610 4821 2500
 d
 4164 
e
 1263 
g
 
Stroke (Second and further 6 months 
after acute event) 
2591 
a
  256 4150 2000 4821 1500
 d
 1014 
e
 1263 
g
 
Clinical heart failure 1444 
b
  189 1856 4000 1021 2948
 d
 1859 
e
 1618 
f
 
a (Annemans et al, 2003); b (Muls et al, 1998); c (Mantovani et al, 2009); d (Morsanutto et al, 2005); e (National Health Fund Poland, 
www.nfz.gov.pl.); f (NHS Department of Health., https://www.gov.uk/government/publications/reference-costs-guidance-for-2012-13--2); g 
(Flack et al, 2007); Bulgaria: 2010 contract between Ministry of Health and National Health Fund; Croatia: Croatian National Health 
Insurance Institute data; Finland: KELA-Social insurance institute of Finland; France: hospital data and reimbursement data. 
 
3. Results 
Base case scenario 
Assuming a 10-year time horizon, a time period often used in CVD prediction (Annemans et 
al, 2007), analyses revealed a higher QALY increase of 0.25 compared with the current 
situation; corresponding with three additional months in perfect health. Likewise optimizing 
prevention is associated with a mean cost increase of € 2493 per patient, resulting in an 
overall cost-effectiveness ratio of  € 12,484/QALY (Figure 2).  
These results differ between countries with lower ratios for Bulgaria (€ 7029/QALY), Poland 
(€ 7161/QALY), Croatia (€ 8406/QALY) and higher ratios for Finland (€ 11,660/QALY), 
Italy (€ 14,627/QALY), France (€ 6939/QALY), Belgium (€ 19,862/QALY), and the UK (€ 
23,491/QALY) (Table 4). 
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Figure 2: Cost-effectiveness results 
 
Results of cost-effectiveness analyses on individual patient data represented in a cost-effectiveness plane. The 
red diagonal line indicates a willingness to pay threshold of €30,000/QALY 
Table 4: Country-specific mean incremental cost, incremental effect, and incremental cost-effectiveness 
ratio (ICER) 
Country Mean Incremental effect (QALY) Mean Incremental cost (€) Mean ICER (€/QALY) 
Belgium 0,25 3200 19,937 
Bulgaria 0,23 1297 6866 
Croatia 0,25 1626 8478 
Finland 0,25 2427 11,678 
France 0,29 3790 16,970 
Italy 0,29 3373 14,671 
Poland 0,20 1175 6922 
UK 0,23 3970 23,666 
 
Result according to risk profile 
As shown in Figure 3, a better cost-effectiveness is more likely to occur in patients with a 
higher cardiovascular risk. Patients with a 2-year risk estimation <5% have a mean ICER of € 
24,862/ QALY, whereas the ICER of patients with a 2-year risk between 5 and 10% equals  € 
12,630/QALY. Those with a 2-year risk exceeding 10% have a mean ICER of € 7,844/QALY. 
Several factors contribute to this relationship. The mean ICER improves with increasing age 
varying from € 26,816/QALY for those <50 years old to € 8786/QALY for those >65 years of 
age. The ICER is the highest in those patients with a single cholesterol problem (ICER = € 
26,069/QALY) and the lowest in those only in need for BP treatment (ICER =€ 9108/QALY). 
Subanalyses reveal a low gain in QALY in smokers and high cholesterol patients (0.024 and 
0.071 QALY, respectively). On the contrary, the physical activity and BP-lowering 
interventions are associated with a high incremental effect (0.22 and 0.13 QALY, 
respectively). Similar but more moderate results were found for patients with more risk 
factors not on target (Table 5).  
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Figure 3: Cost-effectiveness results in function of the risk status. 
 
Table 5: Results according to subgroup classification 
Risk profile ICER 
Patients <50 years old € 26,759/QALY 
Patients <60 years old € 17,920/QALY 
Patients <65 years old € 15,638/QALY 
Patients >65 years old € 8794/QALY 
1 risk factor not on target € 12,627/QALY 
2 risk factors not on target € 11,695/QALY 
3 risk factors not on target € 13,165/QALY 
4 risk factors not on target € 14,924/QALY 
Single risk factor: Cholesterol elevated € 24,369/QALY 
Single risk factor: Smoking € 14,694/QALY 
Single risk factor: Blood Pressure elevated € 9086/QALY 
Single risk factor: Physical inactivity € 10,553/QALY 
Multiple risk factors: Cholesterol among others € 14,825/QALY 
Multiple risk factors: Smoking among others € 15,102/QALY 
Multiple risk factors: Blood Pressure among others € 11,033/QALY 
Multiple risk factors: Physical inactivity among others € 11,775/QALY 
Sensitivity analyses 
The results of the sensitivity analyses are presented in a Tornado diagram (Figure 4). The 
cost-effectiveness result was mainly sensitive for changes in the Framingham risk calibration, 
changes in the risk reduction following cholesterol-lowering therapy and changes in utility 
values. In addition, the method for calculating the total risk reduction, the costs related to 
cholesterol-lowering and BP-lowering treatment and the changes in the risk reduction 
following BP-lowering therapy and smoking cessation were of importance. The cost-
effectiveness acceptability curve clearly shows a higher cost-effectiveness probability at a 
lower threshold for Bulgaria, Croatia, and Poland, compared with the other countries (Figure 
5). At a threshold of 30,000€/QALY, optimizing prevention in the UK and Belgium have the 
lowest probability of being cost-effective (80%). 
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Figure 4: Sensitivity analyses
 
Tornado diagram based on uncertainty around input parameters 
Figure 5: Cost-effectiveness acceptability  
 
The cost-effectiveness acceptability curve for each individual country indicates the probability that the 
intervention is cost-effective given a range of willingness to pay thresholds. 
4. Discussion 
The EUROASPIRE III survey has shown a considerable potential to improve preventive 
strategies in order to achieve risk factor targets (EUROASPIRE Study Group, 1997). The 
current study evaluates the cost-effectiveness of optimizing tailor-made cardiovascular 
prevention in coronary patients. Overall, we found that optimizing secondary prevention is 
cost-effective compared with the current degree of cardiovascular prevention with an ICER of 
€ 12,484/QALY. A willingness to pay threshold of € 30,000/QALY is commonly used. For 
Poland, Bulgaria and Croatia a lower threshold should be applied based on their gross 
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domestic product (GDP) (World Health Organisation, 2001). Incremental cost-effectiveness 
ratios below the willingness to pay threshold are called cost-effective because the 
effectiveness of the intervention exceeds that of the current situation, however, at an 
additional cost. Results differed considerable between countries ranging from € 7029/QALY 
to € 23,491/QALY and were mainly driven by the country-specific costs. These results are 
consistent with the GDP of the eight countries with Bulgaria, Poland, and Croatia having a 
GDP of € 10,700, € 15,300, and € 14,800 per capita, respectively, whereas Belgium, Finland, 
France, Italy, and the UK have a GDP between € 24,000 and € 30,000 per capita 
(EUROSTAT, 2011). To our knowledge this is the first cost-effectiveness analysis on 
optimized, integrated, and tailor-made prevention. In the past, several studies have been 
published focusing on single (risk) factors and comparing prevention vs. no prevention. A 
recent study investigated the cost-effectiveness of a smoking cessation programme based on 
varenicline in smokers with CVD. Promising results were found with ICERs ranging between 
€ 5151 and € 6120 per QALY gained (Wilson et al, 2011). A recent paper, based on the 
treating to new targets study investigating the cost-effectiveness of 80 mg atorvastatin vs. 10 
mg atorvastatin found ratios of € 9500, € 21,000, and € 15,000 per QALY for UK, Spain, and 
Italy, respectively (Taylor et al, 2009). Likewise, Soini et al. evaluated the cost-effectiveness 
of atorvastatin (20 mg), rosuvastatin (10 mg), simvastatin (40 mg) and the combination of 
simvastatin (40 mg) with ezetimibe (10 mg) as secondary prevention strategy, reporting 
analogous results (Soini et al, 2010). Lindgren et al. reported on the cost-effectiveness of high 
dose atorvastatin compared with regular dose simvastatin based on the results from the 
IDEAL trial (Lindgren et al, 2007). The predicted ICER ranged between € 25,210 and € 
62,639. Regarding antiplatelet medication an ICER of $ 36,343/QALY was found for 
clopidogrel plus aspirin vs. aspirin alone (Chen et al, 2009). A comprehensive review by Heeg 
et al., including 21 studies, reported that aspirin dominates placebo in secondary prevention as 
it has both a greater effectiveness and a lower cost (Heeg et al, 2007). A Canadian study 
examined the cost-effectiveness of exercise training for the secondary prevention of CVD and 
reported ICERs around $ 15,000 per life year saved (Lowensteyn et al, 2000). Subanalyses of 
our results revealed a better cost-effectiveness probability in higher risk patients, because of 
their larger room or improvement due to more potentially preventable events. Hence a greater 
absolute risk reduction can be established with similar intervention investments. Optimizing 
prevention seems particular cost-effective in elderly patients, and in those patients with a high 
BP or patients not physically active. Previous studies came to similar conclusions indicating 
the patients’ level of risk being inversely correlated with the cost-effectiveness ratio (Heeg et 
al, 2007; Lindgren et al, 2007; Probstfield, 2003). Some assumptions and limitations of the 
study should be accounted for when interpreting the results. First, the Markov model includes 
only three CVD states whereby each subsequent event can only occur once per patient, 
potentially leading to an underestimation of the costs and an overestimation of QALY’s both 
for optimized and current prevention, therefore in reality, optimizing prevention might be 
associated with a greater health gain. Furthermore, potential savings not related to CVD 
events were not considered. Secondly, our study used Framingham risk equations to estimate 
the subsequent CHD risk, stroke risk, and heart failure risk. However, the Framingham 
population has other characteristics than the EUROASPIRE population; furthermore, the data 
are from an era with little or no revascularization and with available medicines very different 
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from nowadays. However, other available equations to estimate CHD, stroke, and CHF risk 
where not deemed appropriate because they only predict mortality, because they are based on 
patient characteristics not collected within EUROASPIRE III, or because they cannot be used 
in CHD patients. In order to account for the abovementioned shortcomings associated with 
the Framingham equations, a calibration was applied. Furthermore, with the exception of 
ageing of patients, typical changes in individuals’ risk factors due to time progression were 
not accounted for. In addition, average European age-specific regional mortality figures where 
used, despite the differences in the cardiovascular death rate throughout Europe (Markovic et 
al, 2005). Thirdly, assumptions were made with regard to optimizing treatment. For risk 
factors close to target a compliance problem was assumed which could be resolved by 
increasing the number of cardiologist visits. For risk factors with values further away from 
target, optimized prevention consisted of a dose increase or the addition of a supplementary 
drug. Fourthly, some assumptions were made regarding the risk reductions. For those 
strategies for which no RR was available an extrapolation was conducted. To estimate the risk 
reduction associated with a combination of preventive actions individual risk reduction cannot 
simply be added or multiplied, since this would induce an overestimation of the total health 
gain. Therefore a formula was calculated taking into account a correction factor which was 
estimated from existing literature (Dagenais et al, 2006; Sanz et al, 2009; Yusuf et al, 2004). 
In addition, no age-related difference in the risk reductions was applied. It might be, however, 
that older patients, for example, benefit less from a physical activity intervention than younger 
patients (Lowensteyn et al, 2000). Furthermore, losses in the quality of life inherent to the 
intervention, for example the patients’ perspective of losing the quality of life due to the fact 
that he is not allowed to smoke anymore, or due to statin side effects, were not accounted for. 
Moreover, it should also be noted that the quality of life measure used can greatly influence 
the calculated QALYs and hence overall ICER result. In this study we made use of EQ-5D 
utility values, however the use of SF-6D utilities for example would result in other outcomes 
(De Smedt, 2013c).  Finally, cost data were provided by local coordinators, hence although 
several attempts made to minimize heterogeneity between data input, there is no complete 
certainty on consistency between countries. In conclusion, this tailor-made model on 
integrated secondary prevention in Europe is to our knowledge the first attempt to assess the 
cost-effectiveness of optimized tailor made and integrated prevention. Overall, optimizing 
prevention is cost-effective based on the EUROASPIRE III data. The best results are found in 
elderly and in patients with a high BP or in patients not physically active. Introducing 
preventive treatment actions in CHD patients should be based on their individual risk level 
since this is a key driver for cost-effectiveness. 
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Chapter 10. 
General discussion 
 
10.1 INTRODUCTION 
The goal of today’s medicine is not merely to improve patient survival but also to ensure that 
they achieve the best possible health-related quality of life (HRQoL). In essence HRQoL 
captures a person’s self-perceived impact of a medical condition, its symptoms and its 
treatment (Schipper et al, 1996). Despite the extensive use of the concept, consensus is 
lacking on the definition of HRQoL. The term is used to describe a variety of concepts, such 
as functioning, health status, perceptions, life conditions, behaviour, happiness, lifestyle, 
symptoms etc. (Simko et al, 1999), therefore HRQol is sometimes referred to as an umbrella 
term (Feinstein et al, 1987). Although not quite the same, HRQoL and health status or 
functional status are often used interchangeably. Knowledge about HRQoL has increased over 
the years, changing concepts and definitions. Depending on the setting (scientific purpose, 
clinical practice, physicians, sociologists, psychologists, health economists, etc.) the concept 
is being used in different ways. However, the importance of HRQoL -in all it different 
meanings- is well-accepted. Depression, anxiety as well as functional status and general 
health perceptions have been shown to act as a predictor of future cardiovascular outcomes 
and mortality among coronary heart disease (CHD) patients (Agewall et al, 2012; Burstrom et 
al, 2001; DeSalvo et al, 2006; Kato et al, 2011; Pedersen et al, 2007; Spertus et al, 2002; 
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Thombs et al, 2008). Hence, tackling depressive and anxious feelings as well as impaired self-
perceived health status and other HRQoL issues are of particular importance to the patients, 
their family as well as to health care providers and health care policy decision makers. In 
order to set up interventions addressing these issues, it is necessary to investigate the risk 
factors that are associated with worse HRQoL outcomes. 
The general aim of this thesis was to focus on HRQoL/psychological distress among stable 
coronary patient, using the EUROASPIRE III (EUROpean Action on Secondary and Primary 
Prevention through Intervention to Reduce Events) database.  
 
Figure 1: Research questions addressed within this thesis. The blue rounded squares indicate the 
investigated topics. The pink arrow shows what is already known from the literature. The dotted orange 
line indicates how HRQoL can be used in practice. 
The EUROASPIRE III survey has several strengths including its large sample size and the 
inclusion of patients from 22 different European countries. Furthermore, data collection is not 
only based on abstracted medical record data but included face-to-face interviews and 
examinations using standardized methods and instruments, including central laboratory 
analyses of lipids and glucose. The median time interval between hospital admission and 
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interview reached 1.24 years, allowing patients and health care providers to meet the proposed 
guideline standards. At the time of the interview, the acute CHD stage had passed and patients 
were likely to be in a more stable phase of the disease. In addition to risk factor assessment 
and questions about lifestyle changes, the interview questionnaire contained three tools to 
collect information about HRQoL/psychological distress: the EuroQoL 5 dimensions (EQ-
5D), the 12-item short form health survey (SF-12) and the Hospital Anxiety and Depression 
Scale (HADS). 
First, we investigated whether the instruments used were valid and reliable for use in a 
population of stable coronary patients (chapter 3). Some studies have already performed 
psychometric analyses of these instruments in CHD patients, however often in a smaller 
sample, or in a sample of patients with HRQoL data collected shortly after their acute 
coronary event (Ellis et al, 2005; Failde et al, 2010; Schweikert et al, 2006; Barth et al, 2005; 
Cosco et al, 2012). The EUROASPIRE III database allowed us to assess the reliability and 
validity of EQ-5D, SF-12 and HADS, based on a unique sample of 8745 stable CHD patients. 
Furthermore, we were able to compare the results across countries. The interpretation of the 
outcomes is difficult, if not impossible, in the absence of reference values from the general 
population. Hence, EQ-5D results from the EUROASPIRE III sample were compared with 
published normative values (chapter 4). 
Several risk factors are well-known predictors of future cardiovascular outcome and mortality, 
both in the general population as well as in coronary patients (Canto et al, 2011; Conroy et al, 
2003; Perk et al, 2012; Wilson et al, 1998). In the current thesis, we distinguish four risk 
factor categories (Gaziano et al, 2001). First there are the non-modifiable predisposing risk 
factors such as age, gender, family history, genetic predisposition, educational level and 
socio-economic status. Secondly, metabolic risk factors exist such as an elevated total 
cholesterol (TC), a high blood pressure (BP), diabetes, overweight and obesity. Thirdly, 
behavioural risk factors, such as smoking, lack of physical activity, an unhealthy diet and 
excessive alcohol intake are known CHD risk factors. And finally psychosocial factors such 
as stress, anxiety and depression as well as impaired self-perceived well-being are considered 
CHD risk factors (Berry et al, 2012; Buttar et al, 2005; DeSalvo et al, 2006; World Health 
Organisation, 2002; World Health Organisation, 2004). Hence, in addition to medical 
treatment and behavioural changes, it can be assumed that HRQoL issues and psychological 
distress are also important to address. However, knowledge on the key determinants of 
HRQoL/psychological distress is rather scarce. We investigated the underlying variables 
associated with a decline in HRQoL/ increase in psychological distress among coronary 
patients with a particular focus on their cardiovascular risk profile (chapter 5), lifestyle 
changes (chapter 6) and risk factor level awareness (chapter 7).  
Utility scores are often used in health-economic evaluations. Both EQ-5Dindex scores 
(EuroQoL utility value) as well as SF-12 based utility scores can be used. However, in order 
to assess whether these utility instruments are equally suitable, we explored the inter-
changeability of these tools (chapter 8). Finally, the usefulness of HRQoL as a policy tool was 
tested, by performing a cost-utility analysis of secondary cardiovascular prevention (chapter 
9).  
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10.2 MAIN FINDINGS AND DISCUSSION 
10.2.1 Reliability and validity of HRQoL/psychological distress measures in CHD patients 
As mentioned above, HRQoL/psychological distress instruments are increasingly being used 
as assessment tools in coronary patients. Although several studies have previously 
investigated the psychometric properties of HRQoL/psychological distress instruments in 
various samples of CHD patients, cross-European data are limited (Ellis et al, 2005; Failde et 
al, 2010; Schweikert et al, 2006; Barth et al, 2005; Cosco et al, 2012). The added value of our 
study comes from the large sample size, comprising 8,745 patient records from 22 different 
European countries, providing information on three different instruments simultaneously. Our 
results support the use of EQ-5D, SF-12 and HADS in European CHD patients. On the whole, 
all instruments were shown to be valid and reliable for use in coronary patients both on 
aggregate European level, as well as on country-specific level. Internal consistency, i.e. the 
degree of homogeneity across items, was confirmed for all three measures, even on country-
specific level. It should be noted however, that Cronbach's alpha values were somewhat lower 
for the EQ-5Dindex with about half of the countries having a value slightly below 0.70. Two 
possible reasons for these less acceptable values, could be the heterogeneity among the 
different EQ-5D items as well as the small number of items giving rise to lower Cronbach’s 
alfa values (Pallant, 2011). Likewise, confirmatory factor analyses showed a good construct 
validity and known-group discriminative validity was confirmed for all three measures. 
Constructs capturing similar functional or emotional characteristics correlated highly with one 
another, supporting convergent validity. Criterion validity was confirmed using the EQ-VAS 
as well as the SF-12/1 (first question of SF-12 asking about a patient’s general health) as 
overall health criterion. Although, all three tools showed good validity and reliability caution 
is required as we were not able to assess test-retest reliability and responsiveness.  
10.2.2 HRQoL outcomes in coronary patients and associated risk factors 
Comparison with the general population 
Coronary patients are believed to have an impaired HRQoL/psychological distress. Several 
studies have indeed reported worse HRQoL outcomes in coronary patients compared to the 
general population (Boini et al, 2006; Brink et al, 2005; Crilley et al, 2001; Mols et al, 2009; 
Sprangers et al, 2000; Xie et al, 2008), however in-depth examinations, comparing the 
HRQoL dimensions of generic instruments are limited (Schweikert et al, 2009; Mols et al, 
2009; Mols et al, 2009; Urso et al, 2009). Comparison of EQ-5D outcomes between CHD 
patients and the general population, across 11 European countries, demonstrated a significant 
difference. In order to avoid bias due to differences in age distribution between CHD patients 
and the general population, direct age standardization was performed. Results differed across 
countries and gender, but overall the greatest HRQoL loss was seen on the anxiety/depression 
dimension as well as on the EQ-VAS, both in males and females. Furthermore, female 
coronary patients reported a significantly higher proportion of problems on the mobility 
(OR=2.00[1.38;2.90]), usual activity (OR= 2.54[1.81;3.57]) and pain/discomfort dimension 
(OR=1.73[1.23;2.43]) whereas in males, a borderline significant OR was found on the 
CHAPTER 10 
 
 
123 
 
mobility (OR=1.43[0.97;2.11]) and usual activity dimension. No significant difference in the 
self-care dimension could be observed, neither in males nor in females.  
Regarding the SF-12, a theoretical mean value=50 and a standard deviation=10, has been 
proposed as reference value for both the physical component score (PCS-12) and the mental 
component score (MCS-12) (Ware et al, 2002). However, in order to reach a valid conclusion 
about any difference in SF-12 outcomes between CHD patients and the general population, 
age-specific reference values are needed since HRQoL outcomes are known to evolve with 
age. We performed some additional analyses (unpublished, see appendix 1), in order to assess 
whether the EQ-5D findings reported above could be confirmed using the SF-12 instrument. 
The International Quality of Life Assessment (IQOLA) project has gathered age-specific 
reference values on 5 of the included EUROASPIRE III countries: France, Italy, the 
Netherlands, Spain and the UK. According to these reference values, PCS-12 scores worsen 
with increasing age, whereas MCS-12 outcomes remained stable or improved slightly with 
increasing age with the exception of Spain and Italy. Only the component measure values 
were reported, hence we were not able to compare the results on dimension-specific level. 
Furthermore, no distinction between genders was made. Despite these limitations, the 
additional analyses allowed us to gain some insight regarding this matter. Three age 
categories were described by the IQOLA project: 18-44 years; 45-64 years and 65-74 years. 
Conform with the EQ-5D analyses, we did not include the youngest age category. Analyses 
were conducted in a similar manner as the previously performed EQ-5D analyses. Conform 
with the EQ-5D results, some variation was seen across countries. Overall, a significant 
difference was found between CHD patients and the general population both on the PCS-12 
score (-3.49 [-6.00, -0.99]) and the MCS-12 score (-2.29 [-3.65, -0.93]). 
A closer look at the HADS results revealed that 27% of male CHD patients and 44% of 
females CHD patients had a HADS-anxiety (HADS-A) ≥8, and 21% of male CHD patients 
and 32% of female CHD patients had a HADS-depression (HADS-D) ≥8 (Pajak et al, 2013). 
Country-specific scores for the general population are however scarce. Within our knowledge 
age and gender-specific reference values were only available for Germany (Hinz et al, 2011). 
Comparison of German reference data with the German CHD sample, revealed significantly 
higher proportion of elevated HADS-A and HADS-D scores in female but not in male CHD 
patients.  
The above presented results have indicated greater relative impairments in female CHD 
patients compared to males. Furthermore both physical en mental components were affected. 
EQ-5D comparison revealed significant impairments in CHD patients, on all dimensions with 
the exception of self-care (both genders) and pain/discomfort (in males). 
Non-modifiable risk factors 
Detailed analyses of the risk factors associated with an impaired HRQoL/psychological 
distress in CHD patients designated gender as a key variable, with female patients having 
worse HRQoL outcomes (Brink et al, 2005; Duenas et al, 2011; Emery et al, 2004; Norris et 
al, 2008; Norris et al, 2010; Phillips-Bute et al, 2003; Sevinc et al, 2010, Pajak et al, 2013). 
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Similar findings have been reported in the general population, suggesting existing differences 
before any event occurs (Martinelli et al, 2008). However, the relative impairment was greater 
in women, indicating a greater self-perceived impact of CHD on HRQoL in females. Several 
determinants, explaining the differences in gender have been suggested, however many causes 
are not well understood and research is still on-going. During childhood, boys and girls have 
similar HRQoL outcomes, but with increasing age, the HRQoL outcomes in girls deteriorate 
more rapidly than in boys, resulting in significantly worse outcomes in female adolescents 
(Michel et al, 2009). Women are known to verbalize more, consequently it might be assumed 
that women tend to over-report their problems during interview whereas males tend to 
trivialize (Martinelli et al, 2008). This idea is in contrast with some studies stating that both 
sexes report their symptoms accurately (Macintyre et al, 1999; Merrill et al, 1997). Some 
argue however, that women might perceive symptoms in a different way (Norris et al, 2010; 
Phillips-Bute et al, 2003; van Wijk et al, 1997). Although results indicate that both male and 
female coronary patients experience the same symptoms, some studies found differences in 
the proportions of symptoms, with women reporting more angina, pain, nausea, fatigue, 
syncope, weakness, depression and loss of appetite (DeVon et al, 2002; DeVon et al, 2003; 
Kimble et al, 2003). Physiologic differences could be one of the reasons why women 
experience worse HRQoL outcomes. Females have for example smaller coronary arteries, 
which might increase ischemia (Lichtman et al, 2008). Furthermore, the higher depression 
rates in women are strongly associated with poorer recovery rates possibly leading to 
impaired HRQoL results (Lichtman et al, 2008; Norris et al, 2008). In addition, compared to 
men, women often have a lower sense of coherence (SOC, i.e. experiencing the world as 
comprehensible, meaningful and manageable) which is significantly associated with a worse 
HRQoL (Bergman et al, 2012; Eriksson et al, 2006). In addition, some identified social 
support (meeting and talking regularly with friends and family) as an important predictor of 
HRQoL in cardiac women (Emery et al, 2004; Norris et al, 2008). The continuing demands in 
the home environment are also proposed as a possible explanation for worse HRQoL 
outcomes (Emery et al, 2004). According to Charmaz (1995) the HRQoL outcome can also 
depend on how patients deal with their illness. Women struggle with an illness, by adapting to 
the changed circumstances, hence they are more likely to recognize their illness and report 
about the associated symptoms, whereas men struggle against the illness, trying to deny that 
anything has changed, hence reporting fewer symptoms (Brink et al, 2005; Charmaz, 1995). 
Further investigation of the underlying variables responsible for the decline in HRQoL 
indicated geographical region as a predictor, with lower HRQoL estimates in CHD patients 
from eastern European countries. Similar results were seen in a study from the EuroQol 
Group, with lower HRQoL outcomes in less prosperous countries (The EuroQol Group's 
International Task Force on Self-Reported Health, 2004). As stated by the EuroQol Group, 
“Some populations may be more reluctant to give positive answers to the questions in a 
survey than others”, hence cultural differences might underlie these differences, but also 
differences in medical practice can be responsible for these observations. Moreover, the 
patients included in EUROASPIRE III are not always representative for the coronary patients 
within their country, hence a part of the across country differences might be induced by the 
study design. 
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In agreement with previous research, younger patients reported significantly better HRQoL 
outcomes (The EuroQol Group's International Task Force on Self-Reported Health, 2004; 
Brink et al, 2005; Lee et al, 2012; Pragodpol et al, 2012; Schweikert et al, 2009) with the 
exception of the anxiety component, on which younger patients reported more problems (Hinz 
et al, 2011; Spinhoven et al, 1997; Xie et al, 2008).  Again, these findings are not restricted to 
CHD patients. Worse HRQoL outcomes have also been associated with increasing age in de 
general population (The EuroQol Group's International Task Force on Self-Reported Health, 
2004; Golicki et al, 2010; Hinz et al, 2011; Saarni et al, 2006), which seems quite logical, 
since the aging process is associated with physical and mental deterioration.  
Similar to the results reported by Lee et al. (2012), lower educated patients were found to 
have significantly poorer HRQoL outcomes. Education can be seen as a proxy for socio-
economic status (SES), which is related to lower health status. Evidence suggests that low 
educated persons have poorer health habits, an increase in comorbidities and worse access to 
health care facilities (Burstrom et al, 2001; Pappa et al, 2009). Veentra et al (2004) further 
observed that the HRQoL in lower educated coronary patients was less likely to improve 
following invasive coronary procedures.  
Conform with previous research significantly better HRQoL scores were found in patients 
undergoing revascularization as recruiting diagnosis (Kim et al, 2005; Lukkarinen et al, 2006; 
Sevinc et al, 2010; Weintraub et al, 2008). This is most likely caused by a reduction in 
symptoms related to angina (Kim et al, 2005). Furthermore, as expected various comorbidities, 
such as diabetes, history of stroke or recurrent coronary events since the index event were 
associated with worse outcomes (Leach et al, 2011; Peterson et al, 2006; Schwander et al, 
2009; Xie et al, 2008).  
Metabolic risk factors 
With the exception of body mass index (BMI), uncontrolled metabolic risk factors were not or 
not strongly associated with HRQoL. An uncontrolled total cholesterol (TC) was not 
associated with HRQoL, with the exception of the MCS-12 and EQ-VAS (borderline), where 
a significant, but very small gain in HRQoL was observed in controlled patients. Similarly, no 
significant association between HRQoL and cholesterol was found in the literature (Sevinc et 
al, 2010). (Khanna et al, 2012; Lau et al, 2004; Lee et al, 2012). In contrast, an uncontrolled 
BP seemed to be associated with better HRQoL outcomes. This association was however 
eliminated after adjustment for medication intake. Indeed, about 28% of the EUROASPIRE 
III patients were taking nitrates and 30% were taking diuretics at the time of the interview, 
medication which is often prescribed in patients with angina and heart failure respectively 
(Herlitz et al, 2005; Pragodpol et al, 2012). It is assumed that HRQoL impairments associated 
with angina and heart failure will improve when medically treated, leading to an unexpected 
higher HRQoL despite an uncontrolled BP. Contrasting results have been found in the 
literature, with some reporting a correlation between worse HRQoL and elevated BP, whereas 
others did not find any association (Carvalho et al, 2012; Herlitz et al, 2005; Sevinc et al, 
2010; Soini et al, 2010). With regard to glucose levels, results were inconsistent, with 
glycated haemoglobin (HbA1c) but not fasting glucose being significantly associated with 
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HRQoL in patients with diabetes. Khanna et al (2012), found similar results with a significant 
association between elevated HbA1c values and worse HRQoL outcomes, whereas Lau et a 
(2004), only found a significant association with the mental HRQoL components. Lee et al 
(2012) did not find any association with blood glucose. No explanation can be given with 
regard to the inconsistency between HbA1c and blood glucose. In accordance with the 
literature, BMI was inversely associated with HRQoL, with obese patients having inferior 
HRQoL outcomes (Oreopoulos et al, 2010; Schweikert et al, 2009). In contrast, regarding the 
actual weight change, no significant difference was found in HRQoL outcomes (except for 
PCS-12) between those who had lost weight (≥5% weight loss), maintained their weight level 
(±5% weight change), or gained weight (≥5% weight gain) between the recruiting diagnosis 
and the interview. 
Behavioural changes 
In accordance with general population findings (Piper et al, 2012; Sarna et al, 2008), in-depth 
analyses of the association between HRQoL/psychological distress and smoking, revealed 
better outcomes for never smokers and ex-smokers both on their self-perceived physical and 
mental health. In coronary patients however, conflicting results have been reported in the past 
(Haddock et al, 2003; Quist-Paulsen et al, 2006; Schweikert et al, 2009; Taira et al, 2000). 
Within the EUROASPIRE sample, the time since smoking cessation was not significantly 
related to HRQoL/psychological distress. Likewise, Piper et al. (2012) have shown rapid 
HRQoL improvements (1 year) after smoking cessation which sustained for at least 3 years 
whereas in the Nurses’ Health Study, HRQoL scores improved gradually with longer time 
since quitting (Sarna et al, 2008). Especially the mental health component in prior smokers 
seemed to be significantly better compared to current smokers. This result was confirmed by 
others (Mulder et al, 2001). Likewise and in complete agreement with past research, both in 
the general population as well as in coronary patients, the physical activity level in CHD 
patients was also associated with HRQoL/psychological distress, with better outcomes in 
physically active patients (Bize et al, 2007; Sevinc et al, 2010; Romain et al, 2012). Both the 
attempts undertaken to increase physical activity as well as the actual physical activity levels 
were associated with better outcomes. These components seem to reinforce one another, with 
the best scores seen in patients residing in the highest IPAQ class who had moreover made an 
attempt to increase their physical activity. Attempts to alter dietary behaviour were also 
associated with HRQoL/psychological distress, with better outcomes in patients who tried to 
reduce fat and salt intake and increase fish, fruit, and vegetable intake, especially on the 
overall HRQoL and physical dimensions but less on the mental dimension. Similar results 
were seen in the SUN project, with an important association between adherence to 
Mediterranean diet (consumption of fruit, vegetables, and fish and olive oil and reduction of 
meat and dairy intake) and better SF-36 scores (Henriquez Sánchez et al, 2012). In conclusion, 
it seems that the act of exercising and healthy eating behaviour themselves, and not merely 
losing weight, are aligned with better outcomes. 
Due to the cross-sectional design of our study, we were unable to assess causality. Are those 
patients with a better HRQoL/psychological distress more likely to change their behaviour 
accordingly, do behavioural changes have an influence on a patient’s HRQoL/psychological 
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distress, or is there a mutual influence or an external factor leading to both an increase in 
HRQoL/decrease in psychological distress and increase in physical activity (Romain et al, 
2012)? According to the transtheoretical model, behavioural changes can be divided in five 
different stages of change (Prochaska et al, 1983; Romain et al, 2012). First there is the 
precontemplation stage, when the individual has no intention to change. The second stage is 
the contemplation stage, when the individual has the intention to change within the next 6 
months. The third stage is the preparation stage, when the individual is intending to change 
within the next 30 days. Subsequently, individuals can move to the action stage when the 
individual is being engaged in the behaviour for <6 months. Finally the maintenance stage is 
achieved when the individual sustains in the change over time. Investigating the association 
between the different stages of change and HRQoL can be helpful in order to gain insight 
about the causality between behavioural changes and HRQoL. The EUROPASPIRE III 
interview contained questions about the intention of patients to change their behaviour. 
Patients smoking at the time of the interview were asked about their smoking cessation 
behaviour  (no and I do not intend to; yes within the next 6 months; yes within the next 30 
days; yes I have quit <6 months; yes I have quit >6 months). Likewise patients were asked 
about their intention to lose weight (no; yes within the next in the 6 months; yes within the 
next 30 days; yes I have been trying in the past month). Moreover patients were asked if they 
exercised regularly (no and I do not intend to; no but I intend to in next 30 days; no but I 
intend to in next 6 months; yes for less than 6 months; yes for more than 6 months). 
In persistent smokers, no significant differences in HRQoL outcomes were found between 
patients considering smoking cessation versus those not intending to quit, hence it is unlikely 
that those willing to quit smoking had a higher initial HRQoL allowing them to find the 
motivation to quit. Likewise, the intention to become physically active was not associated 
with HRQoL, except in overweight and obese patients, where having no intention to become 
physically active was associated with poorer HRQoL outcomes, although the differences were 
small. Not surprisingly, the greatest HRQoL differences were found in the items capturing the 
current physical health status (PCS-12). After all, physical activity is an important component 
of HRQoL. Patients experiencing problems with their physical health, due to pain/discomfort 
for instance, may be less likely to become physically active. These findings support the 
hypothesis of a vicious circle, where overweight and obese people, known to experience more 
difficulties in walking or climbing stairs, for example, are less inclined to become physically 
active, with a higher possibility to have an increase in weight, which can in his turn lead to 
less exercise (Bauman et al, 2012). Hence, implementing multimodal interventions, focusing 
both on exercise, diet and weight may be necessary. Furthermore, in overweight and obese 
patients, no differences were found between those intending to lose weight versus those not 
intending, except on the PCS-12, on which non-intenders scored better. These results indicate 
worse HRQoL outcomes in the precontemplation, contemplation or preparation phase, and 
better outcomes in the action and maintenance phase. This suggests that the lifestyle changes 
are responsible for an improved HRQoL and not the other way round. Similar results have 
been found by others investigating the link between the stages of behavioural change and 
HRQoL (Laforge et al, 1999; Lee et al, 2006; Romain et al, 2012). Nonetheless, it remains 
possible that patients in the precontemplation, contemplation or preparation phase differ in 
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several unmeasured characteristics from those in the action or maintenance phase, hence these 
results should be interpreted with caution.  
Furthermore, an increase in the number of uncontrolled metabolic and behavioural risk factors 
(raised BP, raised TC, current smoking, low physical activity and central obesity) was 
significantly associated with worse HRQoL outcomes, reaffirming the high importance of a 
holistic approach regarding risk factor prevention.  
Awareness  
Following the above described context, some authors argue that the awareness of having an 
increased cardiovascular risk, might result in worse HRQoL outcomes, also known as “the 
labelling effect” (Mena-Martin et al, 2003). Being aware of an elevated morbidity or mortality 
risk can induce feelings of anxiety and depression. Indeed, as shown by Mena-martin (2003), 
hypertensive patients being aware of their condition have worse HRQoL outcomes compared 
with hypertensive patients not being aware. Likewise, a higher sick leave is reported in such 
patients (Leynen et al, 2006). Within EUROASPIRE III however, an inverse relationship was 
found, with patients being aware on at least one risk factor level (BP, TC, blood glucose), 
having significantly better HRQoL/psychological distress outcomes, compared to those not 
aware of their risk factor levels. It can be argued that coronary patients already received a 
“labelling-effect” at the time of their recruiting diagnosis, hence they are all aware of their 
increased CHD risk. The hypothesis of a labelling effect is therefore not applicable within this 
context. Another mechanism seems to be play here. The association between risk factor level 
awareness and better HRQoL/psychological distress outcomes was seen both in patients with 
a BP, TC or blood glucose on or above target. The relationship between awareness and 
HRQoL/psychological distress seems to be partly mediated by the attempt of patients to adopt 
a healthier behaviour. Patients with a greater awareness are more likely to have made attempts 
in improving their lifestyle. And as discussed above, lifestyle improvements have been shown 
to be associated with patients’ HRQoL/psychological distress outcomes (Ludt et al, 2011). 
Nevertheless, there also seems to be a direct link between awareness and 
HRQoL/psychological distress, in particular with the mental component. Patients who are 
more aware, feel less anxious and depressed and score better on their mental and emotional 
well-being regardless of whether they change their lifestyle behaviour. One possible 
explanation might be that patient involvement in their care and awareness of their risk factor 
profile could possibly affect their illness perception and sense of control. Poor illness 
perception and low sense of control have been associated with worse physical and mental 
outcomes (Lau-Walker et al, 2009; Stafford et al, 2009). Hence, in addition to improved 
adherence to lifestyle changes, a better sense of control might also lead to a decrease in 
anxiety (French et al, 2005). Due to the cross-sectional study design of our dataset, we were 
however not able to assess causality. Hence, there could also be a reverse causality , with 
better HRQoL outcomes ensuring a greater interest of patients in their own risk factor profile. 
Patients with less anxiety or depression and a better health status might be more receptive to 
listen and to remember their risk factor levels. Most likely, some interplay exists between the 
above described pathways reinforcing one another. Despite risk factor level awareness being 
positively associated with HRQoL/psychological distress, insufficient awareness rates among 
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CHD patients were observed. About 82% of patients indicated to be aware of their own BP 
level, 47% of patients indicated to be aware of their own TC level and 44% of the complete 
sample indicated to be aware of their blood glucose level, whereas in diabetes patients blood 
glucose level awareness reached 82%. Those patients not aware about any of their risk factor 
levels, were more likely to have a lower education, to be low physically active or to be a 
smoker, whereas those aware on some or all of their own risk factor levels were more likely to 
have diabetes, to be obese, to have an elevated TC, BP,  or blood glucose level. Hence, our 
results seem to suggest that patients with increased risk factor levels are more likely to be 
aware of their TC, BP or blood glucose level. 
There is a growing interest in the concept of ‘Patient Empowerment’. The rationale is that 
patients take charge of their own health. Small et al, conceptualized empowerment in patients 
with long-term conditions as:  “an enabling process or outcome arising from communication 
with the health care professional and a mutual sharing of resources over information relating 
to illness, which enhances the patient’s feelings of control, self-efficacy, coping abilities and 
ability to achieve change over their condition”(Small 2012). According to Calvillo and 
colleagues (2013), four milestones can be considered in the evolution to patient empowerment. 
The first step is to make patients aware of their condition and to inform them. There is a 
change from passive to active participation in the disease treatment. When the patient is aware 
about his/her own health status, proper action plans and guidance can result in better 
adherence to treatment plans  and consequently better health outcomes. 
10.2.3 Clinical relevance of HRQoL differences 
Due to the large sample size of the EUROAPSIRE III survey, there is a risk that the study is 
somewhat overpowered, resulting in statistically significant differences that are not 
necessarily clinically meaningful. Little is know about the clinical relevance of changes in 
HRQoL, since no general consensus is available on what is perceived as a meaningful 
difference. Some authors have suggested half a standard deviation as the minimal important 
difference (MID) (Norman et al, 2003), while others have proposed a 3–5-point change for 
the SF-12 (Samsa et al, 1999), a MID of 0.074 for EQ-5D (Walters et al, 2005), and a MID of 
1.5 for HADS (Puhan et al, 2008). 
When we apply these MID’s in order to interpret our results we observe a great variation 
across risk factors. A clinical relevant difference in PCS-12 and EQ-VAS was found between 
the lowest and highest age categories. Likewise, differences in PCS-12 and MCS-12 seemed 
to be clinically relevant across the lowest and highest educated patients. Furthermore the 
impact of diabetes on the PCS-12 and of stroke on the PCS-12 and EQ-VAS was clinically 
meaningful. Although smoking cessation was significantly associated with HRQoL, the 
changes were limited and did not reach the MID’s. Likewise, dietary changes did not seem to 
be clinically important. Physical activity on the contrary was associated with clinically 
meaningful improvements in HRQoL, with the greatest  changes seen on the PCS-12 and the 
EQ-VAS. The increase in number of risk factors was associated with very important 
differences on all HRQoL domains, especially with regard to the physical component. 
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10.2.4 How HRQoL can be used in practice 
Thus, in addition to the beneficial effect of optimal CHD risk factor control on morbidity and 
mortality outcomes (Perk et al, 2012), it seems that an optimally controlled CHD risk factor 
profile has also a favourable influence on a coronary patient’s HRQoL. The positive effects of 
optimal prevention are not only of importance for the individual but also for the society. 
Scarce health care resources have led to the development of health economic evaluations, 
used as decision making tool in order to maximize health benefits with the available financial 
means. These analyses include both benefits and costs related to a given treatment option. 
Costs include both expenses related to therapy and saving related to avoided morbidity and 
mortality whereas gains are often expressed as quality adjusted life years (QALY’s). QALY’s 
are calculated by multiplying a utility value (degree of self perceived health) with the number 
of life years a patient is in that particular health state. Utilities usually range between 0 (death) 
and 1 (perfect health) – although values below 0 exist (health states that are perceived worse 
than death). Within this thesis we aimed to asses whether optimized secondary prevention, 
based on the European guidelines on cardiovascular prevention (De Backer et al, 2003), in 
coronary patients is cost-effective across eight EUROASPIRE III countries (Belgium, 
Bulgaria, Croatia, Finland, France, Italy, Poland, and the UK). A tailor-made approach was 
used, estimating patient’s future risk, based on their individual risk profile. 
EQ-5D utility values, as well as SF-12 derived utility values – also known as SF-6D values, 
i.e. 6-dimensional health state classification – can be used in health economic evaluations. As 
reported by Joore et al (2010), differences among both measures can lead to different health 
economic outcomes. Similar to previous studies in various populations, the EQ-5Dindex 
outcomes in the EUROASPIRE sample are significantly correlated with the SF-6D values, 
with ICC’s indicating moderate agreement between the instruments (Brazier et al, 2004a; 
Ferreira et al, 2008; Kontodimopoulos et al, 2011). However, significant differences remain 
between both outcomes, making them not simply interchangeable. Across all EUROASPIRE 
III countries, the median utility values differed significantly from each other with SF-6D 
utility scores being systematically lower than EQ-5Dindex outcomes, both at country specific 
level, as well as after stratification by patient characteristics. Furthermore, a ceiling effect was 
observed in the EQ-5D instrument, but no floor effect was seen on either instrument. These 
results are similar to previously reported outcomes (Joore et al, 2010; van Stel et al, 2006), 
(Bharmal et al, 2006) and Brazier et al. acknowledge a possible ceiling effect of the EQ-5D 
and a possible floor effect of the SF-6D instrument (Brazier et al, 2004a). Subanalyses in the 
EUROASPIRE III population revealed that patients reporting no problems on the EQ-5D still 
reported substantial problems on the SF-6D role limitation and vitality dimensions. This is in 
line with the lower correlations seen between the EQ-5D dimensions and the SF-6D role 
limitation and vitality dimension. Furthermore, within our population, especially mental 
problems are not completely captured by the EQ-5D instrument. Likewise, in the study by 
Brazier et al. (2004), based on 7 patient groups, it was observed that those patients with full 
health on the EQ-5D may still experience problems in SF-6D physical functioning, mental 
health and vitality (Brazier et al, 2004a).  
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As mentioned by others, some of the differences between the instruments might be explained 
by the theoretical construction of the measures (Brazier et al, 2004a; Bryan et al, 2005; van 
Stel et al, 2006). First of all, the recall period is different: ‘today’ versus ‘past four weeks’, 
however we agree with Van Stel et al. (2006), that the influence of the recall period on the 
utility differences might be non-significant within our population as it concerns stable CHD 
patients. Furthermore, the EQ-5D covers only 5 dimensions/questions with 3 answer 
categories each, whereas the SF-6D captures 6 dimensions, based on 11 SF-12 questions with 
3 to 5 response categories each. An increase in number of questions and answers 
automatically leads to a more descriptive and sensitive tool with a higher amount of possible 
outcomes. Likewise, the formulation of the question differs across different HRQoL tools. A 
patient who has sometimes frightened feelings, might for example indicate “I’m not anxious 
or depressed” on the EQ-5D  whereas on the SF-12 the patient might tick the box ‘a little of 
the time’ when asked “have you felt downhearted and depressed”. This is only one example 
of how slightly different questions with different answer possibilities can lead to different 
outcomes. The more refined answer options of the SF-12 make the tool more sensitive, 
however, conversion from SF-12 to SF-6D is associated with loss in sensitivity, particularly 
due to the small range of possible utility scores. The SF-6D outcomes range between 0.296 
and 1, which is almost half of the possible EQ-5D range. Hence, SF-6D outcomes are more 
centred to the middle and the potential difference between health states is larger using the EQ-
5D utility scores. This was also reported in a paper by McDonough et al. (2007), concluding 
that cost-effectiveness analyses using the SF-6D give less favourable cost-effectiveness 
results (McDonough et al, 2007). On the other hand, the EQ-5D outcomes are very much 
skewed to the right, hence the probability of having worse outcomes is rather low, with 
limited room for improvement especially in patients with a mild condition. The SF-6D might 
be more sensitive for smaller impairments and therefore, the impairments associated with a 
mild condition might be better recognized by the SF-6D, which can in his turn lead to better 
cost-effectiveness outcomes. Indeed, the change in utility score rather than the absolute value 
of the score is of most importance in cost-effectiveness analyses. In agreement with the 
literature, EUROASPIRE III results have indicated that patients with worse EQ-5D outcomes 
were more likely to have better SF-6D results, whereas patients with better EQ-5D outcomes 
were more likely to have worse SF-6D results (Joore et al, 2010). Such inconsistencies among 
HRQoL tools can result in remarkable and important differences in cost-effectiveness 
outcomes. 
Despite the discussion concerning different cost-utility outcomes, depending on the utility 
measure used, the general advice on cost-utility analyses is to make use of EQ-5D utility 
values whenever possible (National Institute for Health and Care Excellence, 2013). And 
although comparing the cost-utility outcomes based on both utility techniques would be of 
great value, within this thesis the cost-effectiveness analysis is based on EQ-5D outcomes. 
Literature data on SF-6D values are less widespread and within our knowledge penalty values 
associated with developing different cardiovascular conditions are not available. Overall, the 
cost-effectiveness analyses for the eight countries included, showed mainly favourable results 
with an average incremental cost-effectiveness ratio (ICER) of €12,484/QALY (the cost-
effectiveness threshold is commonly set at 30,000€/QALY). Only in the minority of patients 
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at the lowest risk for recurrent events, intensifying preventive therapy seems not cost-effective. 
Also, the single impact of intensified cholesterol control seems less cost-effective, possibly 
because their initial 2-year risk was already fairly low, hence the room for improvement is 
rather limited. These results underscore the societal value of optimizing prevention in most 
patients with established CHD, but also highlight the need for setting priorities towards 
patients more at risk and the need for additional studies comparing intensified prevention with 
usual care in these patients. However, caution is required when interpreting the results, since 
the use of SF-6D values might result in different outcomes. 
10.3 LIMITATIONS 
In order to correctly interpret the results discussed above, some limitations have to be 
addressed. The major limitation of the EUROASPIRE III study is its cross-sectional design. 
To start, the design made it infeasible to test responsiveness – i.e. to test the sensitivity of the 
instruments to changes in health status over time – and to determine test-retest reliability – i.e. 
to test reproducibility. Secondly, and perhaps even more important, the lack of longitudinal 
data made it hard to assess causality. Although we were only able to test associations, we 
made several efforts to give an indication about the most likely direction. With regard to 
lifestyle changes for example, we investigated whether there was a difference in 
HRQoL/psychological distress among patients with and without any intention to change their 
behaviour, in order to examine whether lifestyle changes improve patient’s 
HRQoL/psychological distress or whether it is more likely that an improved 
HRQoL/psychological distress will result in behavioural changes. 
Furthermore, the results discussed above are mainly based on self-reported data. The main 
disadvantages of this way of data collection are recall bias and social desirability bias. The 
first arises when patients are asked to report on experiences, behaviour and events from the 
past, the latter occurs when patients are inclined to give a more socially acceptable image of 
themselves. Social desirability bias has been frequently associated with self-reported 
behaviour (Adams et al, 2005; Scagliusi et al, 2003; Tooze et al, 2004). Within 
EUROASPIRE III, the included questions did not allow objective assessment of the degree to 
which an attempt was made to alter their behaviour, hence it is likely that patients have 
overestimated their dietary changes, physical activity changes and smoking cessation attempts 
since their recruiting diagnosis. 
CHD patients included in the survey, were mainly identified from academic hospitals, situated 
in selected geographical areas. The participating countries represent different geographical 
areas across Europe with large differences in the organization of medical care and economic 
resources. Only those areas with a large defined population (> half a million of people) were 
selected. Within the selected area, at least one hospital offers interventional cardiology and 
cardiac surgery and one or more hospitals offer acute care for patients with acute myocardial 
infarction and ischemia. Hence, they are not a representative sample of all CHD patients in 
each country. It is likely that the average CHD profile is even worse with higher TC levels, 
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higher BP levels, higher glucose levels, worse behavioural risk factors, worse awareness 
levels, poorer HRQoL and more psychological distress. 
Data collection at interview was organized in a standardized way with structured 
questionnaires and standardised methods of measurement. Additional information about the 
recruiting diagnosis was collected from the available medical records, hence completeness 
and accuracy were dependent on collection methods used by doctors and nurses at that time. 
Furthermore, about 27% of patients eligible for study-inclusion did not participate to the 
interview. The most common reasons for not being interviewed were refusal to participate or 
no response (39.4%), patient’s death (14.9%), change in patient’s location (10.1%) and 
change in health status (6.2%) (Kotseva et al, 2009b). Those patients, unwilling to complete 
the questionnaires were most probably those with a worse health status, and worse HRQoL. It 
is very likely that the above reported results are an underestimation of the true number of 
patients with an impaired HRQoL; hence this limitation might be the greatest cause of bias in 
this thesis. 
The research questions in this thesis were not the main focus of the EUROASPIRE III survey. 
Three self-administered questionnaires on HRQoL and/or psychological distress were 
included. In order to interpret the results of this thesis it is important to discuss their 
advantages and disadvantages. EQ-5D and SF-12 are commonly used generic measures of 
health status, suitable for a wide range of different populations, including coronary patients. 
The main advantage of these tools, is their ability to compare outcomes across patient groups 
and to their ability to assess the impact of a disease compared with the general population. On 
the other hand, generic tools are not always sensitive enough to capture small but clinically 
significant differences between patients. The MacNew quality of life questionnaire would 
have been more appropriate to measure small differences between groups (Thompson, 2003; 
Maes, 2008). Maes and colleagues (2008) also suggest to include a brief anxiety and 
depression measure for psychosocial assessment when evaluating the outcomes in coronary 
patients. In EUROASPIRE III, the HADS instrument was used as a measure of psychological 
distress. The tool is useful as a screening instrument to identify emotional distress but is not 
adequate for use as a diagnostic tool (Brennan et al, 2010). Furthermore, although we have 
found two distinct factors based on the confirmatory factor analyses, some other authors were 
not able to differentiate between anxiety and depression in coronary patients (Martin, 2008). It 
is important to keep in mind that HADS does not necessarily correspond with what is 
clinically considered as anxiety and depression. The Patient Health Questionnaire (PHQ-9) or 
the Beck depression inventory (BDI-II) might be more suitable for assessing depression, since 
these measures incorporate the DSM criteria for depression (Beck et al, 1996). Some aspects 
of particular importance in CHD patients might not be captured with these generic 
instruments. Hence the use of CHD-specific tools can be of additional value, since they are 
often more sensitive in capturing disease specific impairments. Further research should 
preferably include generic as well as disease specific tools, e.g. the HeartQol questionnaire, 
specifically developed for use in CHD patients (Oldridge et al, 2005).   
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10.4 CONCLUSIONS AND FUTURE DIRECTIONS 
Measuring a patient’s self-perceived HRQoL/psychological distress is useful both from a 
patient perspective as well as from a health care provider and policy maker perspective. The 
benefits of medication intake and behavioural changes on metabolic and behavioural risk 
factors are well-accepted, however less is known on how an impaired HRQoL or 
psychological distress can be prevented or improved. Great differences have been observed in 
HRQoL/psychological distress outcomes between patients with the same clinical profile, 
hence assessing patient’s self-perceived health in clinical practice can be useful to identify 
health needs or to measure disease impact, in order to adjust treatment accordingly.  
The EQ-5D, SF-12 and the HADS instrument are valid and reliable for use in CHD patients 
across Europe. Compared to the general population, both the physical and mental well-being 
were significantly (both from a statistical and clinical point of view) impaired in CHD 
patients. Although a great variation was seen across countries, the greatest impairment was 
observed on the anxiety/depression, mobility, usual activities and pain/discomfort (only in 
females) dimensions. Future research should investigate the ability of the tools to capture 
changes and to test reproducibility. Since country-specific normative information is rather 
scarce, there is a need for a coordinated cross-country collection of HRQoL/psychological 
distress information, with well-defined inclusion criteria and additional collection of 
covariates. This will allow easy comparison between the general population and several 
patient groups (not limited to CHD patients). Furthermore the usefulness of other locally 
translated and validated tools should be tested, with a particular focus on how outcomes differ 
from each other depending on the instrument used. These findings might help in formulating 
guidelines regarding the use of utility values in health economic analyses. A particular 
interesting instrument to evaluate will be the HeartQoL tool (Oldridge et al, 2005). This tool 
is developed as a CHD-specific HRQoL questionnaire, with the aim to compare HRQoL 
outcomes in patients with angina pectoris, MI and heart failure. The instrument has two 
subscales from which a global score can be calculated. This allows clinicians and researchers 
to assess baseline HRQoL, to make between-diagnosis comparisons of HRQoL, and to 
evaluate change in HRQoL in CHD patients. The instrument has been included in the 
EUROASPIRE IV survey; hence we are eagerly looking forward to these data. 
Several CHD risk factors were associated with HRQoL/psychological distress. The best 
outcomes were seen among those patients with an optimally controlled risk factor profile. A 
great potential was demonstrated regarding the effect of lifestyle, hence lifestyle interventions 
should be evaluated regarding their effect on HRQoL/psychological distress. Further research 
should focus on a longitudinal assessment in order to better understand the direction of the 
relationship between lifestyle changes and HRQoL/psychological distress. Also, it is unclear 
whether these benefits in HRQoL/psychological distress are sustained over time or whether 
the gains are associated with a one-time benefit inherent to the change itself. Hence the long-
term gains in HRQoL/psychological distress should be investigated. It might also be 
worthwhile to explore the effect of cardiovascular medication on HRQoL/psychological 
distress outcomes, since most CHD patients are taking antihypertensive or lipid lowering 
medication. 
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Within clinical practice, particular attention should be given to females and younger patients, 
less educated patients, and patients with comorbidities, since they are more likely to suffer 
from an impaired HRQoL/psychological distress. In addition to the individual burden on a 
patient’s live, self-perceived health status is also associated with future mortality and 
morbidity as well as with increased health care expenses, hence actions to tackle these 
impairments are needed. Furthermore, patients should be encouraged to adopt a healthier 
lifestyle, not only will this have a direct influence on metabolic risk factors and hence future 
health, a healthier lifestyle can also lead to a better HRQoL/psychological distress. Smokers 
often have concerns about the effect of smoking cessation on their weight, life satisfaction, 
and HRQoL/psychological distress. Likewise, inactive or obese patients do not always see the 
benefits of dietary and physical activity lifestyle changes. In order to convince patients in 
changing their behaviour, doctors and other healthcare professionals should emphasize the 
improvements in HRQoL/psychological distress seen in patients who adopt a healthier 
lifestyle. Furthermore, these findings can be important for decision makers when setting the 
priorities related to their prevention policy. 
When using HRQoL outcomes in policy decision making, particular attention should be given 
to the choice of HRQoL instrument. Although EQ-5D and SF-6D utility values, -often used in 
health economic evaluations- were shown to correlate significantly, large differences between 
the measures were found, with median values significantly different from each other. This can 
pose a real threat on the usefulness and credibility of health economic evaluations. 
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Summary 
 
The assessment of patient reported outcomes has gained importance over the latest decades. 
There is a general consensus that morbidity and mortality rates do not reflect all aspects of 
health. Indeed, patients’ self-perceived emotional, social and physical well-being have 
received increased attention, especially in long-term chronic conditions, when full recovery is 
quite unlikely. The goal of today’s medicine is therefore not merely to extend a person’s life 
expectancy, but also to ensure a sufficiently high long-term Health-Related Quality of Life 
(HRQoL). HRQoL measurement has been proven useful in evaluating medical treatment in 
clinical research, but can just as easily be used in daily clinical practice. Furthermore, HRQoL 
information can also be helpful for audit purposes, as assessment tool for the quality of 
delivered health care and in health policy decision making. 
Coronary patients are particularly vulnerable to have an impaired self-perceived HRQoL. 
Their illness is often associated with pain, worrying thoughts, anxiety and depression, 
physical limitations and social restrictions. The primary purpose of this thesis was to 
investigate the association between Coronary Heart Disease (CHD) and HRQoL and 
psychological distress. Analyses were based on the EUROASPIRE III (EUROpean Action on 
Secondary and Primary Prevention through Intervention to Reduce Events) survey. This 
cross-sectional study (2006-2007) aimed to determine whether the European 
recommendations on cardiovascular disease (CVD) prevention were being followed in 
everyday clinical practice. Patients aged between 18 and 80 years, hospitalized for coronary 
artery bypass graft (CABG), percutaneous coronary intervention (PCI), acute myocardial 
infarction (AMI) or myocardial ischemia, were retrospectively identified from diagnostic 
registers, hospital discharge lists or other sources at 76 different hospital centres across 22 
European countries: Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Poland, Romania, Russian 
Federation, Slovenia, Spain, The Netherlands, Turkey, and the United Kingdom (UK). At 
least 6 months and not later than 3 years after their coronary event, patients were interviewed 
and clinically examined. During interview patients were asked to complete 3 
HRQoL/psychological distress questionnaires: EQ-5D (EuroQol-5D), SF-12 (12-item Short 
Form health survey) and HADS (Hospital Anxiety and Depression scale). 
To start, the validity and reliability of the 3 instruments was assessed. Cronbach's alpha 
indicated good internal consistency for all measures. Discriminative validity analyses 
confirmed significant differences between known groups: age, gender, educational level. In 
addition, all hypothesized correlations between different constructs (convergent validity) and 
items (criterion validity) were confirmed. Also, good construct validity for HADS and SF-12 
dimensions was observed. On country-specific level, results were roughly similar. Based on 
the EUROASPIRE III data, we can conclude that the EQ-5D as well as the SF-12 and the 
HADS are reliable and valid instruments for use in a stable coronary population, both on 
aggregate European level and on country-specific level. 
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Secondly, if available we compared HRQoL outcomes in CHD patients with age-adjusted 
values from the general population, with the aim to identify those dimensions mostly impaired. 
With regard to the EQ-5D a great variation was found across countries (11 countries included). 
Overall, in comparison with reference values, all EQ-5D dimensions in CHD patients were 
significantly impaired with the exception of self-care and pain/discomfort (in males). 
Similarly, significant differences were found between CHD patients and the general 
population both on the PCS-12 score (SF-12 Physical Component Summary scale) and the 
MCS-12 (SF-12 Mental Component Summary scale).  
Detailed investigation of the association between patients’ cardiovascular profile and their 
HRQoL revealed a large heterogeneity in HRQoL values between countries and patient 
groups. Worse HRQoL estimates were found in women, older patients, less educated patients, 
patients with myocardial infarction or ischemia as recruiting diagnosis, patients with a history 
of stroke and patients who suffered from a recurring CHD event. In addition, HRQoL was 
significantly associated with current smoking, central obesity, lack of exercise and 
inappropriate HbA1c control in patients with diabetes. Furthermore, the number of risk 
factors was inversely associated with HRQoL outcomes.  
In-depth analyses investigated the link between lifestyle changes and HRQoL/psychological 
distress. Both smoking cessation, increase in physical activity and dietary changes were 
significantly associated with a better outcome. The lack of association between the intention 
to accept a healthier lifestyle and patients’ HRQoL/psychological distress most likely 
indicates that the lifestyle changes induce better HRQoL/psychological distress outcomes and 
not the other way round. 
Additionally, suboptimal risk factor level awareness rates were found. Whereas about  82% of 
patients indicated to be aware of their own blood pressure level, only 47% of patients 
indicated to be aware of their cholesterol level. Furthermore, only 44% of patients were aware 
of their blood glucose level, whereas in diabetes patients blood glucose level awareness 
reached 82%. A greater risk factor level awareness was significantly associated with better 
HRQoL/psychological distress. Not only are patients with a greater awareness more likely to 
have made attempts in improving their lifestyle, there also seems to be a direct link between 
awareness and HRQoL/psychological distress, in particular with the mental component. It is 
hypothesized that patient involvement in their care and patient awareness of their risk factor 
profile could possibly affect their illness perception and sense of control. 
The inter-changeability between the EQ-5D and the SF-12 measures was assessed in our 
sample of coronary patients. Both measures allow calculating a utility value, which can be 
used in health-economic evaluations. Past research indicated that differences in utility 
measures used can lead to different results with better or worse cost-effectiveness outcomes, 
depending on the instrument used. This can pose a real threat on the usefulness and credibility 
of health economic evaluations. Our results indicate a significant correlation between EQ-5D 
and SF-12 (6 dimensional health state classification - SF-6D) utility values, however, large 
differences between the two measures remain. About 28.8% of patients reported a ceiling 
effect on the EQ-5D instrument, whereas only 4.2% of patients reported full health based on 
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the SF-6D. Especially the mental component does not seem to be completely captured by the 
EQ-5D instrument. Furthermore, patients with worse EQ-5D outcomes were more likely to 
have better SF-6D results, whereas patients with better EQ-5D outcomes were more likely to 
have worse SF-6D results, hence within our population, the measures were not 
interchangeable. Furthermore, as an example of how HRQoL can be used in practice, the 
individual EQ-5D utility outcomes from the EUROASPIRE III sample were applied to assess 
the cost-effectiveness of optimal cardiovascular prevention in coronary patients, which can be 
helpful in health policy decision making. Overall, the cost-effectiveness analyses for the eight 
countries included in the analyses, showed mainly favourable results with an average 
incremental cost-effectiveness ratio (ICER) of €12,484 per Quality Adjusted Life Year 
(QALY). Only in the minority of patients at the lowest risk for recurrent events, intensifying 
preventive therapy seems not cost-effective. Also, the single impact of intensified cholesterol 
control seems less cost-effective, possibly because their initial 2-year risk was already fairly 
low, hence the room for improvement is rather limited. Comparing the cost-utility outcomes, 
based on the EQ-5D utilities on the one hand and the SF-6D utilities on the other, would be of 
great value. However, literature data on SF-6D values are less widespread and within our 
knowledge penalty values associated with developing different cardiovascular conditions are 
not available, hence we were not able to perform this comparison. 
Within clinical practice, particular attention should be given to the self-perceived health status 
of females and younger patients, less educated patients, and patients with comorbidities. In 
addition to the individual burden on a patient’s live, self-perceived health status, anxiety and 
depression are also associated with future mortality and morbidity as well as with increased 
health care expenses, hence actions to tackle these impairments are needed. Patients should be 
encouraged to adopt a healthier lifestyle, not only will this have a direct influence on 
metabolic risk factors and hence future health, a healthier lifestyle can also lead to a better 
HRQoL/psychological distress. Smokers often have concerns about the effect of smoking 
cessation on their weight, life satisfaction, and HRQoL. Likewise, inactive or obese patients 
do not always see which benefits could be given by their dietary and physical activity lifestyle 
changes. In order to convince patients in changing their behaviour, doctors and other 
healthcare professionals should emphasize the improvements in HRQoL/psychological 
distress seen in patients who adopt a healthier lifestyle. Furthermore, these findings can be 
important for decision makers when setting the priorities related to their prevention policy. 
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Samenvatting 
 
De evaluatie van patiënt gerapporteerde uitkomsten heeft aan belang gewonnen gedurende de 
laatste decennia. Er is een algemene consensus dat ziekte en sterfte niet alle aspecten van 
gezondheid weergeven. De subjectieve ervaring van de patiënt zijn emotionele, sociale en 
fysieke welzijn heeft meer aandacht gekregen, voornamelijk in langdurige chronische 
aandoeningen waarbij volledig herstel zeer onwaarschijnlijk is. Het doel van geneeskunde is 
dus niet enkel om de levensduur van patiënten te verlengen, maar ook om te zorgen voor een 
voldoende hoge gezondheidsgerelateerde kwaliteit van leven (HRQoL). Het meten van 
HRQoL is nuttig gebleken bij de evaluatie van medische behandeling in klinisch onderzoek, 
maar kan ook gebruikt worden in de dagelijkse klinische praktijk. Verder kan HRQoL 
informatie ook bruikbaar zijn bij het uitvoeren van audits, als toetsingsinstrument voor de 
kwaliteit van de geleverde zorg en bij de besluitvorming binnen het gezondheidszorgbeleid. 
Coronaire patiënten zijn bijzonder vatbaar om een verminderde HRQoL te ervaren. Hun 
aandoening is vaak geassocieerd met pijn, piekeren, angst en depressie, fysieke en sociale 
beperkingen. Het primaire doel van dit proefschrift is om de associatie tussen hartziekte en 
HRQoL/psychologisch welzijn te onderzoeken. De analyses zijn gebaseerd op de 
EUROASPIRE III (EUROpean Action on Secondary and Primary Prevention through 
Intervention to Reduce Events) survey. Deze cross-sectionele studie (2006-2007) had als doel 
na te gaan of de Europese aanbevelingen inzake cardiovasculaire preventie werden opgevolgd 
in de dagdagelijkse klinische praktijk. Patiënten tussen 18 en 80 jaar oud, gehospitaliseerd 
voor een coronaire bypass (CABG), een percutane coronaire interventie (PCI), een acuut 
myocardinfarct (AMI) of een myocardiale ischemie, werden retrospectief geïdentificeerd via 
diagnostische registers, ontslaglijsten van ziekenhuizen of andere bronnen via 76 
ziekenhuizen in 22 Europese landen: België, Bulgarije, Kroatië, Cyprus, Tsjechië, Finland, 
Frankrijk, Duitsland, Griekenland, Hongarije, Ierland, Italië, Letland, Litouwen, Polen, 
Roemenië, Rusland, Slovenië, Spanje, Nederland, Turkije en het Verenigd Koninkrijk. Ten 
minste 6 maanden en maximaal 3 jaar na hun coronaire gebeurtenis, werden de patiënten 
geïnterviewd en klinisch onderzocht. Tijdens het interview werd aan de patiënten gevraagd 
om 3 algemene vragenlijsten over hun HRQol/psychologisch welzijn in te vullen: EQ-5D 
(EuroQol-5D), SF-12 (12-item Short Form health survey) en de HADS (Hospital Anxiety and 
Depression Scale) . 
Eerst werd de validiteit en betrouwbaarheid van de 3 vragenlijsten geëvalueerd. Cronbach's 
alfa resultaten wijzen op een goede interne consistentie voor de 3 vragenlijsten. Analyses 
inzake de discriminerende validiteit bevestigden significante verschillen tussen bekende 
variabelen zoals leeftijd, geslacht en opleidingsniveau. Daarnaast werden alle veronderstelde 
correlaties tussen verschillende constructen (convergente validiteit) en items 
(criteriumvaliditeit) bevestigd. Goede constructvaliditeit voor HADS en de SF-12 dimensies 
werd waargenomen. Vergelijkbare resultaten werden waargenomen op landen-specifiek 
niveau. Op basis van de EUROASPIRE III data kunnen we concluderen dat de EQ-5D, de 
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SF-12 en de HADS betrouwbare en valide instrumenten zijn voor het gebruik in een populatie 
van stabiele coronaire patiënten, zowel op geaggregeerd Europees niveau als op landen-
specifiek niveau. 
Vervolgens hebben we de HRQoL resultaten van de coronaire patiënten vergeleken met de 
voor leeftijd-gecorrigeerde HRQoL waarden uit de algemene populatie (indien beschikbaar) 
om zo de meest aangetaste dimensies te identificeren. Wat betreft de EQ-5D werd een grote 
variatie vastgesteld tussen de verschillende landen (11 landen werden geïncludeerd). In 
vergelijking met referentiewaarden, waren alle EQ-5D dimensies in de studiepopulatie 
significant aangetast, met uitzondering van zelfzorg en pijn/ongemak (bij mannen). Tevens 
werden significante verschillen gevonden tussen coronaire patiënten en de algemene 
bevolking op zowel de PCS-12 score (SF-12 Physical Component Summary scale) als de 
MCS-12 (SF-12 Mental Component Summary scale). 
Onderzoek inzake de associatie tussen het cardiovasculair profiel van de patiënten en hun 
HRQoL toonde een grote heterogeniteit in HRQoL waarden tussen landen en 
patiëntengroepen. Slechtere HRQoL scores werden gevonden bij vrouwen, oudere patiënten, 
lager opgeleide patiënten, patiënten met een myocardinfarct of ischemie als initiële diagnose, 
patiënten met een voorgeschiedenis van een beroerte en patiënten met een terugkerende 
coronaire gebeurtenis. Daarnaast was HRQoL significant geassocieerd met roken, buikvet, 
gebrek aan lichaamsbeweging en onvoldoende HbA1c controle bij diabetespatiënten. 
Bovendien was een stijging in het aantal risicofactoren geassocieerd met slechtere HRQoL. 
Gedetailleerde analyses inzake het verband tussen levensstijlveranderingen en 
HRQoL/psychologisch welzijn toonden aan dat zowel stoppen met roken als een toename van 
fysieke activiteit en veranderingen in het dieet significant geassocieerd waren met een betere 
HRQoL/psychologisch welzijn. Aangezien het al of niet de intentie hebben om een gezondere 
levensstijl aan te nemen niet geassocieerd is met de HRQoL/psychologisch welzijn van 
patiënten lijkt het zeer waarschijnlijk dat levensstijlveranderingen betere 
HRQoL/psychologisch welzijn induceren en niet andersom. 
Daarnaast bleek bij de patiënten de kennis van hun eigen risicofactoren niveau suboptimaal. 
Ongeveer 82% van de patiënten gaven aan kennis te hebben van hun eigen bloeddruk waarde, 
terwijl slechts 47 % van de patiënten zich bewust waren van hun eigen cholesterolgehalte. 
Bovendien was slechts 44 % van de patiënten op de hoogte van hun bloedsuikerspiegel, 
terwijl 82% van diabetespatiënten kennis had van hun eigen bloedsuikerspiegel niveau. Een 
groter bewustzijn van de eigen risicofactor waarden was significant geassocieerd met een 
betere HRQoL/psychologisch welzijn. Niet alleen hadden patiënten met een groter bewustzijn 
meer pogingen ondernomen om hun levensstijl te verbeteren, er blijkt ook een direct verband 
te zijn tussen bewustzijn en HRQoL/psychologisch welzijn, in het bijzonder met de mentale 
component. Er wordt verondersteld dat de betrokkenheid van patiënten in hun zorg en het 
bewustzijn van hun risicofactor profiel een invloed zou kunnen hebben op de beleving van 
hun aandoening en het gevoel van controle. 
De uitwisselbaarheid tussen het EQ-5D en SF-12 instrument werd onderzocht in onze 
steekproef van coronaire patiënten. Beide instrumenten laten toe om een utiliteitwaarde te 
 SAMENVATTING 
 
 
159 
 
berekenen, die gebruikt kan worden in gezondheidseconomische evaluaties. Eerder onderzoek 
gaf aan dat de verschillen tussen beide instrumenten kan leiden tot andere uitkomsten met 
betere of slechtere kosteneffectiviteit resultaten als gevolg, afhankelijk van het gebruikte 
instrument. Dit kan een reële bedreiging vormen voor wat betreft het nut en de 
geloofwaardigheid van gezondheidseconomische evaluaties. Onze resultaten tonen een 
significante correlatie tussen EQ-5D en SF-12 (6 dimensional health state classification - SF-
6D) utiliteitwaarden, maar er blijven echter grote verschillen bestaan tussen de twee 
instrumenten. Ongeveer 28,8 % van de patiënten rapporteren een plafondeffect op het EQ-5D 
instrument, terwijl slechts 4,2 % van de patiënten een perfecte gezondheid rapporteren op 
basis van de SF-6D. Vooral de mentale component lijkt niet volledig te worden omvat door 
het EQ-5D instrument. Bovendien hadden patiënten met slechte EQ-5D resultaten meer kans 
om betere SF-6D uitkomsten te hebben en vice versa. Binnen de onderzochte populatie zijn de 
instrumenten dan ook niet uitwisselbaar. Als voorbeeld van hoe HRQoL kan worden gebruikt 
in de praktijk werden de individuele EQ-5D utiliteitwaarden van de EUROASPIRE III survey 
aangewend om de kosteneffectiviteit van optimale cardiovasculaire preventie bij coronaire 
patiënten na te gaan. Dit kan nuttig zijn in het beslissingsproces van het 
gezondheidszorgbeleid. De kosteneffectiviteit analyses voor de acht opgenomen landen, 
toonden voornamelijk gunstige resultaten met een gemiddelde incrementele kosteneffectiviteit 
ratio (IKER) van € 12.484 per aan kwaliteit aangepast levensjaar (QALY). Alleen bij een 
minderheid van de patiënten, met de laagste kans om een nieuwe coronair event te krijgen, 
lijkt het versterken van preventie niet kosteneffectief. De invloed van een louter intensievere 
cholesterolcontrole lijkt eveneens minder rendabel, wellicht omdat hun aanvankelijk 2-jarig 
risico al vrij laag was, met dus een beperktere ruimte voor verbetering. Het vergelijken van de 
kosten-utiliteiten uitkomsten, gebaseerd op enerzijds de EQ-5D utiliteitwaarde en anderzijds 
de SF-6D utiliteitwaarden, kan van grote waarde zijn. De literatuurgegevens inzake SF-6D 
utiliteitwaarden zijn echter minder wijdverspreid. Het utiliteitsverlies gepaard gaande met de 
ontwikkeling van verschillende cardiovasculaire aandoeningen was niet beschikbaar in de 
literatuur, waardoor we niet in staat waren om deze vergelijking uit te voeren. 
Binnen de klinische praktijk zou er bijzondere aandacht moeten worden besteed aan de zelf-
ervaren gezondheidstoestand en het psychologisch welzijn van vrouwen en jongere patiënten, 
lager opgeleide patiënten en patiënten met comorbiditeit. Naast de individuele last is de zelf-
ervaren gezondheidstoestand, angst en depressie ook geassocieerd met toekomstige ziekte en 
sterfte, alsook met hogere gezondheidszorguitgaven. Acties zijn daarom noodzakelijk. 
Patiënten moeten aangemoedigd worden om een gezondere levensstijl aan te nemen. Dit zal 
niet alleen een directe invloed hebben op de metabole risicofactoren en bijgevolg hun 
toekomstige gezondheid, maar een gezondere levensstijl kan ook leiden tot een betere 
HRQoL/psychologisch welzijn. Rokers piekeren bijvoorbeeld vaak over het effect van 
rookstop op hun gewicht, hun tevredenheid over het leven en hun HRQoL. Evenzo zien 
inactieve of zwaarlijvige patiënten niet altijd de voordelen in van een gezond dieet en 
lichaamsbeweging. Om patiënten te overtuigen hun gedrag te veranderen, moeten artsen en 
andere zorgverstrekkers de verbeteringen in HRQoL/psychologisch welzijn gelinkt aan een 
gezondere levensstijlverandering benadrukken. Bovendien kunnen deze bevindingen 
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belangrijk zijn voor beleidsmakers bij het stellen van prioriteiten met betrekking tot het 
preventiebeleid.  
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